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ﺔ أﻧﻤѧﺎط وﺧѧﺼﺎﺋﺺ ﻟﺪراﺳѧ ﺑﺎﻟﺘﻌѧﺎون ﻣѧﻊ ﻣﺴﺘѧﺸﻔﻲ اﻟﺨﺮﻃѧﻮم  آﻠﻴѧﺔ اﻟﻄѧﺐ-ﺗﻬѧﺪف ﺟﺎﻣﻌѧﺔ اﻟﺨﺮﻃѧﻮم •
 ﻓѧﻰ اﻻﺻѧﺎﺑﺔ ﺑѧﺎﻟﻤﺮض وﺗﻄѧﻮرﻩ ﺎهﻢ ﻓѧﻰ واﻟﻌﻮاﻣﻞ اﻟﺘﻰ ﺗѧﺴ ﻣﺮض ﻧﻘﺺ اﻟﻤﻨﺎﻋﺔ اﻟﻔﻴﺮوﺳﻲ اﻟﺒﺸﺮي 
  .اﻟﺴﻮدان
ﻣﻌﻈѧﻢ اﻟﻤﺮﺿѧﻰ ﻣѧﻦ آﺎﻓѧﺔ ن ﻷﻹﺟѧﺮاء هѧﺬﻩ اﻟﺪراﺳѧﻪ ﻧѧﺴﺒﺔ ﺗѧﻢ اﺧﺘﻴѧﺎر ﻣﺴﺘѧﺸﻔﻲ اﻟﺨﺮﻃѧﻮم اﻟﺘﻌﻠﻴﻤѧﻰ  •
وﺳѧﻴﻜﻮن ﻣﻮﺿѧﻮع اﻟﺒﺤѧﺚ هѧﻮ ،  ﻢ ﻣﺘѧﺎﺑﻌﺘﻬﻢ ﺘﺗѧ اﻟﻮﻻﻳﺎت واﻟﻤﺴﺘﺸﻔﻴﺎت ﻳﺘﻢ ﺗﺤѧﻮﻳﻠﻬﻢ ﻟﻠﻤﺴﺘѧﺸﻔﻰ ﺣﻴѧﺚ 
  .دراﺳﺔ وﻓﻬﻢ ﻃﺒﻴﻌﺔ اﻟﻤﺮض ﻣﻤﺎ ﺳﻴﺴﺎﻋﺪ ﻓﻰ ﺗﻘﻠﻴﻞ ﺣﺎﻻت اﻹﺻﺎﺑﻪ وﺗﺨﻔﻴﻒ ﺣﺪﺗﻬﺎ
ﻜﺎﻣѧѧﻞ وﺗѧѧﺘﻢ إﻟѧѧﻰ آѧѧﺸﻒ ﻃﺒѧѧﻰ ﻣﺘ ﻟѧѧﺬﻳﻦ ﻳѧѧﺘﻢ إدﺧѧѧﺎﻟﻬﻢ إﻟѧѧﻰ اﻟﻤﺴﺘѧѧﺸﻔﻰ ﺳѧѧﻮف ﻳﺨѧѧﻀﻌﻮا آѧѧﻞ اﻟﻤﺮﺿѧѧﻰ ا  •
  .ﻣﺘﺎﺑﻌﺘﻬﻢ ﻃﺒﻴﺎ إذا دﻋﺖ اﻟﻀﺮورﻩ
هѧѧﺬﻩ اﻟﻌﻴﻨѧѧﺎت ﺳѧѧﻮف ﻳѧѧﺘﻢ ﻣѧѧﻦ اﻟﻤﺮﻳﺾ،( CC 5)ﺑﻌѧѧﺪ اﻟﻔﺤѧѧﺺ اﻟﻄﺒѧѧﻰ اﻟѧѧﺸﺎﻣﻞ ﻳѧѧﺘﻢ اﺧѧѧﺬ ﻋﻴﻨѧѧﺔ دم  •
ﺗﻮزﻳﻊ ﺑﻌѧﺾ اﻟﺠﻴﻨѧﺎت  ﺗﺤﻠﻴﻞ وراﺛﻲ ﻋﻠﻲ ﻣﺴﺘﻮي ﺟﺰﻳﺌﻲ ﻋﺎﻟﻲ اﻟﻮﺿﻮح ﻟﺘﺤﺪﻳﺪ إﺳﺘﺨﺪاﻣﻬﺎ ﻹﺟﺮاء 
 .ﻩﻟﻤﻌﺮﻓﺔ ﺗﺎﺛﻴﺮهѧﺎ ﻋﻠѧﻲ اﺣﺘﻤﺎﻟﻴѧﺔ اﻻﺻѧﺎﺑﺔ ﺑѧﺎﻟﻤﺮض وﻣѧﻦ ﺛѧﻢ ﺗﻘﻴѧﻴﻢ دور اﻟﺨﻠﻔﻴѧﺔ اﻟﻮراﺛﻴѧﺔ ﻓѧﻲ ﺗﻄѧﻮر 
  .أى أﻋﺒﺎء ﻣﺎدﻳﻪ ﻧﺘﻴﺠﻪ ﻹﺷﺘﺮاآﻪ ﻓﻰ اﻟﺒﺤﺚوﻟﻦ ﻳﺘﺤﻤﻞ اﻟﻤﺮﻳﺾ أو ذووﻩ 
  .ﺔﻮاﻓﻘﻪ او اﻟﺮﻓﺾ ﻓﻰ اﻟﺪﺧﻮل ﻓﻰ هﺬﻩ اﻟﺪراﺳﻤﻤﺮﻳﺾ اﻟﺤﻖ ﻓﻰ اﻟﻟﻠ •
ﺗѧﺘﻢ ﻣﺘѧﺎﺑﻌﺘﻬﻢ ﺑﺎﻟﻄﺮﻳﻘѧﻪ اﻟﻤﻌﺘѧﺎدﻩ ﻓѧﻰ  اﻟﻤﺮﺿﻰ اﻟﺬﻳﻦ ﻻ ﻳﺮﻏﺒﻮن ﻓﻰ اﻟﺪﺧﻮل ﻓﻰ هѧﺬﻩ اﻟﺪراﺳѧﻪ ﺳѧﻮف  •
 .اﻟﻤﺴﺘﺸﻔﻰ
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Abstract 
 
 
The study was carried out in Khartoum Teaching Hospital, Khartoum; in the period of August 
2003-April 2004. The objectives of the present study were to determine the distribution of the 
host polymorphic genes; HLA class I and class II alleles and haplotypes and chemokine 
receptor CCR5, in order to study their impact on the susceptibility to HIV-1 infection and to 
evaluate the contribution of the genetic background to the variability of disease progression.  
 
This study is the first report on the association of HLA class I and class II alleles distribution 
with HIV in Sudanese population, as well as on HLA distribution in the population at high-
resolution molecular typing level. The Sudanese information is important, because it 
represents a gap between the understanding of African and Eurasian HLA alleles and 
haplotypes frequencies. 
   
The present study showed that A*3101, Cw*0202, Cw*0304. DRB1*0301, and DQB1*0604 
alleles were significantly associated with protection from HIV-1 infection, whereas A*2902, 
Cw*0705 alleles were associated with susceptibility to HIV-1 infection. On the other hand 
A*2601, A*2902, and DRB1*1102 were associated with rapid progression, while Cw*1203, 
DRB1*1503, and DQB1*0602 were associated with slow progression.  
 
At the population level, the study showed that the Sudanese have a unique HLA genes 
distribution pattern. Several HLA alleles, A*0202, A*3004; B*1503, Cw*0804, DRB1*0804 
which were African-specific alleles were found in  similar frequencies in the Sudanese 
population, as well as some other alleles which were highly distributed in Arabs, North 
African, and Caucasians population such as DQB1*0201, DQB1*0301, DPB1*0401, and 
DPB1*0402. This may reflect a high degree of admixture of the study population. 
 
This study has identified several additional alleles and haplotypes, not previously reported or 
tested in other populations, so far, namely Cw*0418, Cw*0214, Cw*0410104, and 
Cw*070105, and haplotypes A*0201-B*3910, A*3004-B*4101, A*3201-B*4101, B*4101-
Cw*1203, A*3004-Cw*0401, A*3002-Cw*0701, A*2402-Cw*1203, DRB1*0301-
DQB1*0301, DRB1*0804-DQB1*0201, DRB1*1302-DQB1*0301, and DRB1*0804-
DPB1*0201 . They might be considered as markers for this population.  
 
Our results clearly demonstrated that common and unique HLA alleles and haplotypes 
contributed to genetic susceptibility and protection from HIV- infection. However, the present 
data have given information supporting the role of HLA as genetic markers predicting HIV 
disease progression. Furthermore, our results show that the presence of common alleles and 
haplotypes in our population is consistent with historical data showing that the Sudanese 
population is an admixture of various ethnicities, and that they have a unique HLA genes 
pattern. 
 
Regarding CCR5, the CCR5-∆32 allele frequency in Sudanese was found to be similar to that 
reported in African populations (0.6%). One of those who carried the mutant allele was HIV-1 
positive; which suggest that the CCR5-∆32 receptor does not play an important role in HIV 
infection in Sudanese population. 
 
 
 
 
 
 
 
                                             
 
 
 
 
 
 
 
 
 
 
  
  
 ﻣﻠﺨﺺ اﻟﺪراﺳﺔ
 
.  4002 واﺑﺮﻳﻞ 3002اﻏﺴﻄﺲ   اﻟﺪراﺳﺔ ﰱ ﻣﺪﻳﻨﺔ اﳋﺮﻃﻮم ﺧﻼل اﻟﻔﱰة ﻣﺎ ﺑﲔﻳﺖ هﺬة   اﺟﺮ
اﳉﻴﻨﺎت اﳌﺘﻌـﺪدة اﻻﺷـﻜﺎل اﻟﻌﺎﺋﻠـﺔ ﳌـﻀﺎدات اﻟﻜﺮﻳـﺎت  ﲥﺪف اﻟﺪراﺳﺔ اﱃ ﲢﺪﻳﺪ ﺗﻮزﻳﻊ
                   II اﳌﺼﻨﻔﺔو اﻷﻟﻴﻼتI    اﳌﺼﻨﻔﺔ اﻷﻟﻴﻼتﺎء اﻟﺒﺸﺮﻳﺔاﻟﺒﻴﻀ
، ﳌﻌﺮﻓﺔ ﺗﺎﺛﲑهﻢ ﻋﻠﻰ اﺣﺘﻤﺎﻟﻴﺔ اﻻﺻﺎﺑﺔ 5RCC  وﻣﺴﺘﻘﺒﻼت)II ssalc dna I ssalc ALH( 
اﳋﻠﻔﻴﺔ اﻟﻮراﺛﻴﺔ ﰱ اﻟﺘﻐﲑ ﰱ ردوﺗﻘﻴﻴﻢ   وﻣﻦ ﰒVIH()اﳌﻨﺎﻋﺔ اﻟﻔﲑوﺳﻰ اﻟﺒﺸﺮى ﲟﺮض ﻧﻘﺺ
   .اﳌﺮض ﺗﻄﻮر
 
  ﺗﻮزﻳـﻊ ﻣـﻀﺎدات اﻟﻜﺮﻳـﺎت اﻟﺒﻴـﻀﺎء  ﻩ اﻟﺪراﺳﺔ اول ﺗﻘﺮﻳﺮ ﻋﻠﻤﻰ ﺣﻮل ﻋﻼﻗﺔﺗﻌﺘﱪ هﺬ
ﺑﺎﻻﺿـﺎﻓﺔ .  اﻟـﺴﻮداﱏ   ﰱ اﺘﻤـﻊ  ) VIH(      اﻟﺒﺸﺮى ﻣﻊ ﻧﻘﺺ اﳌﻨﺎﻋﺔ اﻟﻔﲑوﺳﻰ )ALH(
ﰱ اﺘﻤﻊ ﻋﻠـﻰ ﻣـﺴﺘﻮى ﺟﺰﻳﺌـﻰ ﻋـﺎﱃ  ) ALH( اﻟﻜﺮﻳﺎت اﻟﺒﻴﻀﺎء اﻟﺒﺸﺮﻳﺔ ﺎداتﺗﻮزﻳﻊ ﻣﻀ
ﺗﻜـﺮار  ﻣﻬﻤﺔ ، ذﻟﻚ ﻻﺎ ﲤﺜﻞ ﻓﺠﻮة ﺑﲔ ﻓﻬﻢ ﻋـﺪد اﳌﻌﻠﻮﻣﺎت اﻟﺴﻮداﻧﻴﺔ وﺗﻌﺘﲑ. اﻟﻮﺿﻮح
  .ﺳﻴﻮاورﺑﻴﺔﻵﻓﺮﻳﻘﻴﺔ واﻷ ا)sepytolpaH( واﻟﻨﻤﻂ اﻟﻔﺮداﻧﻲ)selellA(اﻷﻟﻴﻼت 
 
 BQD ,1030*1BRD ,4030*wC ,2020*wC ,1013*A  اﻷﻟﻴﻼتﻟﻘﺪ اوﺿﺤﺖ اﻟﺪراﺳﺔ اﳊﺎﻟﻴﺔ ان
 .يﺎﻋﺔ اﻟﻔﲑوﺳـﻰ اﻟﺒـﺸﺮ ﲟﺮض ﻧﻘﺺ اﳌﻨﺑﺎﻣﻜﺎﻧﻴﺔ اﻻﺻﺎﺑﺔ  ﺗﺮﺗﺒﻂ ارﺗﺒﺎﻃﺎ آﺒﲑا 4060*1
ﻣﻊ اﺣﺘﻤﺎﻟﻴﺔ اﻟﺘﻌﺮض ﻟﻼﺻﺎﺑﺔ ﲟـﺮض    5070*wC   2092*A ,اﻷﻟﻴﻼتﺑﻴﻨﻤﺎ ﺗﺮﺗﺒﻂ ) VIH(
 2092*A ,1062*A وﻣـﻦ ﺟﻬـﺔ اﺧـﺮى ﺗـﺮﺗﺒﻂ  )VIH(. ﻧﻘـﺺ اﳌﻨﺎﻋـﺔ اﻟﻔﲑوﺳـﻰ اﻟﺒـﺸﺮى 
 ,2060*1BQD  3051*1BRD ,3021*wCﻟﻠﻤﺮض ، ﺑﻴﻨﻤـﺎ  ﻣﻊ اﻟﺘﻄﻮر اﻟﺴﺮﻳﻊ   1020*1BQD,
 .ﺗﻄﻮرﻩﺗﺮﺗﺒﻂ ﻣﻊ ﺑﻂء 
 
ﳌـﻀﺎدات  وﻋﻠﻰ ﻣﺴﺘﻮى اﺘﻤﻊ ، اوﺿﺤﺖ اﻟﺪراﺳﺔ ان ﻟﻠﺴﻮداﻧﻴﲔ ﳕـﻂ ﺗـﻮزﻳﻌﻰ اﺳـﺘﺜﻨﺎﺋﻰ 
  ﻣـﻀﺎدات اﻟﻜﺮﻳـﺎت اﻟﺒﻴـﻀﺎء  اﻷﻟـﻴﻼت ﻓﺎﻟﻌﺪﻳﺪ ﻣﻦ ) ALH(اﻟﻜﺮﻳﺎت اﻟﺒﻴﻀﺎء اﻟﺒﺸﺮﻳﺔ
 اﻟﱴ ﺗﻌﺘﱪ ذات ﺻﻠﺔ ﺑﺎﻓﺮﻳﻘﻴﺎ  4080*1BRD ,4080*wC 3051*B ,2020*A ,  ﻣﺜﺎلاﻟﺒﺸﺮﻳﺔ
  ﺑﻌـﺾ  أنهـﺬا ﺑﺎﻻﺿـﺎﻓﺔ اﱃ   ﰱ ﳎﺘﻤﻌـﺎت ﺟﻨـﻮب اﻟـﺼﺤﺮاء، ﳌﻮﺟﻮدةﻌﺪﻻت اﳌﺗﻮﺟﺪ ﺑﻨﻔﺲ ا
ﴰﺎل اﻓﺮﻳﻘﻴﺎ وﳎﺘﻤﻌﺎت ﻣﻨﻄﻘﺔ   اﻟﱴ ﺗﻨﺘﺸﺮ ﺑﻜﺜﺮة ﺑﲔ اﺘﻤﻌﺎت اﻟﻌﺮﺑﻴﺔ وﳎﺘﻤﻌﺎتاﻷﻟﻴﻼت
 ,1040*1BPD ,1030*1BQD    ,1020*1BQD,   اﻟﻘﻮﻗ ــﺎز، ﻋﻠ ــﻰ ﺳ ــﺒﻴﻞ اﳌﺜ ــﺎل 
وﳝﻜﻦ ان ﻳﻌﻜـﺲ هـﺬا درﺟـﺔ اﳌﻌﺪل واﻟﱴ ﺗﻮﺟﺪ أﻳﻀﺎ ﰱ اﺘﻤﻊ اﻟﺴﻮداﱏ ﺑﻨﻔﺲ 2040*1BPD
  . ﳎﺘﻤﻊ اﻟﺪراﺳﺔاﺧﺘﻼط وﲤﺎزجﻋﺎﻟﻴﺔ ﻣﻦ 
 
رﺻـﺪهﺎ او   اﻻﺿﺎﻓﻴﺔ اﻟـﱴ ﱂ ﻳـﺴﺒﻖ  اﻷﻟﻴﻼت واﻟﻨﻤﻂ اﻟﻔﺮداﻧﻲوﺗﻌﺮﻓﺖ اﻟﺪراﺳﺔﻋﻠﻰ ﺑﻌﺾ
، 501070*wC,401040*wC,4120*wC,8140*wC وﺑـﺎﻷﺧﺺ اﺧﺘﺒﺎرهﺎ ﰱ ﳎﺘﻤﻌﺎت اﺧﺮى ﺣﱴ اﻻن، 
 ,3021*wC-1014*B ,1014*B-1023*A ,1014*B-4003*A ,0193*B-1020*A ﺑﺎﻻﺿ ــﺎﻓﺔ اﱄ
 ,1030*1BQD-1030*1BRD ,3021*wC-2042*A ,1070*wC-2003*A ,1040*wC-4003*A
 ، . 1020*1BPD-4080*1BRD dna ,1030*1BQD-2031*1BRD ,1020*1BQD-4080*1BRD
                  .                              واﻟﱵ ﳝﻜﻦ اﻋﺘﺒﺎرهﺎ آﻤﺤﺪدات ﳍﺬا اﺘﻤﻊ
 
                                 
ات ﺎد اﻟﻌﺎدﻳـﺔ واﻻﺳـﺘﺜﻨﺎﺋﻴﺔ ﳌـﻀ واﻟـﻨﻤﻂ اﻟﻔﺮداﻧـﻲ   اﻷﻟﻴﻼت ﻟﻘﺪ اوﺿﺤﺖ اﻟﺪراﺳﺔ ان 
 اﻟﺒﻴﻀﺎء اﻟﺒﺸﺮﻳﺔ اﻟﻜﺮﻳﺎت
اﻻﺻﺎﺑﺔ  ﳍﺎ دور ﰱ اﺣﺘﻤﺎﻟﻴﺔ اﻻﺻﺎﺑﺔ او اﳊﻤﺎﻳﺔ ﻣﻦ ) sepytolpaH dna selellA ALH( 
اﻟﺒﻴﺎﻧـﺎت  وﻋﻠﻰ اﻟﺮﻏﻢ ﻣﻦ ذﻟﻚ ، ﻟﻘﺪ ﺧﻠـﺼﺖ  )VIH( ﻰ اﻟﺒﺸﺮىﲟﺮض ﻧﻘﺺ اﳌﻨﺎﻋﺔ اﻟﻔﲑوﺳ
ﳏـﺪدات  اﳊﺎﻟﻴﺔ اﱃ ﻣﻌﻠﻮﻣﺎت ﺗﺪﻋﻢ دور ﻣﻀﺎدات اﻟﻜﺮﻳﺎت اﻟﺒﻴﻀﺎء اﻟﺒﺸﺮﻳﺔ ﺑﺎﻋﺘﺒﺎرهـﺎ 
 اﺿﺎﻓﺔ اﱃ ذﻟﻚ ﺧﻠﺼﺖ اﻟﻨﺘﺎﺋﺞ.  اﻟﺒﺸﺮيوراﺛﻴﺔ ﺗﻨﱮء ﺑﺘﻄﻮر ﻣﺮض ﻧﻘﺺ اﳌﻨﺎﻋﺔ اﻟﻔﲑوﺳﻰ
 ﻣﻊ اﻟﺒﻴﺎﻧﺎت ﻳﺘﻨﺎﺳﺐ ﳎﺘﻤﻊ اﻟﺪراﺳﺔ  اﻟﻌﺎدﻳﺔ ﰱ اﻟﻨﻤﻂ اﻟﻔﺮداﻧﻲ ﻟﻴﻼت و اﱃ ان وﺟﻮد اﻷ 
ﻟﺪﻳﻬﻢ ﳕﻂ   وانﺧﻠﻴﻂ ﻣﻦ ﳐﺘﻠﻒ اﻷﻋﺮاقاﻟﱴ ﺗﺒﲔ ان اﺘﻤﻊ اﻟﺴﻮداﱏ ﻋﺒﺎرة ﻋﻦ  اﻟﺘﺎرﳜﻴﺔ
  .اﺳــــ ــﺘﺜﻨﺎﺋﻰ ﳌــــ ــﻀﺎدات اﻟﻜﺮﻳــــ ــﺎت اﻟﺒﻴــــ ــﻀﺎء اﻟﺒــــ ــﺸﺮﻳﺔ 
  
وﻟﻘѧﺪ .  )%6.0( ﺗﻮﺟﺪ ﺑﻨﻔﺲ اﻟﻤﻌѧﺪﻻت اﻟﻤﻮﺟѧﻮدة ﻓѧﻲ اﻟﻤﺠﺘﻤﻌѧﺎت اﻷﻓﺮﻳﻘﻴѧﺔ 23∆-5RCCﻟﻘﺪ أوﺿﺤﺖ اﻟﺪراﺳﺔ ان ﻣﺴﺘﻘﺒﻼت
اﳌﻨﺎﻋـﺔ  ﻧﻘـﺺ ا  اﻷﻟﻴﻞ ﻻ ﻳﻠﻌﺐ دورا ﻣﻬﻤѧﺎ ﻓѧﻲ اﻻﺻѧﺎﺑﺔ ﺑﻤѧﺮض ﺬا اﻷﻟﻴﻞ ﻓﻲ أﺣﺪ اﻟﻤﺮﺿﻲ، ﻣﻤﺎ ﻳﺪل ﻋﻠﻲ أن هﺬوﺟﺪ ه
  .  ﻓﻲ اﻟﻤﺠﺘﻤﻊ اﻟﺴﻮداﻧﻲاﻟﻔﲑوﺳﻰ اﻟﺒﺸﺮى
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1. Introduction. 
 
Human Immunodeficiency Virus-1 (HIV-1) has caused one of the most devastating epidemics 
in recorded history. Despite our substantial progress in understanding its transmission and 
pathogenesis, we are challenged by the harsh reality that now in 2006 the epidemic shows 
little sign of slowing in a global context. HIV/AIDS is the leading cause of death and loss of 
productive life years in adults aged 15-59 years across the world (1). The virus debilitates the 
host’s immune defense primarily by infecting and depleting a crucial cell in the adaptive 
immune system, the CD4 helper T cell. The diminishing capacity to replace such cells results 
in a progressive disintegration of immune defense (2). 
 
Acquired Immunodeficiency Syndrome (AIDS) has killed more than 25 million people since 
it was first recognized in 1981, making it one of the most destructive epidemics in recorded 
history. Despite recent, improved access to antiretroviral treatment and care in many regions 
of the world, the AIDS epidemic claimed 3.1 million lives in 2005; more than half a million 
were children. The total number of people living with the human immunodeficiency virus 
(HIV) reached its highest level: an estimated 40.3 million people are now living with HIV. 
Close to 5 million people were newly infected with the virus in 2005 (3). 
 
Sub-Saharan Africa has been experiencing the worst public health and socioeconomic 
problems associated with the HIV/AIDS pandemic (4). 
 
By the end of 2004 the WHO African Region claimed close to two thirds of all the people 
living with HIV/AIDS worldwide. Some 26 million people in the region are living with 
HIV/AIDS, implying that 9% of adults aged 15–49 years are HIV-infected. Millions of people 
are in need of HIV treatment and care; an estimated 4.7 million need antiretroviral drugs 
(ARVs) (3). 
 
The Sudan is located between countries with low HIV prevalence to the north (Egypt and 
Libya) and those, to the east and south (Ethiopia and Uganda) with some of the highest rate in 
the world (5). 
  
Little is known about the HIV epidemic in the Sudan, according to estimates derived from the 
WHO/UNAIDS Meeting on HIV Estimation and Projection in 2003, 380.000 cases of 
HIV/AIDS had been reported in the Sudan. The average adult prevalence of HIV/AIDS is 
2.3% (6). 
 
Since the early years of the HIV epidemic, significant differences in the rate of disease 
progression have been observed (7). Although replication of HIV-1 produces disease, host 
factors appear to strongly influence these rates of replication in different persons, in that they 
account for a wide range of incubation periods observed for AIDS (8). 
 
A growing body of evidence suggests that host genetic factors play an important role in both 
susceptibility to HIV infection and progression to AIDS (9). More genetic factors seem to 
influence disease progression in HIV infections (10, 11). Among the host factors that have 
been shown to affect susceptibility to HIV infection and disease progression are chemokine 
receptor polymorphism, HIV-specific immune responses and polymorphisms in molecules 
that play a key role in antiviral immune responses (12). 
 
Several HLA genes or haplotypes appear to influence disease progression, although their 
effects are complex and may depend on interactions with other host genes (7). 
 
Numerous investigations have suggested an influence of HLA alleles and closely linked genes 
of the major histocompatibility complex (MHC) on HIV-1 disease progression (13). Some 
HLA class I and class II alleles were shown to be associated with protection against the 
disease progression, A*0202, A*0214, A*6802, B*18, DRB1*0102, DRB1*13 and 
DQB1*0603, while A*24, B*35, Cw*04, DR*11 were associated with susceptibility to the 
disease progression (14). 
 
Non-MHC genetic factors such as members of the family of receptors for β-chemokine 
receptor genes (CCR) and mannose binding protein (MBP) gene have also been proposed to 
determine the course of HIV-1 disease and also influence susceptibility to HIV infection (13). 
CCR5 is a major co-receptor for HIV-1 (15); it mediates together with CD4+ the virus entry 
into target cells (16). Some studies confirmed the protective role of homozygosity of a 32 base 
pair deletion in the chemokine receptor gene (CCR5-∆32), against HIV infection (17, 18). 
This has been linked to resistance to HIV-1 infection in exposed adults and to the delay of 
disease progression in infected adults (19) because the frame shift leads to a truncated protein 
not expressed on the cell surface (20).  
 The aim of this study was to study the effect of host genetic factors polymorphism, HLA and 
chemokine receptor CCR5, on HIV-1 disease progression in the Sudanese population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1. Human Immunodeficieny Virus (HIV). 
 
1.1.1. History. 
 
HIV is a human retrovirus that is related most closely to other animal lentiviruses. (21). 
Human immunodeficiency viruses type 1 and type 2 (HIV-1 and HIV-2) are the etiologic 
agents of acquired immunodeficiency syndrome (AIDS) in humans (22). 
 
The acquired immunodeficiency syndrome (AIDS) epidemic was first reported in New York 
and California in 1981, in previously healthy male homosexuals who presented with 
opportunistic infections and Kaposi’s sarcoma. The term AIDS was officially adopted in 
1982. The causative retrovirus, called Lymphadenopathy-Associated Virus (LAV), was 
identified first in 1983 by Montagnier and colleagues at the Pasteur institute in Paris (23). In 
1984, Robert Gallo and colleagues in the USA reported isolation from patients of a virus, 
which they called Human T-cell Lymphotropic Virus type III (HTLV-III) (24). 
 
Investigations confirmed the identity of LAV and HTLV-III. By international agreement this 
virus is referred to now as the Human Immunodeficiency Virus type 1(HIV-1). In 1985, 
another retrovirus of the HIV family was isolated from persons living in West Africa. This 
virus was called LAV-2 by the French, who found it in patients with AIDS or AIDS-related 
complex (ARC). The same virus was isolated from healthy West African prostitutes and also 
in Europe and America by other workers who called it HTLV-IV. This Virus is now referred 
to as HIV-2 (24). 
 
1.1.2. Acquired Immuno Deficiency Syndrome (AIDS). 
AIDS results from the depletion of CD4-positive T lymphocytes in HIV-infected individuals 
(22). The CD4+ T-lymphocyte is the primary target for HIV infection because of the affinity 
of the virus for the CD4 surface marker (25).The CD4+ T-lymphocyte coordinates a number 
of important immunologic functions, and a loss of these functions results in progressive 
impairment of the immune response (26). 
 
By killing or damaging cells of the body’s immune system, HIV progressively destroys the 
body’s ability to fight infections and certain cancers. People diagnosed with AIDS are 
susceptible to get life-threatening disease called opportunistic infections, which are caused by 
microbes such as viruses or bacteria that usually do not make healthy people sick (27). The 
clinical presentation of HIV ranges from asymptomatic infection to severe immunodeficiency 
manifesting as severe life-threatening infectious disease or malignancies (28). 
 
1.1.3. Structure and life cycle of HIV. 
 
The genome of HIV-1 is similar to that of other retroviruses. It is 10 kb in length and encodes 
a total of three structural proteins, two envelope proteins, three enzymes, and six accessory 
proteins (21, 29). 
 
Its membrane envelope contains two linked glycoproteins, gp 120 and gp 41, cleaved from a 
common precursor, gp 160. The gp 120 protein binds to CD4 and the virus enters cells 
carrying this marker. These include CD4 T cells and cells of the monocytes macrophage 
lineage, such as the dendritic cells of lymphoid tissue and skin (Langerhans’ cells) and the 
microglia of the central nervous system. HIV binds to specific receptors on the cell and may 
gain entry by endocytosis. Chemokine receptors such as CXCR-4 and CCR-5 appear to be the 
major HIV-1 co-receptors that mediate infection with T cell line-tropic and macrophage-tropic 
HIV-1 strains, respectively by the same mechanism (30) (Fig 1.1). 
 
The nucleocapsid of HIV contains four proteins, with the single stranded RNA genome, p24, 
p17, p9, and p7, which are cleaved from the p53 encoded by the gag gene of the virus. Also in 
the nuclear region is reverse transcriptase, which is a DNA polymerase that uses RNA as a 
template. 
 
Fusion of the viral surface with the host-cell surface is the first step in the life cycle of the 
virus. The process of HIV fusion into a host cell is determined by two discrete functional sites 
on the viral surface unit glycoprotein, gp120. First, a segment near  
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 1.1. HIV-1 structure and genomic organization 
 
 
the C terminus of gp120 directly binds to the CD4 molecule on the surface of a host cell. Next 
the third variable region loop of gp120, V3, mediates in virus fusion (31). 
 Fusion of the viral membrane with the cell surface membrane during infection by HIV type 1 
(HIV-1) involves collaboration between the CD4 receptor and a co-receptor. Co-receptors are 
seven transmembrane G protein-coupled receptors for pro-inflammatory chemokines. The 
major co-receptor for macrophage-tropic (M-tropic) HIV-1 isolates is CCR5, which is 
activated by the chemokines MIP-1α, MIP-1β, and RANTES, whereas that for T-cell-tropic 
HIV-1 isolates is CXCR4, which is activated by SDF-1. The gp120 envelope glycoprotein of 
HIV-1 forms a ternary complex with CD4 and chemokine coreceptors (32-34). 
 
HIV-1 replication is initiated by attachment of the virus to the cell surface via high affinity 
binding of the envelope glycoprotein to CD4 on the cell surface. Subsequently, the viral 
envelope fuses to the cell membrane, depositing the viral core in the cytoplasm (34). The 
genetic material of the virus, which is RNA, is released and undergoes reverse transcription 
into DNA. An enzyme, reverse transcriptase is necessary to catalyze this conversion of viral 
RNA into DNA. Once the genetic material of HIV has been reverse transcribed into DNA, 
this viral DNA enters the host cell nucleus where it can be integrated into the genetic material 
of the cell. The enzyme integrase catalyzes this process. Once the viral DNA is integrated into 
genetic material of the host, it is possible for HIV to persist in a latent state for many years. 
This ability of HIV to persist in certain latency infected cells is the major barrier to 
eradication or cure of HIV (21). 
 
Activation of the host cells results in the transcription of viral DNA into messenger RNA, 
which is then translated into viral proteins. The new viral RNA forms the genetic material of 
the next generation of viruses. The viral RNA and viral proteins assemble at the cell 
membrane into a new virus. Amongst the viral proteins is HIV protease, which is required to 
process other HIV proteins into their functional forms (21). 
 
 
 
 
 
1.1.4. Clinical manifestation and treatment 
 
The signs and symptoms of acute HIV-1 infection appear within days to weeks after initial 
exposure (35). The most common signs and symptoms include fever, fatigue, rash, headache, 
lymphadenopathy, pharyngitis, and yeast infections (oral or vaginal). 
Seroconversion to HIV-1 antibody positivity occurs within 3-12 weeks (36).  After years of an 
asymptomatic period, a considerable number of the patients develop AIDS characterized by 
the deficit and dysfunction of CD4+ T lymphocytes (37). The patients may begin to develop a 
spectrum of clinical conditions, after a variable period of years, as a result of the deteriorated 
immune system. The clinical manifestations of AIDS can include systemic, neurological, 
gastrointestinal, infectious and malignant complications. Some infected individuals progress 
after less than three years of infection (rapid progressors, RP), while others can remain 
asymptomatic for 10 years or more (long-term nonprogressors, LTNP), but the majority of 
cases, develop AIDS in 3-10 years (intermediate progressors, IP) (38). 
 
Most of the antiretroviral drugs used against HIV have been nucleoside analogues, which are 
incorporated by the RT into the growing viral DNA, leading to its termination. The most used 
anti-HIV agent in clinical trials is AZT (3’-azido-3’-deoxythymidine). It has been reported 
that the treatment of infected individuals with AZT decreases mortality rate, reduces 
frequency of opportunistic infections and increases the number of CD4+ cells. It has been 
shown that AZT in combination with another nucleoside analogue, 3TC (2’-deoxy-3’-
thiacytidine), reduces the risk of progression and death by 50% (36). 
 
Current therapeutic strategies include the use of a combination of drugs directed at different 
steps in the viral life cycle to maximize the magnitude and durability of virus suppression and 
minimize the emergence of escape mutants. Protease inhibitors are potent drugs that prevent 
the maturation of viral particles (36). 
 
The combination of two nucleoside analogues and one protease inhibitor, also known as 
highly active antiretroviral treatment (HAART), has been shown to dramatically decrease 
viral load, increase CD4+ counts, delay disease progression and prolong survival (39). 
Combination therapy offers the advantage of a greater reduction of viral load and a greater 
chance of preventing the emergence of drug-resistant mutants when compared to monotherapy 
(36). 
 
1.1.5. HIV in the Sudan. 
 The Sudan is the largest country in Africa with an area of 2.5 million square Kilometers. It 
shares lengthy borders with 9 African countries, some of which have high prevalence of 
HIV/AIDS. HIV/AIDS is a growing problem in Sudan. HIV probably started to spread in 
Sudan in the late 1970s or early 1980s. Although HIV prevalence was very low in Sudan 
during the early 1980s, it has been increasing since then (40). 
 
 Many factors facilitate the spread of HIV: geographical location of the country with 
extending border with other countries, some of which with high prevalence, as well as high 
population movement in Sudan, due to civil war, national disasters, economic factors and 
immigration for work (40). 
 
All states of the country are affected, but mostly Southern states, Eastern states and 
Khartoum. 12.369 cases of HIV/AIDS have been reported to the Sudan National AIDS 
Control Program, since the 1st case was described (40). However, the true number of 
HIV/AIDS cases in Sudan is not known. According to estimates derived from the 
WHO/UNAIDS Meeting on HIV Estimation and Projection in 2003, 380.000 cases of 
HIV/AIDS had been reported in the Sudan. The average adult prevalence of HIV/AIDS is 
estimated to be 2.3% (41). 
 
1.2. The major Histocompatibility Complex (MHC). 
 
The MHC gene complex, located on chromosome 6p21.3, contains many individual genes 
that regulate the immune function (42). Multiple genetic loci within the major 
histocompatibility complex (MHC) encode human leukocyte antigen (HLA) molecules (43), 
which comprise the most polymorphic set of genes known in humans (44-46) (Figure 1.2).  
 
More than 2000 different alleles are currently identified at the six main loci (121 at DPB1, 69 
at DQB1, 511 at DRB1, 748 at B, 217 at C and 429 at A) according to a recent record (47) 
(Table 1.1.). 
 
HLA class I and II molecules are polymorphic membrane glycoproteins found on the cell 
surface. Class I HLA molecules are expressed on all nucleated cells except germ cells, 
whereas class II HLA molecules are expressed on immunologically specialized cells, such as 
dendritic cells, B-cells, macrophages and activated T-cells. HLA molecules are recognized by 
T cells together with viral antigens. They are also targets of antibodies and cytotoxic T 
lymphocytes (CTL) during rejection of allogenic transplants (43). 
 
High levels of polymorphism are exhibited by class I and class II loci. The most polymorphic 
residues are concentrated in the peptide-binding regions of the molecules and alter their 
peptide-binding specificity (48, 49). There is some evidence that this genetic diversity is 
maintained in part by natural selection acting over long periods of time (50, 51). 
 
1.2.1. The organization of HLA genes. 
 
The genes that encode the HLA class I and class II alloantigens are closely linked to each 
other on the short arm of human chromosome 6. This part of the genome constitutes the 
human major histocompatibility complex (MHC) and is called the HLA complex (52). The 
HLA complex encompasses some four million base pairs of DNA.  
 
Within the HLA complex, three constituent regions are distinguished. Nearest the centromere 
of chromosome 6 is the class II region that contains the class II genes (DM, DP, DQ, DR); 
while nearest the telomere of the short arm of chromosome 6 is the class I region that contains 
the class I genes; classical genes (A,B,C) and non-classical genes (E,F,G) (53). In addition, 
there are HLA-H, -J, -K and –L, which are non-functional pseudogenes closely related in 
nucleotide sequence to the functional class I genes (52). 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
        Figure 1.2 HLA class I and class II since 1968 
 
 
 
 
 
 
 
 
  
 
 
Alleles Number 
HLA-A 473 
HLA-B 809 
HLA-C 256 
HLA-DRB1 541 
HLA-DQB1 71 
HLA-DPB1 125 
 
 
                    Table 1.1. Numbers of HLA alleles (July 2006) 
 
 
 
 
 
 
 
 
 Located between the class I and class II regions is the class III region. It contains some 75 
genes encoding a variety of different proteins, transporters for antigen processing (TAP), low 
molecular weight polypeptides of the proteasome, complement components factors 
(Bf,C2,C4), and tumor necrosis factors (TNF-α, TNF-ß) (52, 13) (Fig1. 3). 
 
1.2.2. HLA class I. 
 
MHC class I molecules are non-covalently linked heterodimers composed of two polypeptide 
chains; a heavy chain glycoprotein (α–chain) and a water-soluble light chain (β2-
microglobulin or β2m). The 45 KDa heavy chain is encoded within the MHC and spans the 
membrane bilayer, oriented with its N-terminal major portion on the outside of the cell. The 
exracellular portion of the heavy chain has been divided into three domains called α1, α2 and 
α3, composed of 90, 92, and 92 amino acids, respectively, and encoded by separate exons. 
Following the α3 domain is a membrane spanning-region of 25 amino acids and a cytoplasmic 
tail of 30 amino acids (54). 
 
The genes encoding HLA class I heavy chains have a characteristic structure in which 
different domains of the protein are encoding by separate exons. The leader peptide is 
encoded by exon 1, the three exracellular domains (α1, α2 and α3) are encoded by exons 2, 3 
and 4, respectively, the transmembrane anchor is encoded by exon 5, the cytoplasmic tail by 
exons 6 and 7, and the 3` untranslated region by exon 8. Exons of class I heavy chain genes 
consist of 1089-1101 nucleotides (including the termination codon) and encode heavy chains 
of 362-366 amino acid residues (54). 
 
The light chain (ß2m) is encoded by a gene on chromosome 15 for which no polymorphic 
variation in the expressed proteins has been discovered (52). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 HLA gene organization 
 
 
 
 
 
 
 
 
 
HLA-class I molecule consists of two pairs of structurally similar domains: α1 has the same 
tertiary fold as α2, while α3 has the same tertiary fold as β2m. The α3 and β2m domains are 
proximal to the cell membrane. They are both β-sandwich structures composed of two 
antiparallel β-pleated sheets, which resemble that of immunoglobulin constant regions, 
connected by a disulfide bond. Domains α1 and α2 form the top of the molecules with their 
helical sides facing away from the cell. They consist of an antiparallel β-pleated sheet spanned 
by a long α-helical region that is C-terminal to the four β-strands in the sheet (43).The two α-
helices form a deep cleft between them that functions as the binding site for antigenic peptides 
with a length of 8-10 amino acids (55). The β2m domain interacts extensively with all three α 
domains stabilizing the three-dimensional structure of HLA class I molecules (54). 
  
The HLA-A, -B and -C heavy chain genes are highly polymorphic. The antigenic 
polymorphism of HLA-A, -B and -C molecules is due to differences in the amino acid 
sequence of the HLA class I heavy chain. Most of these differences arise from nucleotide 
substitutions in exons 2 and 3. In contrast, the HLA-E and -G heavy chain genes exhibit only 
limited polymorphism (52). 
 
1.2.3. HLA Class II. 
 
The class II molecules are non-covalently linked heterodimers consisting of two 
transmembrane MHC-encoded glycoprotein chains, a 34 KDa α-chain and a 28 KDa  β-chain 
(54). HLA class II structure is similar to that of class I HLA. The two α-chain domains, α1 
and α2, of DR1 superimpose closely on the corresponding α1 domain and β2-m subunit, 
respectively, of class I HLA. The two β-chain domains, β1 and β2, of DR1 superimpose on 
the α2 and less closely on the α3 domains, respectively, of class I HLA (52). 
 
The extracellular part of both chains of class II molecules contains two distinct sections, the 
α1, α2 and β1 (94 amino acids), β2 (84 amino acids) domains, respectively. The membrane-
distal polymorphic α1 and β1 domains jointly form a peptide binding cleft consisting, like in 
class I molecules, of a β-pleated sheet with two α-helices resembles the groove in class I 
molecules but accommodates longer antigenic peptides with no apparent restriction on peptide 
length. The membrane- proximal conserved domains α2 and β2 are, like the α3 and β2m 
domains of class I molecules, similar to the constant domains of immunoglobulin heavy 
chains (54). 
 
The α-chains are encoded by A genes, the β-chains are encoded by B genes. Thus the genes 
encoding for the HLA class II antigens DR, DQ or DP are called DRA and DRB, DQA and 
DQB, DPA and DPB (54). 
 
HLA class II presents peptides derived from exracellular antigens to helper T cells as part of 
the mechanism for identifying foreign antigens and producing an immune response. HLA 
class II is polymorphic in the human population and different types selectively bind different 
sets of peptides (56). 
 
1.2.4. Functions of HLA molecules. 
 
The HLA region in humans controls immune response functions and tissue rejection and 
influences susceptibility to neoplasia, autoimmune diseases and infectious diseases including 
HIV (57). 
 
The function of the MHC molecules is to bind peptides and engage T cells to trigger an 
immune response. T cells recognize peptide antigens only when they are bound to MHC 
molecules on the cell surface (56). This may be self-peptide (i.e. peptides derived from the 
host’s own proteins) or foreign peptides derived from the proteins of parasites (58). 
 
During an infection, binding of peptides from the infectious pathogens to HLA proteins is the 
first step for initiation of the host-specific immune response (59). Products of these genes 
present antigenic peptide to T cells, initiating an immune response and clearance of the 
foreign material (44).  The peptide-binding groove on HLA molecules contains pockets which 
are binding sites for anchor residues in peptides; different HLA molecules have slightly 
different peptide-binding clefts and accordingly bind and present different sets of peptides to 
T cells (60). This difference is determined by polymorphic residues. Because of the extensive 
polymorphism of HLA in the population, the immune response against a pathogen will thus 
vary among individuals (61).  
 
In infected cells, HLA class I bind and present endogenous peptide fragments, synthesized 
and processed in the infected cells by intracellular bacteria and viruses,  to T-cell receptors on 
CD8+ T-lymphocytes, which are usually cytotoxic and cause lysis of the infected cells (62). 
Class II HLA display exogenously derived epitopes on the surface of antigen-presenting cells 
for immune recognition by CD4+ helper T-lymphocytes as part of the mechanism for 
identifying foreign antigens and producing cytokines that stimulate the immune response. (56, 
63) (Fig 1.4). 
 
1.3. Chemokine receptors structure and functions. 
 
1.3.1. Chemokine receptors structure. 
 
CC chemokine receptor 5 (CCR5) is a member of the G-protein-coupled receptor superfamily 
(64), which is a seven-transmembrane-spanning domain structure, which shared with other 
receptors; e.g., the rhodopsin and the thyrotropin receptors. It consists of three exracellular 
domains, three intracellular domains and seven transmembrane domains. Extracellular 
domains are involved in chemokine binding, while intracellular domains are involved in cell 
signalling (Fig 1.5) (65). 
 
It has as its natural ligands RANTES (regulated on activation normal T-cell expressed and 
secreted), MIP-alpha (macrophage inflammatory protein) and MIP-beta, which are members 
of the CC subfamily of chemokines (66). The chemokines are classified into two major 
families, according to the configuration of a conserved two-cysteine motif in their primary 
sequences. The β chemokines contains adjacent cysteine (C-C) are RANTES, macrophage 
inflammatory protein 1(MIP-1 α), MIP-1 β and the α-chemokine, in which the two-cysteine 
are separated by a single amino acid (C-X-C) is stromal cell-derived factor 1 (SDF-1) (67, 
68). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Figure 1.4 HLA mechanism of action 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  Figure 1.5 Structure of chemokine receptor (CCR5) 
 
 
 
 
 
 
1.3.2. Functions of Chemokine receptors. 
 
The effect of receptor-ligand interactions is usually mediated through G-protein coupled 
interactions. It leads to alterations in cell function such as activation, motion (69) or migration 
of the receptor-bearing cells toward injured tissues that secrete chemokines into the blood 
stream (70) along a chemokine concentration gradient; and vary depending on the chemokine 
bound and cell type. Some chemokine receptors have a role in infectious disease susceptibility 
or pathogenesis. (65). It is through this mechanism that leukocytes are recruited into sites of 
inflammation (71, 72). 
 
A second class of ligands for CCR5 were shown to be the envelope glycoproteins of 
macrophage-tropic (M-tropic) isolates of HIV-1 (73). The CCR5 proteins, in concert with 
CD4, mediate the internalization of HIV in macrophages and monocytes (74, 75). 
 
HIV-1 enters cells through an interaction involving chemokine receptors. The CCR5 
chemokine receptor that selectively binds RANTES, MIP-1 α, and MIP-1 β appear to be the 
main coreceptor for macrophage tropic or nonsyncytium-inducing (NSI) HIV-1 strains (76, 
77); these isolates are present early after seroconversion indicating their role in initiation of 
HIV-1 infection (71), whereas the T cell tropic or syncytium-inducing (SI) strains 
preferentially use the SDF-1 chemokine receptor CXCR4. Some HIV-1 isolates are dual 
tropic in being able to use both CCR5 and CXCR4 receptors (13). 
 
1.3.3. Chemokine receptors mutation (CCR5-∆32). 
 
The ∆32 bp deletion occurs at a site of a repeat motif in the CCR5 in the region corresponding 
to the second exracellular loop (78, 79) This deletion results in the loss of three of the seven 
transmembrane domains; two of the three outer loops and the intracellular signalling domain 
(65), results in a frame shift in the coding sequence (at amino acid 185) and a loss of HIV 
coreceptor activity (13).A 10-bp direct repeat flanking the deleted region on both sides is 
expected to have promoted the recombination an event leading to the deletion (80). It causes 
CCR5 to be retained in the endoplasmic reticulum resulting in reduced cell surface expression 
(71). 
 
 
On the basis of the geographic distribution of CCR5-∆32 allele, it has been estimated that the 
32-bp deletion occurred on the order of 4,000 years ago. Since that time, the allele has 
increased to a frequency of as high as 13% in Northern Europeans, but it is lacking in 
Africans and Asians (81). The frequency of this mutant allele is approximately 1% in the 
homozygous state and 10 to 20% for the heterozygous state among Caucasians in North 
America or Europe, but is lower or absent in subjects of African, Asian, and Latin American 
heritage (71, 82) and its frequency in African Americans (2%) can be explained by admixture. 
The rapid increase in frequency of this mutation over a relatively short period of time suggests 
that the CCR5-∆32 mutation has been subject to positive selection (71, 72). 
 
1.3.4. CCR5 gene organization. 
 
The gene is located in the p21.3 region of human chromosome 3 (83). It encodes for a protein 
of 352 amino acids with molecular mass of 40600 Da (84), and is organized into four exons 
and two introns. Exons 2 and 3 are not interrupted by an intron. Exon 4 contains the open 
reading frame, 11 nucleotides of the 5’-UTR and the complete3’-UTR. The transcripts appear 
to be initiated from two distinct promoters: an upstream promoter (Pu), upstream of exon 1, 
and a downstream promoter (Pd), that includes the intronic region between exons 1 and 3. The 
5’-UTR for these genes reside on multiple exons and alternative splicing may generate 
multiple mRNA isoforms (85, 86). 
 
1.4. Genetic control of complex diseases. 
 
Complex diseases generally do not exhibit classic Mendelian dominant, recessive or sex 
linked inheritance attributable to a single gene locus. Genetic dissection of complex disease 
phenotypes is complicated by several factors which complicate the search for genetic control 
because no single locus is strictly required in expression of phenotype (87). Thus, to 
understand complex diseases, it is essential to evaluate the role of both genetic and 
environmental factors in disease development (88). 
 
In animal studies, genetic dissection of complex trait can be done by setting of appropriate 
crossings to study the role of genetic factors in predisposition to diseases. Since in humans 
such type of studies cannot be done, genetic dissection is always carried out using statistical 
models for genetic analysis. 
 
1.4.1. Segregation analysis. 
 
Segregation analysis is a statistical method usually performed on family data to study the 
pattern of distribution of a phenotype in pedigrees. The analysis determines whether a 
phenotype is distributed randomly or whether a Mendelian locus is likely to exert a large 
effect on the phenotype distribution. The parameters usually estimated by segregation analysis 
include the allele frequencies, the genotype means (for quantitative traits) and the penetrance 
for each genotype (for qualitative traits), and the variance within genotype (89, 90). 
 
1.4.2. Linkage analysis. 
 
Linkage analysis is used to find the chromosomal location of a phenotype susceptibility locus. 
It is the next step in genetic analysis after segregation analysis. The approach to be taken in 
linkage analysis is usually determined according to the results of segregation analysis. If 
evidence for a major genetic control has been provided by segregation analysis, model based 
linkage analysis is usually recommended. This approach of linkage analysis is called “model 
based” because it considers the genetic model and its parameters that are provided by 
segregation analysis. On the other hand, when segregation analysis is not done or has 
provided no evidence for a major genetic control, linkage analysis is usually done taking the 
“model free” approach. The parameters estimated by linkage analysis include the allele 
frequencies, the penetrance, and the variance. This approach is powerful in detection of 
linkage when the parameters of the genetic model are correctly specified (91). 
 
In linkage analysis, two approaches can be used; the whole genome search in which all the 
human genome is screened for localization of the phenotype locus (92), and the candidate 
gene approach in which some chromosomal loci or genes that are expected to influence the 
phenotype are studied (93). 
 
 
1.4.3. Association studies. 
 
Association studies are the most popular type of genetic studies; they do not concern familial 
inheritance. An allele A at a gene of interest is said to be associated with a trait if it occurs at a 
significantly different frequency among affected individuals compared to unaffected controls 
(94). 
 
1.4.3.1 Case-control studies. 
 
The case-control association studies are based on comparison of unrelated affected and 
unaffected individuals from a population. The studies are particularly meaningful when they 
are performed with functionally significant variation in genes having a clear biological 
relation to the trait (94). 
 
The main disadvantage of the association studies is that it may be impossible to exclude the 
possibility that unrecorded differences between the cases and the controls (95). Thus, some 
other methods of analysis have been developed to overcome this problem; the family-based 
association studies in which the parent’s non-transmitted alleles are used as controls (96), and 
the transmission disequilibrium test for linkage (TDT) have been developed to overcome 
some of the limitations of the case control studies (97). 
 
1.4.3.2. The transmission linkage disequilibrium test. 
 
The classical TDT is a test for association that uses data of affected individuals and their 
parents. The test can be used to detect linkage in the presence of linkage disequilibrium (97). 
The parents should be heterozygous for the marker allele under study. The test looks whether 
the affected siblings have inherited the allele under study at a frequency higher or lower than 
0.5, the expected value under random assortment (98). 
 
In the field of infectious disease several association studies were performed. Examples are the 
studies in P. falciparum malaria, the increased risk to cerebral malaria was found to be 
associated with a polymorphism in the TNF-α promoter region. The polymorphism is 
associated with increased expression of the TNF-α gene (99, 100). Furthermore, HLA-B53 is 
associated with protection from severe malaria (101), whereas HLA-DQB1*0201, DR3, and 
DR7 were strongly associated with insulin-dependent diabetes mellitus (IDDM) (102). 
Studies in HIV-1 infection reported association of several HLA alleles with the disease 
susceptibility and progression (12-14). Furthermore, the mutation in the chemokine receptor 5 
(CCR5) due to a 32 base pair deletion (∆32) that results in truncated receptor which is 
associated with protection against HIV-1 infection (86, 103). The benefits of identifying 
disease-associated genes include: 
1. Better risk prediction for individuals and populations will be of value in management 
of the disease and planning of the control programs. 
2. Better understanding of the pathophysiology of the disease. 
3. Better understanding of the natural resistance to infectious pathogens and opening of 
new avenues in therapeutics and vaccination (95, 98). 
 
The present study is an example of the application of the case control association studies in 
the field of the genetics of complex diseases. 
 1.5. HIV and host genetic factors. 
 
Infection with HIV-1 and progression to its end-stage manifestation, AIDS, are controlled by 
numerous factors. Human genetics is believed to be one of these factors because not all people 
exposed to HIV become infected with the virus (104).  
 
1.5.1. HIV and HLA. 
 
Human allelic variants influence the susceptibility to HIV-1 infection and/or the subsequent 
rates of disease progression towards AIDS that average approximately 10 years (105). 
 
Effects of host genetic diversity on susceptibility or resistance to HIV-1 infection have been 
documented for several HLA loci (106). The role of host HLA genes in AIDS progression has 
been examined in different populations and among most major risk groups (107). Certain 
MHC class II alleles have been associated with protection against HIV-1 infection and/or 
better control of infection or rapid progression upon infection (108, 109). 
 
Many cohort studies have looked for associations between HLA alleles and HIV disease 
progression; a number of alleles were associated with nonprogression, such as B14, B27, B57, 
C8 and C14, whereas A29, B22, B35, C16 and DR11 favoured rapid progression (59). A 
significantly lower frequencies of DRB1*14 and DQA1*0103 alleles were found in the 
seropositive individuals when compared with HIV-negative controls (110). B*18 has also 
been found to predict slower progression of HIV disease (111). 
 
Several cohort studies examining HLA associations in HIV-1 infected persons have suggested 
that heterozygosity of HLA class I loci is associated with the delayed onset of AIDS (112). 
Strong association of HLA-B*35 heterozygotes with rapid progression was observed, whereas 
even more rapid AIDS progression was observed among HLA-B*35 homozygotes. Similarly, 
HLA-Cw*04 heterozygosity promotes rapid progression as does HLA-Cw*04 homozygosity. 
One mechanism to explain rapid progression to AIDS in individuals with certain HLA 
genotypes may involve the regulation of the natural killer (NK) cell activity. A number of 
studies have indicated that rapid disease progression after HIV-1 infection is correlated with 
decreased NK cell activity. Like CTLs, NK cells are involved in surveillance and killing of 
virus infected cells through a mechanism involving HLA molecules (44). 
 
Several studies have reported different findings, depending on the populations analyzed; 
accordingly HLA alleles associated with the susceptibility or resistance to HIV-1 infection are 
different among different ethnic groups (113). In Caucasians, HLA-DQB1*0203 and 
DRB1*01 exhibited a decreased frequency in HIV-1 patients while DRB1*13 was observed 
more frequently (114). Also, DQB1*0603 and DQB1*0303 were found to be positively 
associated with HIV-1 infection in Caucasians but not African Americans, whereas 
DQB1*0201 was found to be associated with HIV-1 infection in African Americans (57). 
  
Significant differences in population frequencies between the Botswana study population and 
North American Caucasians were found in the DRB1*04, DRB1*07, DRB1*08, DRB1*11, 
DRB1*13 and DRB1*14 allele groups (12). 
 
HLA-B*27 and HLA-B*57 show robust protection against AIDS progression relative to all 
other HLA class I alleles, whereas certain HLA-B*35 (115, 116) show strong influence on 
susceptibility to developing AIDS rapidly (117-119). Consistent with previously findings on 
B*57 in Caucasian populations, a study in Rwandans revealed the favourable effects of 
B*5703 on HIV-1 slow disease progression, whereas B*5701 in Caucasians has the same 
effect (120). HLA-B*5703 seems to be a highly protective allele against the progression of 
HIV infection (121, 122). In contrast, these alleles were significantly decreased in Asians 
population (37). 
 
Certain class II DR5 and DR6 alleles were associated in some studies with rapid progression 
to disease (123-125), but correlate with slow disease progression in another study (126). 
Several HLA genes or haplotypes appear to influence disease progression, although the effects 
are complex and may depend on interactions with other host genes (7).Two extended 
haplotypes, HLA A1-Cw7-B8-DR3-DQ2 and HLA A11-Cw4-B35-DR1-DQ1, were found in 
several studies to be associated with a faster progression to AIDS. Associations were also 
reported between faster HIV-1 disease progression and other HLA types: A23, A24, A26, B21 
and B38. Conversely, some studies have shown association between delayed AIDS 
progression and DR4, DR7, B17, B27, B51 and B57 (13).  
 
HLA-B*57 is found in haplotypes with at least 7 other class I antigens in Caucasians and 
African populations alone. In Rwandans, the B*57-Cw*07 haplotype was common, whereas 
B*57-Cw*06 is predominant in European Caucasians (120). 
 
The haplotype analysis revealed that DRB1*1501-DQA1*0102-DQB1*0601, DRB1*0405-
DQA1*0302-DQB1*0401 and DRB1*1401-DQA1*0104-DQB1*05031 were found to be 
significantly higher in HIV seropositive individuals compared to HIV negative controls, but 
DRB1*1501-DQA1*0102-DQB1*0502 was significantly lower. The DRB1*1602-
DQA1*0101-DQB1*0502 haplotype was found to be significantly higher in HIV seropositive 
individuals when compared to HIV negative controls but the DRB1*1502-DQA1*0101-
DQB1*0501 haplotype was lower (110). Thus, in this study we aimed to study the HLA 
diversity in different Sudanese ethnic groups to help to identify the mechanism by which HLA 
alleles may affect the disease progression. 
 
 
 
1.5.2. HIV and CCR5-∆32. 
 
Some studies confirmed a protective role of homozygosity of a 32 base pair deletion in the 
chemokine receptor gene (CCR5-∆32) against HIV infection (103,127, 128).The homozygous 
state for the CCR5-∆32 allele has been shown to be associated with a high degree of 
protection against HIV infection in vivo. Individuals homozygous for CCR5-∆32 display no 
clinical symptoms and appear to be healthy. This protection is not absolute as demonstrated 
by identification of one HIV-1 CCR5-∆32 homozygote (129). Other homologous chemokine 
receptors bind an overlapping set of chemokine ligands and may compensate for the absence 
of CCR5 (71). 
  
 Another effect includes slow progression to AIDS after HIV-1 seroconversion in individuals 
heterozygous for the mutation (130). However, no evidence was found to suggest that 
heterozygotes were protected against HIV-1 infection, but a limited protective role against 
disease progression was noted (131). 
 
Rare cases of HIV-1 infection in the absence of CCR5 have been reported (132-134), 
suggesting that T-tropic viruses may also initiate HIV-1 infection in rare cases (135). 
 1.6. Population genetics. 
 
There is a genetic basis to the most common immune-mediated diseases. Identifying disease 
susceptibility genes, however, has been a challenge. The underlying principle in human 
genetics is that genetic diversity is the basis for inherited phenotypic variability, including 
susceptibility to common diseases (136). 
 
DNA sequencing and polymorphism have widely been used to study ethnic groups in order to 
outline population history and to detect their possible migrations and interactions with 
neighbours over time. However, highly polymorphic DNA variants are often able to define 
population or ethnic groups and thus allow inferences about their historical-prehistorical 
interactions (137). 
 
Different populations have been analyzed with classical markers, i.e. blood group systems and 
serum proteins polymorphism, and more recently using mitochondrial DNA (mtDNA) and Y 
chromosomal variation (138, 139). 
 
The HLA system has proven to be a useful marker in human population genetics to define 
ethnic groups even when its polymorphism was still low (140), because they are extremely 
variable and because new molecular techniques allow large-scale analyses of DNA 
frequencies (141). It is also very informative in anthropological studies, where it is used to 
describe population genetic relationships in relation to past migration events (142). 
 
HLA genes and haplotypic frequencies in normal population are important in anthropological 
studies, disease susceptibility studies and transplantation. HLA population genetic studies 
have been performed on numerous population samples. However, few data have been 
collected on HLA class I and class II polymorphism in North African and Arab populations 
(143). 
 
The extensive body of knowledge about the function and structure of MHC molecules makes 
evolutionary, population genetics and medical research on MHC unique, as molecular, 
functional and immunological information relationship (58).  
 
The existence or absence of gene flow among neighbouring populations (142) and among 
ethnic groups may be assessed by studying HLA frequencies and corresponding genetic 
distances (144). HLA allele frequency distributions as well as pattern of linkage 
disequilibrium significantly differ among different human populations (145). 
 
Other molecular markers, like mitochondrial DNA (mt DNA) and Y chromosome (146), are 
widely used for this type of research. They are also subject to selection since they are linked 
to diseases similar to HLA alleles. Microsatellites are more risky to use since their location in 
the genome is not always known (some of them are located in introns), and their biological 
significance is sometimes doubtful. In addition, their Mendelian inheritance does not always 
occur and they are often unable to define populations, probably because of their low degree of 
polymorphism (147). 
 
1.6.1. Sudanese Population. 
 
Sudan is the largest country in Africa, with a land mass approximately the size of Europe, and 
a population of about 30 million (148). Sudan’s advantageous geographic location has made it 
the recipient to the migrations of many people of different ethnic origins. Sudan’s ethnic and 
linguistic diversity remained one of the most complex in the world in the 1990s. It is 
comprised nearly 600 different ethnic groups speaking over one hundred languages and 
dialects (149), many of them intelligible to only a small number of individuals (150). Most of 
population is in the North, comprised principally of Arabic-speaking Muslims groups (151), 
whereas Southern Sudan is largely populated by black African ethnic groups who are mostly 
Christian or follow traditional indigenous religions (148). The population is composed of 
many endogamous tribes of either original Negroid or mixed Arab-Negro ancestry (149, 152). 
The aboriginal Negroid tribes include the Nilotes, Nuba and Fur, while the Gaalin, Hawazma, 
Messeria and Beja are some of the important Arab tribes (152). 
 
Language differences have served as a partial basis for ethnic classification and as symbols of 
ethnic identity (150). According to the most widely accepted classifications, proposed by 
Greenberg, these languages belong to four major families: Khoisan, Niger-Kordofanian, Nilo-
Saharan and Afro-Asiatic. Three of these are represented in Sudan; they are Afro-Asiatic, 
Nilo-Saharan and Niger-Congo, a branch of Niger-Kordofanian (150,153).   
These populations have not been studied extensively for genetic markers (149), however, 
some studies of blood genetic markers (149, 152), as well as HLA (154,155) were carried out. 
 
 
 
 
 
 
 
 
 
1.7. Objectives of the study. 
 
1. To determine HLA class I and class II allele frequencies in HIV-seropositive subjects and 
compare them with matched healthy control subjects. 
2. To study the relationships between HLA class I and class II alleles and the progression to 
AIDS. 
3. To determine the mutation in the chemokine receptor gene (∆32 CCR5) in the population 
and its association with the disease. 
4. To study the genetic diversity of HLA class I and class II alleles in the Sudanese population 
and the major ethnic groups and to compare them to other populations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Subjects, Materials and Methods. 
  
2.1. Subjects. 
2.1.1. Study area. 
 
This study was conducted in Khartoum state. Samples and data were collected from Khartoum 
Teaching Hospital, in the period between August 2003-April 2004. 
 
2.1.2. Study population. 
 
The study population consisted of 120 confirmed adults HIV-1 seropositive patients at various 
stages of the disease, who presented to the hospital for follow-up, were enrolled in this study. 
Informed consent was obtained from the patients before being enrolled in the study. Full 
history and detailed symptoms of illness were taken from each patient (appendix1). 
 
200 healthy individuals matched by sex, age and ethnicity were included as control group. 
The study population represented the 3 major ethnic groups, Afro-Asiatic, Nilo-Saharan and 
Niger-Congo (153). 
 
Institutional ethical approval for this study was obtained from the Research Board- Faculty of 
Medicine- University of Khartoum. 
 
2.2. Materials. 
2.2.1. Sample collections and storage. 
 
5 ml peripheral venous blood was collected in EDTA tubes. 500 µl blood was kept in 1.5ml 
Eppendorf tubes for DNA isolation. The rest was centrifuged for 10 minutes, the plasma 
separated and kept frozen at -20°C, and the puffy coat was also kept at -20°C for further DNA 
isolation if required.  
 
 
 
 
2.2.2. Instruments. 
 
1. Thermal cycler (GeneAmp PCR System 9700 Thermal cycler, Applied Biosystems, 
Foster City, CA), used to perform SBT-PCR amplification reactions, purification of the PCR 
products and sequencing reactions.  
2. Centrifuge. 
3. Vortexer. 
4. Microplates. 
5. Micropipettes and filter tips. 
6. Multichannel pipettes. 
7. Water bath. 
8. Robots for DNA isolation, amplification and sequencing reactions. 
9. Electrophoresis and gel documentation system.  
10. Automated DNA Sequencer (ABI 3100 and 3730 Genetic Analyzer, Applied 
Biosystems, Foster City, CA), used to perform the sequence analysis of the HLA class I and 
class II and CCR5.  
 
2.2.3. Chemicals. 
 
1. Commercial kits for: 
• DNA isolation (FlexiGene Kit, Qiagen-Hilden- Germany and NucleoSpin® Blood 
QuickPure kit, Machere-Nagel, Düren, Germany).  
• Whole genome amplification (REPLI-g Kit, Qiagen, Hilden, Germany). 
•  PCR amplification (Amplification Unit, S3 – S4 HLA Sequencing Kits, Protrans, 
Hockenheim, Germany). 
• Sequencing (Sequencing Unit, S3 – S4 HLA Sequencing Kits, Protrans, Hockenheim, 
Germany). 
• Dye Terminators 1.1 (Ready Reaction Dye Terminator Mix, Applied Biosystems, 
Darmstadt, Germany)  
•  Montage SEQ96 Sequencing Reaction Cleanup Kit (Millipore, Schwalbach, Germany). 
  were used according to the manufacturer’s instructions. 
2. HPLC water, molecular biology grade agarose gel, ethidium bromide solution    (10mg/ml) 
and TBE buffer (Sigma-Aldrich, Steinheim, Germany) 
3. Sephadex G-50 Fine DNA grade (Amersham Biosciences, Freiburg, Germany) 
4. AmpliTaqGoldTM DNA Polymerase (5U/ µl) (Applied Biosystems, Darmstadt, Germany) 
 
2.2.4. Software. 
 
Protrans Sequence PilotTM Allele Identification Software Version 2.1. and 2.2 (Protrans, 
Hockenheim, Germany). This program performs  HLA class I and class II allele identification, 
allows manual reviewing or editing of the sequencing data as well as reporting, exporting and 
archiving of sequences and results. It consists of 3 parts: 
 
1. Lis: 
Creates the order list, which includes the sample ID, the genes to be analyzed and the analysis 
profile (resolution desired and type of amplification unit used). 
 
2. Sequence Assistant: 
  Controls the complete sample management  process following DNA isolation. 
a. Creates pipetting schemes, used to document the pipettings of samples for PCR 
amplification, which can be used for manual processing or transferred to the PCR set-up 
robot. It is compatible with 96-well formats. 
b. Creates pipetting schemes for sequencing reactions, after identification of the agarose 
gel-based or fluorescence-based read-outs of the multiple primer mixes which are then further 
processed by the soft ware, which selectively picks the positive PCR products for sequencing. 
c. Automatically chooses the sequencing primers, depending on the PCR result, as well 
as the direction of sequencing which should be used for each PCR amplification mix to 
perform sequencing reactions.  
 
 
 
 
 
3. SeqPilot: 
Analyzes the sequencing data and performs allele assignment. 
1. Pairs or joins the sequencing result files that belong together to the same order (forward and 
reverse sequencing direction of the same PCR product, different exons of the same PCR 
product). 
2.  Starts allele identification for paired or joined result files by comparing the result 
sequences with the HLA sequence library. The HLA library is updated with each new 
Sequence Database release of the HLA informatics group (www.anthonynolan.com/HIG). 
3. Displays the electropherograms and result of allele assignment, edit and reanalyze the result 
sequences if required. 
4. Validates allele identification, saves data in the result database, and pints the final report for 
documentation. 
 
2.3. Methods. 
2.3.1. DNA isolation. 
 
DNA was isolated from the whole blood. 0.25µl Proteinase K was added to200µl whole blood 
in a 1.5µl microcentrifuge tube, then 200 µl of the lysis buffer was added and the sample was 
vortexed for 10 seconds and incubated at 70°C for 10 min. 200µl of absolute ethanol was 
added and vortexed for 10 seconds. The samples were transferred to the NucleoSpin® Blood 
QuickPure Columns and centrifuged at 14000xg for 1 min; then the flow-through was 
discarded. 
 
200 µl washing buffer was added to the column and centrifuged at 14000xg for 1 min, then 
350 µl washing  buffer were added and centrifuged at 14000xg for 3 min. The flow-through 
was discarded. The column was placed in a 1.5 ml microcentrifuge tube and a prewarmed 
HPLC-H2O (70°C) was added, the sample was incubated at room temperature for 1 min and 
then centrifuged at 14000xg for 1 min. The column was then discarded and the DNA was 
stored at -20 °C until used. 
 
 
 
 
2.3.2. Whole Genome Amplification (WGA). 
 
In order to get a high DNA quality, WGA was used. It is based on Multiple Displacement 
Amplification (MDA) technology, in which DNA polymerase moves along the DNA template 
strand displacing the complementary strand. The displaced strand becomes a template for 
replication and allows high yields of molecular weight DNA to be generated. 
 
It carries out isothermal genome amplification utilizing a uniquely processive DNA 
polymerase capable of replicating 100kb without dissociating from genomic DNA template. 
The DNA polymerase has a 3`→5` exonuclease proofreading activity to maintain high fidelity 
during replication and is used in the presence of exonuclease resistant primers to achieve a 
high yield of the DNA product. 
1 µl of the previously prepared DNA was placed into a 1.5 ml microcentrifuge tube and 
suspended in 0.75 µl TE buffer, then 1.25 µl freshly prepared denaturation buffer was added 
(390 µl HPLC-H2O+ 100 µl 2M KOH+ 10 µl 0.5 EDTA) and the sample was incubated at 
room temperature for 3min. 2.5 µl neutralization buffer was then added to the sample. Then 
19.5µl of the master mix was added (13 µl HPLC-H2O+6.25 µl REPLI-g buffer, 4x +0.25 µl 
REPLI-g DNA polymerase).The sample was incubated in a thermal cycler as follows: 
 
                               30°C for 16 hours 
                               65°C for 10 min.     (To inactivate REPLI-g DNA polymerase). 
                               8°C for ever            (Terminal cooling) 
Then the DNA was kept at -20 until further use.  
 
2.3.3. Amplification  Reaction (SBT-PCR). 
 
2.3.3.1. For HLA Amplification. 
 Amplification reactions for HLA class I and class II were carried out as previously described 
by Kotsch et al (156,157). A master mix for each DNA sample was prepared of 280 µl PCR 
solution (PSD) and 3 µl AmpliTaqGoldTM DNA Polymerase (5U/ µl). After vortexing, 15 µl 
of the master mix was added to the negative control well. Then 20 µl DNA was added to the 
master mix, vortexed and dispensed to the prepipetted primer mixes, which have been 
designed to be specific for a single group of alleles only. The plate was sealed and placed in 
the thermal cycler under the following conditions: 
                                  95°C, 2min            (Initial denaturation) 
               15 cycles: 96°C, 40 sec          (Denaturation) 
                                  64°C, 1min            (Annealing)  
                                  72°C, 2min            (Extension) 
               15 cycles: 96°C, 20 sec          (Denaturation) 
                                  60°C, 1min            (Annealing)  
                                  72°C, 2min            (Extension) 
               10 cycles: 96°C, 20 sec          (Denaturation) 
                                 56°C, 1min             (Annealing)  
                                 72°C, 2min             (Extension) 
                                 8°C, forever           (Terminal cooling) 
 
2.3.3.2. For CCR5 Amplification. 
 
The region of the CCR5 gene flanking the ∆32 deletion (nucleotide 518-700) was amplified. 
A master mix  for each sample was prepared as follows: 
10.175µl  HPLC-water 
1.5µl 10x PCR.SBT buffer 
1.5µl Betaine (5M) 
0.3µl dNTPs (10mM) 
0.1875 µl CCR503 F (20µM) 
0.1875 µl CCR504 R (20µM) 
0.15µl Taq gold  
 
14µl   Total 
Tailed amplification primers flanking the deletion region (32 bp) were designed for PCR 
amplification 
Sense           5´CAG GAA ACA GCT ATG ACC …CCC AGG AAT CAT CTT TAC CAG 3` 
Antisense   5`TGT AAA ACG ACG GCC AGT… TGA AGA TAA GCC TCA CAG CC 3` 
Then 1µl DNA was added. The same thermal cycler program as for HLA amplification was 
used. 
 
2.3.4. Characterization of PCR products. 
 
2 g of DNA-grade agarose was placed in a flask and 100 ml of TBE buffer (10ml 5 fold TBE 
and 90ml deionized water) was added and mixed. Then the mixture was heated. 
The solution was cooled on the bench-top for a minute and 3 µL ethidium bromide (10µg/ml) 
was added. 
The gel was poured into a gel-casting plate with microplate-compatible 8-teeth combs in place 
and allowed about 20 minutes to set. The comb was removed and the solid gel was transferred 
to the gel tank with TBE buffer covering the gel (submarine electrophoresis).  
 
Then 5 µl of each PCR product was added to 2µl of agarose gel-loading buffer (25% Ficoll 
400; 0.25% Bromophenol blue; 0.25% Xylolcyanol). The samples were then loaded into the 
wells and electrophoresed at 200 mV for 20 minutes. 
The gel was viewed and photographed on the UV illuminator using MP-4® Polaroid camera 
with a yellow filter and Polaroid Polaplan 667 film. An amplification reaction is considered 
positive if an intensive PCR fragment occurs. Depending on the HLA alleles present in the 
DNA sample to be investigated one, two, three or four primer mixes could be positive 
 
2.3.5. Purification of the PCR products with ExoSap-IT. 
 
This method was used to purify the positive PCR products before using them as sequencing 
templates for sequencing reactions, because residual PCR primers and dNTPs can interfere 
with the sequencing chemistry resulting in lower data quality. It utilizes two hydrolytic 
enzymes, Exonuclease-I and Shrimp Alkaline Phosphatase in a specially formulated buffer 
(USB, Cleveland, USA). Exonuclease-I degrades residual single- stranded primers and any 
single-stranded DNA produced in the PCR, while the Shrimp Alkaline Phosphatase 
hydrolyzes remaining dNTPs from the PCR mixture. 
 PCR products with the least specificity overlap were chosen for purification. 3 µl ExoSap-IT 
was added to 10 µl of the selected PCR product in a 96-microplate, which was then 
centrifuged briefly and incubated in a thermal cycler under these conditions: 
                  
                   37 °C, 15min                (to degrade primers and dNTPs) 
                   80 °C, 15min                (to degrade enzymes) 
                   8 °C,    forever              (Terminal cooling) 
 
2.3.6. Sequencing reaction. 
 
2.3.6.1. For HLA. 
 
The Big DyeTM Terminator Cycle Sequencing Ready Kit Version 1.1 (BDT), which contains 
AmpliTaqTM  DNA Polymeryase FS and the four ddNTPs with different fluorescence labels, 
was used to perform the class I and class II sequencing reaction as previously described 
(156,157). 
 
The freezed BDT and sequencing primers were thawed at room temperature and spinned at 
2000 rpm for 10 seconds before use. 
In a microplate, 1 µl BDT was mixed with 1 µl HPLC water and 6 µl sequencing primer, 
forward or reverse primer for each sequencing reaction. For HLA class I, exon 2 and 3 were 
sequenced in both directions, while in HLA class II only exon 2 in both directions was 
sequenced. Then 2 µl of the purified PCR product was added to each sequencing reaction, 
mixed and placed in the thermal cycler under the following conditions: 
 
                                      96°C, 1min             (Initial denaturation) 
                    25 cycles: 96°C, 10 sec         (Denaturation)  
                                      50°C, 5 sec           (Annealing)  
                                      60°C, 4min            (Extension) 
                                      8°C, forever           (Terminal cooling) 
 
 
 
 2.3.6.2. For CCR5. 
 
The method has been used for HLA sequencing was used with slight modification to sequence 
the CCR5 alleles. 1 µl BDT was mixed with 5 µl HPLC water and 2 µl sequencing primer, 
tail-specific primers (M13F, -21M13R) forward or reverse primer, respectively (Protrans, 
Hockenheim, Germany). Then 2 µl of the purified PCR product was added to each sequencing 
reaction, mixed and subjected to thermal cycling under the same conditions as with HLA. 
 
2.3.7. Sequencing reactions purification. 
 
2.3.7.1. Sephadex columns. 
 
It removes contaminating salts and unincorporated dye terminators from DNA sequencing 
reaction products. Sephadex columns were prepared as follows: 
 
2 gm Sephadex G-50 was added to 24 ml HPLC water, which is enough for 30 columns, 
mixed and incubated for 30min in a 50ml Falcon tube at room temperature. Then the 
sephadex was dispensed into closed DyePUR columns filling for ¾, which were then 
transferred in 2ml receiver tubes. 
 
Columns were centrifuged at 2000xg for 2min to remove the HPLC water. Then columns 
were transferred into marked 1.5 ml collection tubes. The sequencing reactions were then 
pipetted on the centre of the sloping Sephadex surface and centrifuged at 2000xg for 1min to 
remove unincorporated dye terminators. The columns were discarded and the purified 
sequencing reactions were transferred into a microplate to be placed in the sequencer for 
further analysis. 
 
2.3.7.2 Montage SEQ96 Sequencing Reaction Cleanup Kit. 
 
20µL injection solution was distributed in the sequencing reaction plate, and then 30µL were 
transferred into the SEQ96 Filterplate Millipore, which was placed on the vacuum manifold. 
Vacuum was set for 800 mbar and applied for about 5min until the solution was completely 
removed from the wells. The vacuum source was then shut off for about 4min. 25µl injection 
solution were added to the filter plate for washing, vacuum was applied for about 4min until 
the solution was completely removed from the wells. The vacuum source was then shut off for 
about 4min. 30µl injection solution was added again to resuspend the purified sequencing 
reaction products. Finally 25µl purified sequencing reaction products were transferred to a 
new plate.  
 
2.3.8. Electrophoresis on the sequencer. 
 
Plates that contained sequencing reaction products were placed directly in the sequencer if 
they were purified with Montage SEQ96 Sequencing Reaction Cleanup Kit, or prepared for 
electrophoresis by adding 90µl HPLC water to the sequencing products in a 96-well 
microplate if they were purified with Sephadex columns.  
 
The plate was placed in the sequencer, which contains either 16 (ABI 3100) or 48 (ABI 3730) 
capillaries filled with a denatured polymer (ABI Prism® 3730 POP-7TM Polymer, Applied 
Biosystems). The mixture of strands, all of different length and all endings on a fluorescently 
labelled ddNTP have to be separated. DNA has a negative charge and migrates to the positive 
side; they are separated on their sizes. The fluorescently labelled molecules were passing a 
laser beam. The laser excites the fluorescent molecule, which sends out light of a distinct 
wave length. That light is collected and focused by lenses into a spectrograph. Based on the 
wave length, the spectrograph separates the light across a CCD camera (charge coupled 
device). Each base has its own colour, so the sequencer can detect the order of the bases in the 
sequenced gene. 
 
2.3.9. Allele assignment. 
 
Result files from the sequencer were then imported to the SeqPilot software, which 
automatically joins result files that belong together and have to be analyzed together (forward 
and reverse sequences, different exons from the same PCR product). Allele identification was 
started by comparing the result sequences with the HLA sequence library. The 
electropherograms and result of allele assignment were displayed to be used to check the 
results by editing or re-analyzing the result sequences, if required. Then the results were 
validated, printed and archived. 
 
For CCR5 analysis, the resulting sequences were compared with previously published 
sequences. 
 
2.3.10. Statistical Analysis. 
 
The statistical package for social sciences (SPSS version14.0 for windows, Chicago, IL, USA) 
software was used for the statistical analysis for the analysis of the clinical and other 
characteristics of patients and control groups. Simple frequency distributions cross tabulation, 
descriptive statistics, chi-square tests (or odds ratio); two-tailed Fisher’s exact tests were used 
when applicable.  
 
Alleles and haplotypes frequencies were calculated using chi-squire test. The odds ratio (OR) 
and its 95% confidence interval (CI) were computed to estimate the degree of association 
between the presence of the allele and the disease. Two –locus haplotypes were tested for 
linkage disequilibrium by computing the correlation coefficient between the two alleles and 
tested by x2 test. P-value < 0.05 was considered significant for testing the hypothesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Results 
 3.1. Introduction. 
 
In this hospital-based study we aimed to study the HLA class I and class II allele frequencies 
distribution among HIV/AIDS patients, since HIV/AIDS is now a growing health problem in 
Sudan. 
  
Of the 320 individuals who participated in the study, 120 individuals (37.5%) were HIV 
infected; 80 (66.7%) of them were males and 40 (33.3%) were females. A control group of 
200 individual (62.5%) consisted of 120 (60%) males and 80 (40%) females. The study 
groups distributed among different age groups ranging from 18-57 years, with the mean age 
of 35.8±8.2 for the patients and 31.4±10.3 for the controls. 73.3% of the patients were in the 
most sexually active age group (23-42 years).   
 
The study group represented the three major ethnic groups in the Sudan; 178 of the total 
population were Afro-Asiatic (55.6%), 111 were Nilo-Saharan (34.7%) and 31 were Niger-
Congo (9.7%) (Table 3.1). 
 
3.2. Clinical findings. 
 
HIV/AIDS patient was defined as any HIV positive patient with or without clinical symptoms, 
who fulfilled the case definition of the revised guidelines of the Centre for Disease Control 
Prevention (CDC). 
 
The patients represented different stages of the disease; 58 patients (48.3%) belonged to stage 
I, 50% of them were asymptomatic, 19 patients (15.8%) belonged to stage II and 43 patients 
(35.8%) belonged to stage III.The duration of the disease varied between 1-18 years among 
patients with a mean of 2.66±2.22. The most common symptoms presented in patients were 
loss of weight. (59.2%), Diarrhea (54.2%), fever (50.8%), anorexia (31.7%), Candidiasis 
(30.8%), tuberculosis (29.2%), generalized lymphoadenopathy (19.2%) and Kaposi’s sarcoma 
(5.0%). They were infected by different mode of transmission, 85.8% of them were 
heterosexually infected (table 3.2). 
 
3.3. HLA alleles distribution. 
 3.3.1. HLA frequency distribution in the Sudanese population and the major ethnic 
groups. 
 
Most of the studies of the population of HLA alleles, specially for HLA class I among 
Africans were performed by serological procedures or by utilizing low-resolution tests (158-
161). Thus, in this study we performed high-resolution molecular typing (sequencing-based 
typing) to determine the distribution of HLA class I and class II alleles diversity in different 
Sudanese ethnic groups to help to identify the mechanism by which HLA alleles may affect 
the disease progression. Part of this data is now available in the HLA database (162).  
 
A total of 36 HLA-A alleles have been identified in this population; the most common allele 
was A*0201 (30.9%), followed by A*3004 (15.3%) and A*3001 (12.2%). 
 
Nine HLA-A alleles showed significant frequency difference between ethnic groups (p<0.05); 
A*0202, A*0302, A*1101, A*2402, A*2902, A*3104, A*3201, A*3301, A*6602. The 
frequency of A*0201 was higher in Afro-Asiatic compared to Nilo-Saharan and Niger-Congo, 
but the difference was not statistically significant. A*0302, A*1101, A*2402 and A*3201 
showed higher frequencies in Afro-Asiatic, lower frequencies in Nilo-Saharan, but they were 
absent in Niger-Congo (Table 3.3). 
 
With respect to HLA-B, the most polymorphic locus in this population, 67 alleles have been 
detected. Alleles B*1503, B*4101 were the most frequently found in the population (11.6% 
each), followed by B*5101, B*5801 and B*3910 (10.9%, 10.6% and 10.03%, respectively). 
The latter is an African-specific allele found in a higher frequency in Sudanese, in contrast 
with previous studies in which this allele was found in several African populations in low 
frequency (162). 
 
Fourteen alleles showed significant frequency differences between ethnic groups (p<0.05); 
B*1302, B*1401, B*1403, B*1503, B*1531, B*1537, B*3801, B*4012, B*4201, B*5001, 
B*5101, B*5133, B*5201, B*5801, B*7801. B*1503 and B*5801 showed higher frequencies 
among Nilo-Saharan compared to other groups (15.3% and 17.1%, respectively), which were 
statistically significant (p=0.031 and 0.008, respectively), whereas B*4101 and B*5101 were 
higher in Afro-Asiatic compared to other groups (14.0% and 15.7%, respectively), but the 
differences were statistically not significant. Only 20 alleles were presented in Niger-Congo, 
the most frequent alleles among this group were B*1302 and B*5301 (19.4% each) (Table 
3.4). 
 
Concerning the HLA-C locus, 30 alleles were identified. The allele Cw*0701 was 
overrepresented in the population (33.8%), followed by Cw*0401, Cw*0602 and Cw*1203 
(24.7%, 20.6% and 20.6%, respectively).  
 
Three alleles showed statistically significant difference between the 3 ethnic groups; they 
were Cw*0701 the most frequent allele among all ethnic groups (>22%), it was significantly 
higher in Nilo-Saharan (p=0.004), Cw* 1202, which was found in a higher frequency in Afro-
Asiatic (7.3%, p=0.012) compared to other groups and Cw*1801, which was more frequent in 
Niger-Congo (13.0%, p=0.002). An African-specific allele Cw*0804 showed significant 
difference among ethnic groups (p=0.012), it was detected only in Niger-Congo which 
support the findings of previous studies (162). In addition, Cw*1502 showed a marginal 
significant difference between ethnic groups, it was more frequent in Afro-Asiatic (7.3%, 
p=0.057) (Table3.5). 
 
A total of 32 DRB1 alleles have been observed in the population, among which DRB1*0804 
was very common (21.9%), followed by DRB1*1302 (21.3%), DRB1*0301 (19.7%) and 
DRB1*1101 (19.0%). The most frequent alleles in Afro-Asiatic were DRB1*0301 and 
DRB1*1302 (24.2% each), whereas DRB1*0804 was the most frequent one in both Nilo-
Saharan and Niger-Congo (19.8% and 22.6%, respectively). DRB1* 1101 and DRB1*1102 
showed a higher significant difference in Nilo-Saharan (p=0.001 and 0.002, respectively), 
whereas DRB1* 1503 was highly frequent in Afro-Asiatic compared to other ethnic groups 
(p=0.008). The frequencies of DRB1*1104 and DRB1*1503 were also higher, but the 
difference was not statistically significant; however, the difference was of borderline 
significance (p=0.051 and 0.052, respectively) (Table 3.6). 
 
At the DQB1 locus, 14 alleles were identified. The most common alleles were DQB1*0301 
(40.9%), DQB1*0201 (34.7%) and DQB1* 0501 (27.8%). DQB1*0301 was the most frequent 
allele in Nilo-Saharan and Niger-Congo (43.2% and 32.3%, respectively), whereas 
DQB1*0201 was the most frequent one in the Afro-Asiatic group (42.1%). DQB1*0501, and 
DQB1*0602 were significantly higher in Nilo-Saharan (p= 0.025, 0.013, respectively), 
whereas DQB1*0601 was significantly higher in Afro-Asiatic (p=0.004) (Table 3.7). 
 
At the DPB1 locus, 24 different alleles were observed in the study population. DPB1*0201 
was the most frequent allele (47.5%), followed by DPB1*0401 and DPB1*0402 (33.1% and 
24.7%, respectively). The Nilo-Saharan differ from the other two populations by a higher 
frequency of DPB1*0201 (49.4% vs 48.9% and 32.3% respectively), on the other hand, 
DPB1*0101 was the most frequent allele among the Niger-Congo (38.7%) compared to other 
groups (38.7% vs 9.0% and 18.0%, respectively). DPB1*0101, DPB1*0401 and DPB1*0402 
showed a significant difference among ethnic groups (p=0.000, 0.000 and 0.013, respectively) 
(Table 3.8). 
 
3.3.2. HLA frequency in controls and patients. 
 
This study is the first report on the association of HLA class I and class II alleles distribution 
with HIV in the Sudanese population.   
 
Five HLA-A alleles were found more frequently in patients than in controls, A*0101, 
A*2301, A*2902, A*3001, and A*3303 (above 10%). In comparison of patients to controls, 
two alleles were found to be statistically significant; A*2902 was found in 3.5% of controls 
compared to 12.5% of patients, which supports a positive association with HIV infection 
(p=0.003). Conversely, A*3101 was found in 6.0% of controls and 0.8% of patients, which 
indicates a negative association with HIV infection (p=0.036) (Table 3.9).   
 
Five HLA-B alleles were found at a higher frequency in patients, B*5801 (13.3%), B*5301 
(13.3%), B*3501 (11.7), B*1503(11.7%), B*4101 (10.8%), whereas B*4101 (12.0%), 
B*1503 (11.5%), B*5101 (11.5%) were the most frequent alleles in controls. None of the 
HLA-B alleles showed significant frequency differences in patients compared to controls 
(Table 3.10). 
 
As for the HLA-Cw locus, 4 alleles were found at a frequency above 20% in either or both 
groups, these alleles were Cw*0401, Cw*0602, Cw*0701, and Cw*1203. HLA-Cw*0701 
was found to be the most frequent allele in both groups, it was more frequent in patients 
(40.7%) compared to controls (29.5%), the difference is of borderline significance (p=0.050), 
which might indicate a positive association with the disease. 4 alleles showed a significant 
frequency difference between patients and controls. HLA-Cw*0202 was found to be the most 
frequent allele in controls (12.0%) and it was relatively rare in patients (3.3%), which 
indicates a negative association with HIV-1 infection (p=0.007). Cw*0304 was observed 
exclusively in controls (3.5%), suggesting its association with protection from HIV-1 
infection (p=0.048). In contrast, Cw*0302 was found to be more frequent in patients (5.8%) 
than in controls (1.0%) (p=0.029), and Cw*0705 was observed exclusively in patients (4.2%), 
which indicates a positive association with HIV-1 infection (p=0.007) (Table 3.11). 
 
For the HLA-DRB1 locus, the most frequent allele was DRB1*1101 in patients (24.2%) 
compared to controls (16.0%), but the difference was not statistically significant. 3 alleles 
were widely observed with a similar frequency in both groups, DRB1*0701, DRB1*0804 and 
DRB1*1302. Only DRB1*0301 was significantly increased in controls (24.0%) compared to 
patients (12.5%), which supports a negative association with HIV-1 infection (p=0.013) 
(Table 3.12).  
 
Regarding HLA-DQB1, only 4 alleles were present above 5% frequency in either or both 
patients and controls. DQB1*0201, DQB1*0301, DQB1*0402, and DQB1*0609. 
DQB1*0604 was significantly increased in controls (2.0%) compared to patients (0.8%), 
which supports a negative association with HIV-1 infection (p=0.03) (Table 3.13). 
 
For HLA-DPB1, HLA-DPB1*0201 was overrepresented in both groups (51.0% in controls 
and 41.7% in patients), followed by DPB1*0401 with a frequency of 35.0% in controls 
compared to 30.0% in patients and DPB1*0402 which was present in 29.2% of the controls 
and 22.0% of the patients. None of the HLA-DPB1 alleles showed significantly frequency 
difference in patients compared to controls (Table 3.14). 
 
 
 
3.3.3. HLA frequency and disease progression. 
 
The criteria used to determine slow and rapid progression of the disease in this study was 
based primarily on the length of time of the disease after the first diagnosis. According to the 
1993 definition of CDC, we were able identify 43 patients in whom AIDS developed within 3 
years since HIV-1 was diagnosed, these patients were classified as rapid progressors to AIDS. 
We also identified a second group of 77 HIV-positive patients in whom AIDS-defining 
illnesses had not developed or remained asymptomatic for more than 3 years since HIV 
infection was diagnosed. These patients were included in the A1 or A2 classification of the 
CDC and were classified as slow progressors to AIDS. The duration of HIV-1 infection was 
established by referring to the patients’ medical records (1-18 years). 
 
As shown in table 3.15, A*0201 was found to be the most frequent allele in both groups. 4 
HLA-A alleles were found more frequently in rapid progressors group than in slow 
progressors group, A*2301, A*2902, A*3001, and A*3004. Only 2 alleles showed 
statistically significant difference, A*2601 was found only in rapid progressors (p=0.044), 
whereas A*2902 was found in a higher frequency in rapid progressors compared to slow 
progressors, which indicates a positive association with the disease progression (p=0.047). 
 
Four HLA-B alleles were found to be present at a higher frequency in rapid progressors than 
in slow progressors, B*1302, B*1503, B*3501, and B*5101. The most frequent allele in rapid 
progressors was B*3501 (18.6%), whereas B*5801 was the most frequent one among slow 
progressors (15.6%). No significant frequency differences between the two groups for any 
allele were detected (Table 3.16). 
 
Four HLA-Cw alleles were overrepresented in either or both groups (above 20%); they were 
Cw*0401, Cw*0602, Cw*0701, and Cw*1203. The most frequent allele was Cw*0701, 
followed by Cw*0401 in both groups. Cw*1203 was commonly observed in slow progressors 
(26.0%) compared to rapid progressors (9.3%), the difference was statistically significant, 
which indicates a negative association with the disease progression (p=0.033) (Table 3.17). 
 
HLA-DRB1*1101, DRB1*0804, DRB1*1302, and DRB1*0701 alleles were most frequent in 
both groups. DRB1*1503 was the most frequent allele among slow progressors (23.4%), 
whereas DRB1*1101 was the most frequent one among rapid progressors (27.9%). 
DRB1*1102 showed a higher frequency in rapid progressors (23.3%) compared to slow 
progressors (7.8%), the difference was statistically significant (p=0.024), which indicates a 
positive association with the disease progression. In contrast, DRB1*1503 was more frequent 
in slow progressors (23.4%) compared to rapid progressors (7.0%), suggesting a negative 
association with the disease progression (p=0.025) (Table 3.18). 
 Three HLA-DQB1 alleles were present more frequently in rapid progressors compared to 
slow progressors; DQB1*0201, DQB1*0301, DQB1*0501. DQB1*0301 allele was the most 
frequent allele in both groups. Only DQB1*0602 showed a negative association with the 
progression of the disease (p=0.033) (Table 3.19). 
 
HLA-DPB1*0201, DPB1*0401, DPB1*0402 alleles were present more frequently in both 
groups, among which DPB1*0201 was the most frequent in both groups (above 40.0%). None 
of the DPB1 alleles showed significant frequency difference in rapid progressors compared to 
slow progressors (Table 3.20). 
 
3.3.4. HLA frequency and stages of the disease. 
 
Having the clinical information, the patients were classified into three stages, according to 
CDC classification and the data was re-analyzed to compare the distribution of HLA-A allele 
frequencies between the three stages of the disease.  
 
Results showed that HLA-A*0201 (above 25%) was observed in all stages of the disease was, 
followed by HLA-A*3004 (above 10%). Among HLA-A alleles, A*2902 showed a higher 
frequency in patients with stage III of the disease (20.9%),  a lower frequency in patients with 
stage II of the disease (10.3%), and it was absent from patients in stage II of the disease. Only 
the frequency of HLA-A*2601 was significantly higher in patients with stage III of the 
disease compared to other stages (p=0.046) (Table 3.21). 
 
In the HLA-B locus, HLA-B*5801 was the most frequent allele in patients with stage I of the 
disease (17.2%), whereas HLA-B*3910 and HLA-B*4901 were the most frequent alleles in 
patients with stage II of the disease ((15.8% each) and B*3501 was the most frequent allele 
among patients with stage III of the disease (18.6%). There were no significant differences 
between different stages of the disease, except for B*3508, which was only detected in 
patients with stage I of the disease, however the difference was of a marginal significance 
(p=0.053) (Table 3.22). 
For the HLA-Cw locus, Cw*1203 was the most frequent allele in patients with stage I of the 
disease (25.9%), whereas Cw*0701 was the most frequent allele in patients with stage II and 
III of the disease (44.2% each). None of HLA-Cw alleles showed significant frequency 
difference among the different stages (Table 3.23). 
 
Regarding HLA-DRB1, DRB1*1503 was the most frequent allele in patients with stage I of 
the disease (25.9%), whereas DRB1*1301 was the most frequent allele in patients with stage 
II of the disease (26.3%), and DRB1*0804 and DRB1*1101 were the most frequent allele in 
patients with stage III of the disease (26.3%). DRB1*1102 was significantly increased in 
patients with stage III of the disease (23.3%) compared to other stages, which supports a 
positive association with HIV-1 infection (p=0.48) (Table 3.24). 
 
The most frequent HLA-DQB1 alleles found were DQB1*0201, DQB1*0301 and 
DQB1*0501 in all stages of the disease. Only DQB1*0201 was significantly higher in stage 
III, which supports a positive association with the disease progression (p=0.031) (Table 3.25). 
 
In the HLA-DPB1 locus, a high frequency of DPB1*0201 (43.1%) in patients with stage I of 
the disease was noticeable, as well as in stage II (36.8%) and stage III (41.9%). DPB1*0201 
showed statistically significant difference between stages of the disease (p=0.019). It was 
absent in patients with stage III which indicates a negative association with the disease 
progression (Table 3.26). 
 
3.3.5. HLA frequency distribution between asymptomatic and symptomatic groups. 
 
Here, the data was re-analyzed again to compare between the HLA allelic distribution 
between asymptomatic patients (n=29) and symptomatic patients (n=91). 
For the HLA-A locus, A*0201 was highly frequent in the symptomatic group (30.8%) 
compared to the asymptomatic group (17.2%), whereas A*3001 was more frequent in the 
asymptomatic group (20.7%) compared to the symptomatic group (9.9%); but the difference 
was statistically not significant (Table 3.27). 
  
For the HLA-B locus, the most frequent alleles in asymptomatic group were B*4101 (13.8%), 
B*5301 (24.1%), and B*5801 (17.2%), whereas B*3501 (13.2%), B*1503 (12.1%), and 
B*3910 (12.1%) were the most frequent alleles in the symptomatic group. Only B*3508 
showed a marginally significant difference between the two groups (p=0.057); this might 
indicate a tendency towards protection (Table 3.28). 
 For the HLA-Cw locus, Cw*0401 was overrepresented in the asymptomatic group (34.5%), 
whereas Cw* 0701 was overrepresented in the symptomatic group (45.1%).  No statistically 
significant difference between groups was observed as shown in table 3.29. 
 
Three HLA-DRB1 alleles were present more frequently in both groups, among which 
DRB1*1101 was the most frequent in both groups (above 20.0%), followed by DRB1*0804 
(> 19.0%) and DRB1*1302 (> 17%). None of DRB1 alleles showed significant frequency 
differences between the groups (Table 3.30). 
 
Regarding the HLA-DQB1 locus, DQB1*0201 was observed in a higher frequency in the 
symptomatic group (39.6%) compared to the asymptomatic group (10.3%), the difference was 
significant and indicates a positive association with the disease (p=0.003). Alleles 
DQB1*0301 and DQB1*0501 were highly frequent in both groups (above 30.0%), but no 
significant frequency differences were observed (Table 3.31). 
 
For the HLA-DPB1 locus, the most frequent allele in the asymptomatic group was 
DPB1*0401 (41.4%), whereas DPB1*0201 (42.9%) was the most frequent allele in the 
symptomatic group. Only DPB1*3001 showed a significant frequency difference (p=0.043), 
suggests its association with slow progression of the disease (Table 3.32). 
 
 
 
 
3.4. HLA haplotypes frequency distribution. 
 
3.4.1. HLA haplotype frequencies in Sudanese population. 
 
Allelic heterogeneity is common and, consequently, a large number of haplotypes were 
computed. The most frequently observed HLA class I A/B, B/C, A/C and class II DR/DQ, 
DR/DP and DQ/DP haplotypes have been listed in tables 3.33-3.38, which show  two-locus 
haplotype frequencies in the Sudanese population for the first time. Only the most frequent 
HLA haplotypes (higher than 1%) which were found in significant association (significant 
correlation coefficient) have been listed. Several haplotypes were reported for the first time. 
 We observed that the most frequent haplotypes contained the most frequent HLA alleles 
identified in each locus, and some alleles showed significant associations with different alleles 
in the second locus.  
 
For HLA class I, the association between HLA-A-Cw and HLA-A-B alleles was weaker than 
those observed for HLA-B-Cw. 
 
Twenty four HLA-A-B haplotypes were identified. The most frequent haplotypes were 
A*0201-B*4901 (4.4%) and A*3001-B*1503 (4.1%), A*0201-B*3910 (5.6%), which was 
absent in other populations (Table 3.33). 
 
Forty one HLA-B-Cw haplotypes were identified, the most frequent haplotypes were B*3910-
Cw*1203 (8.4%), B*5801-Cw*0701 (8.4%) and B*5301-Cw*0401 (7.2%) (Table 3.34).  
 
Twenty eight HLA-A-Cw haplotypes were identified, only 4 of them were found to be present 
at a frequency higher than 5%; A*3004-Cw*0401 (5.9%) and A*0205-Cw*0701 (5.3%) 
(Table 3.35).  
 
For HLA-DRB1-DQB1 haplotypes, 35 haplotypes were detected. The most frequent 
haplotypes were DRB1*0301-DQB1*0201 (18.8%), followed by DRB1*0804-DQB1*0301 
(18.4%), and DRB1*1302-DQB1*0604 (12.8%). The most frequent haplotypes containing the 
most frequent HLA-DRB1 or DQB1 allele were identified in this population (Table 3.36). 
 
Ten HLA-DRB1-DPB1 haplotypes were identified, the most frequent haplotypes were 
DRB1*0804-DPB1*0201 (12.8%) which was not observed in other populations, 
DRB1*1301-DPB1*0201 (7.2%), and DRB1*1503-DPB1*0402 (6.6%) (Table 3.37). 
 
Twelve HLA-DQB1-DPB1 haplotypes were identified. The most frequent haplotypes were 
DQB1*0602-DPB1*0402 (8.1%) and DQB1*0501-DPB1*1701 (7.5%), and DQB1*0603-
DPB1*0201 (7.2%) (Table 3.38). 
 
3.4.2. HLA haplotype frequencies in patients and control. 
 
A comparison of the frequency of haplotypes between patients and control groups revealed  
significant association of some haplotypes with the disease susceptibility or protection from 
HIV-1 infection. 
 
In HLA class I, haplotypes A*3001-B*4501, A*3303-B*4901, and B*3501-Cw*0705 were 
commonly observed in patients compared to control (3.3%, 3.3%, 4.2%, respectively), which 
suggests a positive association with the susceptibility to HIV-1 infection (p<0.05) as shown in 
tables 3.33-3.35.  
 
Regarding HLA class II, DRB1*0301-DQB1*0201, DRB1*1302-DQB1*0604, and 
DQB1*0603-DPB1*0201 were found more frequent in control group compared to patients 
group (23.0%, 16.0%, and 10.0%, respectively), suggesting their association with protection 
from HIV-1 infection (p<0.05), whereas DRB1*1102-DQB1*0301, DRB1*1503-
DQB1*0602, DRB1*1102-DPB1*0402, and DRB1*1503-DPB1*0402 were presented in a 
higher frequencies in patients compared to control group (13.3%, 15.8%, 6.7%, and 10.8%), 
which indicates their association with the susceptibility to HIV-1 infection (p<0.05) (Tables 
3.36-3.38).  
 
 
 
 
3.5. HLA new alleles. 
 
Four new HLA-Cw alleles (1.3%) in the study population were identified for the first time; 
hinting at the yet insufficiently explored HLA diversity in this population.  These new alleles 
were found in different ethnic groups. The nucleotide sequences and amino acid sequences of 
these alleles are shown in Fig. 3.1-3.4. 
 
HLA-Cw*0214 was detected in Nilo-Saharan individual, it is identical to Cw*020204 except 
for a non-synonymous nucleotide exchange at position 24 in exon 2 (T→G), changing codon 
33 from tyrosine (TAC) to aspartate (GAC) (AM180651). 
Cw*040104 was detected in Afro-Asiatic individual. It is identical to Cw*040101 except for 
synonymous nucleotide exchange at position 56 (constant position) in exon 3(C→T), resulting 
in a silent mutation at codon 133, both code for leucine (CTC) → (CTT) (AM180722). 
Cw*0418 was detected in Niger-Congo individual. It is identical to Cw*040101 except for a 
non-synonymous nucleotide exchange at position 171 in exon 3(G→A), resulting in a change 
in the amino acid sequence at codon 172 from glutamte (GAG) to lysine (AAG) (AM180629). 
 
Cw*070105 was detected in Niger-Congo individual. The new allele is identical to 
Cw*070101 except for a synonymous nucleotide exchange at position 275 in exon 3(A→G), 
resulting in a silent mutation at codon 206, both code for alanine (GCA) → (GCG) 
(AM180941). 
 
The data have been submitted to the IMGT/HLA database (163) and the names have been 
officially assigned by the WHO Nomenclature Committee in January 2006. This follows the 
agreed policy that, subject to the conditions stated in the most recent Nomenclature Report 
(164); names will be assigned to new sequences as they are identified. Lists of such new 
names will be published in the following WHO Nomenclature Report. The nucleotide 
sequence is available in the EMBL, GenBank and DDBJ Nucleotide Sequence Databases 
under the accession numbers mentioned above. 
 
 
 
3.5. Chemokines receptors (CCR5). 
 
This non-HLA genetic gene also influences susceptibility to HIV infection and the course of 
HIV disease. Thus, we sequenced a segment flanking the ∆32 deletion to determine the 
distribution of this mutant allele and its role in the outcome of HIV infection in our 
population.  
 
Of the 320 individuals who participated in the study, 318 individuals (99.4%) had the wild 
type allele, whereas the mutant allele (CCR5-∆32) was detected in only 2 individuals (0.6%). 
One of those who carried the mutant allele was HIV-1 positive. No heterozygous individuals 
were detected (Table 3.39). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1.  The main characteristics of study participants, comparison between patients and 
control groups 
 
 
 
 
Characteristics Controls  Patients 
No. (%) of participants 200 (62.5) 120 (37.5) 
 
Gender No. of males: No. of 
females (%) 
120: 80 
(60: 40) 
 
80: 40 
(66.7:33.3) 
Age (years) (mean±SD) 
(range) 
31.4 ± 10.3 
(18-53) 
 
35.8 ± 8.2 
(18-57) 
Ethnicity No. (%) 
Afro-Asiatic 
Nilo-Saharan 
Niger-Congo 
 
122 (38.1) 
64 (20.0) 
14 (4.4) 
 
 
56 (17.5) 
47 (14.7) 
17 (5.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2.  Clinical characterization of  HIV-1 patients participated in the study, August 2003-
April 2004 
 
 
Clinical characterization % 
No. of patient (%) in different 
clinical stages  
 
58 (48.3) 
Stage I 
Stage II 
Stage III 
19 (15.8) 
43 (35.8) 
Duration of the disease 
(mean±SD) (range) 
2.66±2.22 
(1-18) 
Mode of the disease 
transmission 
Heterosexual 
Homosexual 
Blood transfusion 
Others 
 
103 (85.8) 
3 (2.5) 
10 (8.3) 
4 (3.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3. Distribution of HLA-A Allele frequencies identified by DNA molecular typing 
among the Sudanese population, and comparison between different Sudanese ethnic groups. 
 
 
    
HLA-A 
Afro-Asiatic 
N=178 (%) 
Nilo-Saharan 
N=111 (%) 
Niger-Congo 
N=31 (%) 
Total 
N=320 (%) 
 
P 
*0101 18 (10.1) 13 (11.7) 6 (19.4) 37 (11.6) 0.312 
*0103 5 (2.8) 1 (0.9) 1 (3.2) 7 (2.2)) 0.850 
*0201 52 (29.2) 40 (36.0) 7 (22.6) 99 (30.9) 0.800 
*0202 5 (2.8) 9 (8.1) 2 (6.5) 16 (5.0)) 0.023 
*0205 21 (11.8) 12 (10.8) 2 (6.5) 35 (10.9) 0.187 
*0214 1 (0.6) 1 (0.9) 0 2 (0.6) 0.948 
*0301 16 (9.0) 10 (9.0) 2 (6.5) 28 (8.8) 0.695 
*0302 12 (6.7) 1 (0.9) 0 13(4.1) 0.018 
*0304 1 (0.6) 0 0 1 (0.3) 0.440 
*0305 1 (0.6) 0 0 1 (0.3) 0.440 
*1101 9 (5.0) 0 0 9 (2.8) 0.019 
*2301 20 (11.2) 9 (8.1) 5 (16.1) 34 (10.6) 0.777 
*2402 20 (11.2) 5 (4.5) 3 (9.7) 28 (8.8) 0.045 
*2403 4 (2.2) 1 (0.9) 0 5 (1.6) 0.317 
*2601 8 (4.5) 1 (0.9) 0 9 (2.8) 0.073 
*2612 6 (3.3) 4 (3.6) 0 10 (3.1) 0.706 
*2901 0 2 (1.8) 0 2 (0.6) 0.221 
*2902 7 (3.9) 13 (11.7) 2 (6.5) 22 (6.9) 0.017 
*3001 21 (11.8) 15 (13.5) 3 (9.7) 39 (12.2) 0.469 
*3002 13 (7.3) 6 (5.4) 2 (6.5) 21 (6.6) 0.973 
*3004 24 (13.5) 25 (22.5) 0 49 (15.3) 0.634 
*3101 8 (4.5) 5 (4.5) 0 13 (4.1) 0.600 
*3104 1 (0.6) 8 (7.2) 0 9 (2.8) 0.038 
*3201 23 (12.9) 6 (5.4) 0 29 (9.1) 0.015 
*3301 4 (2.2) 4 (3.6) 4 (13) 12 (3.8) 0.002 
*3303 14 (7.9) 5 (4.5) 4 (13) 23 (7.2) 0.448 
*3402 3 (1.8) 3 (2.7) 2 (6.5) 8 (2.5) 0.059 
*3601 1 (0.6) 0 0 1 (0.3) 0.440 
*6601 2 (1.1) 1 (0.9) 1 (3.2) 4 (1.3) 0.342 
*6602 0 0 1 (3.2) 1 (0.3) 0.012 
*6801 12 (6.7) 4 (3.6) 0 16 (5.0) 0.184 
*6802 14 (7.9) 13 (11.7) 4 (13) 31 (9.7) 0.177 
*6901 1 (0.6) 0 0 1 (0.3) 0.440 
*7401 1 (0.6) 0 1 (3.2) 2 (0.6) 0.221 
*7403 1 (0.6) 0 0 1 (0.3) 0.440 
*8001 0 1 0 1 (0.3) 0.388 
 
P values computed by x2 test and Fisher’s exact test.  
   
               
 
Table 3.4. Distribution of HLA-B Allele frequencies identified by DNA molecular typing  
among the Sudanese population, and comparison between  different Sudanese ethnic groups. 
 
 
 
  HLA-B Afro-Asiatic 
N=178 (%) 
Nilo-Saharan 
N=111 (%) 
Niger-Congo 
N=31 (%) 
Total 
N=320 (%) 
 
P 
*0702 11 (6.2) 4 (3.6) 0 15 (4.7) 0.184 
*0705 0 2 (1.8) 0 2 (0.6) 0.221 
*0801 10 (5.6) 10 (9.0) 0 21 (6.6) 0.832 
*1301 1 (0.6) 0 0 1 (0.3) 0.440 
*1302 10 (5.6) 12 (10.8) 6 (19.4) 28 (8.8) 0.000 
*1401 0 2 (1.8) 1 (3.2) 3 (0.9) 0.014 
*1402 8 (4.5) 3 (2.7) 3 (9.7) 14 (4.4) 0.286 
*1403 0 0 1 (3.2) 1 (0.3) 0.012 
*1501 1 (0.6) 1 0 2 (0.6) 0.948 
*1503 16 (9.0) 17 (15.3) 4 (13) 37 (11.6) 0.031 
*1510 3 (1.8) 2 (1.8) 0 5 (1.6) 0.791 
*1516 0 1 (0.9) 0 1 (0.3) 0.388 
*1517 5 (2.8) 1 (0.9) 0 6 (1.9) 0.218 
*1518 1 (0.6) 1 (0.9) 0 2 (0.6) 0.948 
*1531 0 0 1 (3.2) 1 (0.3) 0.012 
*1537 0 0 1 (3.2) 1 (0.3) 0.012 
*1555 1 (0.6) 0 0 1 (0.3) 0.440 
*1567 0 2 0 2 (0.6) 0.221 
*1801 9 (5.0) 5 (4.5) 1 (3.2) 15 (4.7) 0.973 
*1807 1 (0.6) 0 0 1 (0.3) 0.440 
*2702 2 (1.1) 0 0 2 (0.6) 0.275 
*2703 4 (2.2) 4 0 8 (2.5) 0.895 
*2705 2 (1.1) 1 0 3 (0.9) 0.694 
*2707 0 2 0 2 (0.6) 0.221 
*3501 17 (9.6) 13 (11.7) 0 30 (9.4) 0.717 
*3502 6 (3.4) 1 (0.9) 0 7 (2.2) 0.151 
*3503 3 (1.8) 0 0 3 (0.9) 0.180 
*3508 4 (2.2) 1 (0.9) 0 5 (1.6) 0.317 
*3701 4 (2.2) 1 (0.9) 1 (3.2) 6 (1.9) 0.910 
*3801 21 (11.8) 3 (2.7) 0 24 (7.5) 0.004 
*3809 1 (0.6) 0 0 1 (0.3) 0.440 
*3910 20 (11.2) 12 (10.8) 1 (3.2) 33 (10.3) 0.637 
*3924 2 (1.1) 1 (0.9) 0 3 (0.9) 0.694 
*4001 3 (1.8) 0 0 3 (0.9) 0.180 
*4002 2 (1.1) 2 (1.8) 0 4(1.3) 0.926 
*4012 0 4 (3.6) 1 (3.2) 5 (1.6) 0.007 
*4016 1 (0.6) 0 0 1 (0.3) 0.440 
*4101 25 (14.0) 12 (10.8) 0 37 (11.6) 0.119 
*4201 2 (1.1) 4 (3.6) 2 (6.5) 9 (2.8) 0.014 
*4202 2 (1.1) 4 (3.6) 0 6 (1.9) 0.432 
*4402 3 (1.8) 0 0 3 (0.9) 0.180 
*4403 6 (3.4) 2 (1.8) 0 1 (0.3) 0.300 
*4407 0 1 (0.9) 0 8 (2.5)) 0.388 
*4418 0 1 (0.9) 0 1 (0.3) 0.388 
*4501 10 (5.6) 7 (6.3) 0 18 (5.6) 0.678 
*4701 5 (2.8) 1 (0.9) 0 6 (1.9) 0.218 
*4703 6 (3.4) 13 (11.7) 0 19 (5.9) 0.119 
*4901 18 (10.1) 6 (5.4) 1 (3.2) 25 (7.8) 0.197 
*5001 15 (8.4) 3 (2.7) 0 18 (5.6) 0.030 
*5002 1 (0.6) 0 0 1 (0.3) 0.440 
*5101 28 (15.7) 6 (5.4) 1 (3.2) 35 (10.9) 0.013 
*5108 3 (1.8) 1 (0.9) 0 4 (1.3) 0.466 
*5133 0 0 2 (6.5) 2 (0.6) 0.000 
*5201 16 (9.0) 1 (0.9) 1 (3.2) 18 (5.6) 0.030 
*5301 19 (10.7) 10 (9.0) 6 (19.4) 35 (10.9) 0.109 
*5501 1 (0.6) 0 0 1 (0.3) 0.440 
*5601 1 (0.6) 0 0 1 (0.3) 0.440 
*5701 5 (2.8) 4 (3.6) 1 (3.2) 10 (3.1) 0.502 
*5702 3 (1.8) 3 (2.7) 0 6 (1.9) 0.910 
*5703 5 (2.8) 1 (0.9) 0 6 (1.9) 0.218 
*5801 12 (6.7) 19 (17.1) 3 (9.7) 34 (10.6) 0.008 
*5802 0 1 0 1 (0.3) 0.388 
*5808 1 (0.6) 0 0 1 (0.3) 0.440 
*7301 3 (1.8) 2 (1.8) 0 5 (1.6) 0.791 
*7801 0 1 (0.9) 1 (3.2) 2 (0.6) 0.017 
*8101 0 3 (2.7) 0 3 (0.9) 0.134 
*8202 1 (0.6) 1 (0.9) 0 2 (0.6) 0.948 
 
 
P values computed by x2 test and Fisher’s exact test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.5. Distribution of HLA-C Allele frequencies identified by DNA molecular typing  
among the Sudanese population, and comparison between  different Sudanese ethnic groups. 
 
 
 
 
HLA-Cw Afro-Asiatic 
N=178 (%) 
 
Nilo-Saharan 
N=111 (%) 
Niger-Congo 
N=31 (%) 
Total 
N=320 (%) 
P 
*0102 5 (2.8) 1 (0.9) 0 6 (1.9) 0.218 
*0202 18 (10.1) 9 (8.1) 1 (3.2) 28 (8.8) 0.475 
*0214 0 1 (0.9) 0 1 (0.3) 0.388 
*0302 4 (2.2) 3 (2.7) 2 (6.5) 9 (2.8) 0.129 
*0303 2 (1.1) 1 (0.9) 0 3 (0.9) 0.694 
*0304 6 (3.4) 1 (0.9) 0 7 (2.2) 0.151 
*0401 45 (25.3) 28 (25.2) 4 (13.0) 79  (24.7) 0.943 
*0404 1 (0.6) 5 (4.5) 0 6 (1.9) 0.145 
*0407 1 (0.6) 0 0 1 (0.3) 0.440 
*0418 1 (0.6) 0 0 1 (0.3) 0.000 
*0501 4 (2.2) 3 (2.7) 0 7 (2.2) 0.850 
*0602 40 (22.5) 22 (19.8) 4 (13.0) 66 (20.6) 0.796 
*0701 49 (27.5) 52 (46.8) 7 (22.6) 108 (33.8) 0.004 
*0702 11 (6.2) 8 (7.2) 0 19 (5.9) 0.709 
*0704 5 (2.8) 4 (3.6) 0 9 (2.8) 0.892 
*0705 2 (1.1) 3 (2.7) 0 5 (1.6) 0.637 
*0715 0 1 (0.9) 0 1 (0.3) 0.388 
*0802 10 (5.6) 6 (5.4) 4 (13.0) 20 (6.3) 0.085 
*0804 0 0 1 (3.2) 1 (0.3) 0.012 
*1202 13 (7.3) 1 (0.9) 0 14 (4.4) 0.012 
*1203 44 (24.7) 20 (18.0) 2 (6.5) 66 (20.6) 0.107 
*1402 2 (1.1) 3 (2.7) 0 5 (1.6) 0.637 
*1403 1 (0.6) 2 (1.8) 0 3 (0.9) 0.580 
*1502 13 3 (2.7) 0 16 (5.0) 0.057 
*1505 11 (6.2) 5 (4.5) 0 16 (5.0) 0.286 
*1601 25 (14.0) 9 (8.1) 4 (13.0) 38 (11.9) 0.793 
*1602 9 (5.0) 3 (2.7) 0 12 (3.8) 0.201 
*1604 5 (2.8) 0 0 5 (1.6) 0.083 
*1701 18 (10.1) 8 (7.2) 3 (9.7) 29 (9.1) 0.920 
*1801 4 (2.2) 4 (3.6) 4 (13.0) 12 (3.8) 0.002 
 
P values computed by x2 test and Fisher’s exact test.  
 
 
 
 
 
 
 
 
Table 3.6. Distribution of HLA-DRB1 Allele frequencies identified by DNA molecular typing  
among the Sudanese population, and comparison between  different Sudanese ethnic groups. 
 
 
 
 
DRB1 Afro-Asiatic 
N=178 (%) 
Nilo-Saharan 
N=111 (%) 
Niger-Congo 
N=31 (%) 
Total 
N=320 (%) 
 
P 
*0101 2 (1.1) 0 0 2 (0.6) 0.275 
*0102 6 (3.4) 4 (3.6) 3 (9.7) 13 (4.1) 0.074 
*0301 43 (24.2) 16 (14.4) 4 (13) 63 (19.7) 0.076 
*0302 1 (0.6) 2 (1.8) 1 (3.2) 4 (1.3) 0.083 
*0401 1 (0.6) 2 (1.8) 0 3 (0.9) 0.580 
*0402 5 (2.8) 0 0 5 (1.6) 0.083 
*0403 2 (1.1) 2 (1.8) 0 4 (1.3) 0.926 
*0405 12 (6.7) 4 (3.6) 0 16 (5.0) 0.137 
*0406 1 (0.6) 0 1 (3.2) 2 (0.6) 0.221 
*0701 32 (18.0) 9 (8.1) 5 (16.1) 40 (14.4) 0.081 
*0804 41 (23.0) 22 (19.8) 7 (22.6) 70 (21.9) 0.820 
*0901 0 1 (0.9) 0 1 (0.3) 0.388 
*1001 18 (10.1) 16 (14.4) 5 (16.1) 39 (12.2) 0.119 
*1101 20 (11.2) 37 (33.3) 4 (13) 61 (19.1) 0.001 
*1102 8 (4.5) 20 (18.0) 2 (6.5) 30 (9.4) 0.002 
*1103 2 (1.1) 0 0 2 (0.6) 0.275 
*1104 9 (5.0) 1 (0.9) 0 10 (3.1) 0.051 
*1114 1 (0.6) 0 0 1 (0.3) 0.440 
*1116 1 (0.6) 0 0 1 (0.3) 0.440 
*1201 4 (2.2) 1 (0.9) 0 5 (1.6) 0.317 
*1301 20 (11.2) 12 (10.8) 0 32 (10.0) 0.346 
*1302 43 (24.2) 19 (17.1) 6 (19.4) 68 (21.3) 0.256 
*1303 17 (9.6) 6 (5.4) 4 (13) 27 (8.4) 0.808 
*1316 0 1 (0.9) 0 1 (0.3) 0.388 
*1401 4 (2.2) 1 (0.9) 1 (3.2) 6 (1.9) 0.910 
*1404 1 (0.6) 0 0 1 (0.3) 0.440 
*1406 2 (1.1) 0 0 2 (0.6) 0.275 
*1501 12 (6.7) 3 (2.7) 1 (3.2) 16 (5.0) 0.286 
*1502 19 (10.7) 3 (2.7) 0 22 (6.9) 0.008 
*1503 17 (9.6) 21 (18.9) 4 (13) 42 (13.1) 0.052 
*1601 1 (0.6) 0 0 1 (0.3) 0.440 
*1602 4 (2.2) 1 (0.9) 1 (3.2) 6 (1.9) 0.910 
 
 
P values computed by x2 test and Fisher’s exact test.  
 
 
 
 
 
Table 3.7. Distribution of HLA-DQB1 Allele frequencies identified by DNA molecular typing  
among the Sudanese population, and comparison between  different Sudanese ethnic groups. 
 
 
 
 
 
DQB1 Afro-Asiatic 
N=178 (%) 
Nilo-Saharan 
N=111 (%) 
Niger-Congo 
N=31 (%) 
Total 
N=320 (%) 
 
P 
*0201 75 (42.1) 25 (22.5) 11 (35.5) 111 (34.7) 0.072 
*0301 73 (41.0) 48 (43.2) 10 (32.3) 131 (40.9) 0.685 
*0302 14 (7.9) 7 (6.3) 0 21 (6.6) 0.284 
*0303 7 (3.9) 1 (0.9) 0 8 (2.5) 0.105 
*0402 9 (5.0) 4 (3.6) 2 (6.5)  15 (4.7) 0.691 
*0501 42 (23.6) 41 (36.9) 6 (19.4) 89 (27.8) 0.025 
*0502 6 (3.4) 1 (0.9) 1 (3.2) 8 (2.5) 0.651 
*0503 5 (2.8) 1 (0.9) 1 (3.2) 7 (2.2) 0.850 
*0601 21 (11.8) 3 (2.7) 0 24 (7.5) 0.004 
*0602 18 (10.1) 26 (23.4) 7 (22.6) 51 (15.9) 0.013 
*0603 24 (13.5) 8 (7.2) 3 (9.7) 35 (10.9) 0.057 
*0604 30 (16.9) 12 (10.8) 2 (6.5) 44 (13.8) 0.073 
*0608 4 (2.2) 6 (5.4) 0 10 (3.1) 0.502 
*0609 12 (6.7) 10 (9.0) 4 (13) 26 (8.1) 0.213 
 
P values computed by x2 test and Fisher’s exact test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.8. Distribution of HLA-DPB1 Allele frequencies identified by DNA molecular typing  
among the Sudanese population, and comparison between  different Sudanese ethnic groups. 
 
 
 
 
DPB1 Afro-Asiatic 
N=178 (%) 
Nilo-Saharan 
N=111 (%) 
Niger-Congo 
N=31 (%) 
Total 
N=320 (%) 
 
p 
*0101 16 (9.0) 20 (18.0) 12 (38.7) 48 (15.0) 0.000 
*0201 87 (48.9) 55 (49.5) 10 (32.3) 152 (47.5) 0.619 
*0301 34 (19.1) 23 (20.7) 3 (9.7) 60 (18.8) 0.759 
*0401 76 (42.7) 26 (23.4) 4 (13) 106 (33.1) 0.000 
*0402 34 (19.1) 37 (33.3) 8 (25.8) 79 (24.7) 0.013 
*0801 1 (0.6) 0 0 1 (0.3) 0.440 
*0901 3 (1.8) 0 0 3 (0.9) 0.180 
*0902 15 (8.4) 9 (8.1) 1 (3.2) 25 (7.8) 0.786 
*1101 9 (5.0) 4 (3.6) 1 (3.2) 14 (4.4) 0.787 
*1401 4 (2.2) 0 0 4 (1.3) 0.121 
*1501 3 (1.8) 2 (1.8) 0 5 (1.6) 0.791 
*1701 31 (17.4) 22 (19.8) 3 (9.7) 56 (17.5) 0.560 
*1801 1 (0.6) 0 0 1 (0.3) 0.440 
*3001 14 (7.9) 1 (0.9) 1 (3.2) 16 (5.0) 0.057 
*3301 1 (0.6) 0 0 1 (0.3) 0.440 
*3401 3 (1.8) 1 (0.9) 0 4 (1.3) 0.466 
*3901 1 (0.6) 1 (0.9) 1 (3.2) 3 (0.9) 0.134 
*4001 0 1 (0.9) 0 1 (0.3) 0.388 
*4701 0 1 (0.9) 0 1 (0.3) 0.388 
*5001 1 (0.6) 0 0 1 (0.3) 0.440 
*5501 1(0.6) 1 (0.9) 0 2 (0.6) 0.948 
*7201 1 (0.6) 0 0 1 (0.3) 0.440 
*9101 1 (0.6) 0 0 1 (0.3) 0.440 
*9201 1 (0.6) 0 0 1 (0.3) 0.440 
 
 
P values computed by x2 test and Fisher’s exact test.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.9. HLA-A Allele frequencies in HIV-1 patients compared to controls 
 
 
    A Control 
N=200 (%) 
Patients 
N=120 (%) 
p OR 95% CI 
*0101 20 (10.0) 17 (14.2) 0.260 1.485 0.745-2.963 
*0103 6 (3.0) 1 (0.8) 0.263 0.272 0.032-2.285 
*0201 66 (33.0) 33 (27.5) 0.320 0.770 0.468-1.266 
*0202 7 (3.5) 9 (7.5) 0.120 2.236 0.810-6.168 
*0205 26 (13.0) 9 (7.5) 0.142 0.543 0.245-1.201 
*0214 1 (0.5) 1 (0.8) 1.000 1.672 0.104-26.985 
*0301 19 (9.5) 9 (7.5) 0.684 0.772 0.338-1.767 
*0302 9 (4.5) 4 (3.3) 0.773 0.732 0.220-2.430 
*0304 0 1 (0.8) 0.375 0 0 
*0305 0 1 (0.8) 0.375 0 0 
*1101 7 (3.5) 2 (1.7) 0.492 0.467 0-095-2.287 
*2301 19 (9.5) 15 (12.5) 0.445 1.361 0.663-2.791 
*2402 19 (9.5) 9 (7.5) 0.684 0.772 0.338-1.767 
*2403 2 (1.0) 3 (2.5) 0.367 2.538 0.418-15.414 
*2601 6 (3.0) 3 (2.5) 1.000 0.829 0.203-3.378 
*2612 5 (2.5) 5 (4.2) 0.510 1.696 0.481-5.983 
*2901 0 2 (1.7) 0.140 0 0 
*2902 7 (3.5) 15 (12.5) 0.003 3.939 1.557-9.964 
*3001 24 (12.0) 15 (12.5) 1.000 1.048 0.526-2.086 
*3002 11 (5.5) 10 (8.3) 0.355 1.562 0.643-3.796 
*3004 32 (16.0) 17 (14.2) 0.749 0.867 0.458-1.639 
*3101 12 (6.0) 1 (0.8) 0.036 0.132 0.017-1.026 
*3104 4 (2.0) 5 (4.2) 0.304 2.130 0.561-8.094 
*3201 22 (11.0) 7 (5.8) 0.159 0.501 0.207-1.211 
*3301 7 (3.5) 5 (4.2) 0.768 1.199 0.372-3.865 
*3303 10 (5.0) 13 (10.8) 0.072 2.308 0.979-5.443 
*3402 4 (2.0) 4 (3.3) 0.479 1.690 0.415-6.885 
*3601 1 (0.5) 0 1.000 0 0 
*6601 3 (1.5) 1 (0.8) 1.000 0.552  0.057-5.366 
*6602 0 1 (0.8) 0.375 0 0 
*6801 12 (6.0) 3 (2.5) 0.181 0.402 0.111-1.454 
*6802 21 (10.5) 10 (8.3) 0.565 0.775 0.352-1.707 
*6901 1 (0.5) 0 1.000 0 0 
*7401 1 (0.5) 1 (0.8) 1.000 1.672 0.104-26.985 
*7403 0 1 (0.8) 0.375 0 0 
*8001 0 1 (0.8) 0.375 0 0 
 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
OD, odds ratio ; 95% CI , 95% confidence interval 
 
 
 
 
 
 
Table 3.10. HLA-B Allele frequencies in HIV-1 patients compared to controls 
 
 
 
    B Controls 
N=200 (%) 
Patients 
N=120 (%) 
 
P OR 95% CI 
*0702 9 (4.5) 6 (5.0) 1.000 1.117 0.387-3.220 
*0705 2 (1.0) 0 0.530 0 0 
*0801 15 (7.5) 5 (4.2) 0.340 0.536 0.190-1.515 
*1301 0 1 (0.8) 0.375 0 0 
*1302 15 (7.5) 13 (10.8) 0.314 1.498 0.687-3.269 
*1401 2 (1.0) 1 (0.8) 1.000 0.832 0.075-9.274 
*1402 7 (3.5) 7 (5.8) 0.399 1.708 0.584-4.995 
*1403 0 1 (0.8) 0.375 0 0 
*1501 2 (1.0) 0 0.530 0 0 
*1503 23 (11.5) 14 (11.7) 1.000 1.016 0.501-2.060 
*1510 4 (2.0) 1 (0.8) 0.654 0.412 0.045-3.728 
*1516 1 (0.5) 0 1.000 0 0 
*1517 3 (1.5) 3 (2.5) 0.675 1.684 0.334-8.479 
*1518 1 (0.5) 1 (0.8) 1.000 1.672 0.104-26.985 
*1531 0 1 (0.8) 0.375 0 0 
*1537 0 1 (0.8) 0.375 0 0 
*1555 0 1 (0.8) 0.375 0 0 
*1567 1 (0.5) 1 (0.8) 1.000 1.672 0.104-26.985 
*1801 9 (4.5) 6 (5.0) 1.000 1.117 0.387-3.220 
*1807 1 (0.5) 0 1.000 0 0 
*2702 2 (1.0) 0 0.530 0 0 
*2703 7 (3.5) 1 (0.8) 0.266 0.232 0.028-1.907 
*2705 3 (1.5) 0 0.295 0 0 
*2707 1 (0.5) 1 (0.8) 1.000 1.672 0.104-26.985 
*3501 16 (8.0) 14 (11.7) 0.323 1.519 0.713-3.235 
*3502 2 (1.0) 5 (4.2) 0.108 4.304 0.822-22.544 
*3503 2 (1.0) 1 (0.8) 1.000 0.832 0.075-9.274 
*3508 3 (1.5) 2 (1.7) 1.000 1.113 0.183-6.758 
*3701 4 (2.0) 2 (1.7) 1.000 0.831 0.150-4.604 
*3801 19 (9.5) 5 (4.2) 0.123 0.414 0.150-1.140 
*3809 0 1 (0.8) 0.375 0 0 
*3910 20 (10.0) 13 (10.8) 0.850 1.093 0.523-2.287 
*3924 3 (1.5) 0 0.295 0 0 
*4001 3 (1.5) 0 0.295 0 0 
*4002 2 (1.0) 2 (1.7) 0.632 1.678 0.233-12.070 
*4012 3 (1.5) 2 (1.0) 1.000 1.113 0.183-6.758 
*4016 1 (0.5) 0 1.000 0 0 
*4101 24 (12.0) 13 (10.8) 0.857 0.891 0.435-1.824 
*4201 4 (2.0) 4 (3.3) 0.479 1.690 0.415-6.885 
*4202 6 (3.0) 0 0.087 0 0 
*4402 3 (1.5) 0 0.295 0 0 
*4403 6 (3.0) 2 (1.7) 0.715 0.548 0.109-2.760 
*4407 0 1 (0.8) 0.375 0 0 
*4418 0 1 (0.8) 0.375 0 0 
*4501 12 (6.0) 5 (4.2) 0.610 0.681 0.234-1.983 
*4701 5 (2.5) 1 (0.8) 0.416 0.328 0.038-2.839 
*4703 10 (5.0) 9 (7.5) 0.464 1.541 0.608-3.906 
*4901 17 (8.5) 8 (6.7) 0.669 0.769 0.321-1.840 
*5001 10 (5.0) 8 (6.7) 0.618 1.357 0.520-3.539 
*5002 0 1 (0.8) 0.375 0 0 
*5101 23 (11.5) 12 (10.0) 0.716 0.855 0.409-1.788 
*5108 2 (1.0) 0 0.301 0.980 0.961-1.000 
*5133 1 (0.5) 1 (0.8) 1.000 1.672 0.104-26.985 
*5201 13 (6.5) 5 (4.2) 0.459 0.625 0.217-1.800 
*5301 19 (9.5) 16 (13.3) 0.355 1.466 0.722-2.973 
*5501 1 (0.5) 0 1.000 0 0 
*5601 1 (0.5) 0 1.000 0 0 
*5701 6 (3.0) 4 (3.3) 1.000 1.115 0.308-4.034 
*5702 1 (0.5) 4 (3.3) 0.202 3.414 0.616-18.927 
*5703 5 (2.5) 1 (0.8) 0.416 0.328 0.38-2.839 
*5801 18 (9.0) 16 (13.3) 0.262 1.556 0.761-3.181 
*5802 0 1 (0.8) 0.375 0 0 
*5808 0 1 (0.8) 0.375 0 0 
*7301 3 (1.5) 2 (1.7) 1.000 1.113 0.183-6.758 
*7801 0 2 (1.7) 0.140 0 0 
*8101 2 (1.0) 1 (0.8) 1.000 0.832 0.075-9.274 
*8202 1 (0.5) 1 (0.8) 1.000 1.672 0.104-26.985 
 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
OD, odds ratio ; 95% CI , 95% confidence interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.11. HLA-Cw Allele frequencies in HIV-1 patients compared to controls 
 
 
 
       
Cw Controls 
N=200 (%) 
Patients 
N=120 (%) 
 
P OR  95% I C 
*0102 6 (3.0) 0 0.087 0 0 
*0202 24 (12.0) 4 (3.3) 0.007 0.253 0.086-0.748 
*0214 1 (0.5) 0 1.000 0 0 
*0302 2 (1.0) 7 (5.8) 0.029 6.133 1.253-30.024 
*0303 2 (1.0) 1 (0.8) 1.000 0.832 0.075-9.274 
*0304 7 (3.5) 0 0.048 0 0 
*0401 48 (24.0) 29 (24.2) 1.000 1.009 0.595-1.713 
*0404 5 (2.5) 1 (0.8) 0.416 0.328 0.038-2.839 
*0407 0 1 (0.8) 0.375 0 0 
*0418 0 1 (0.8) 1.000 1.672 0.104-26.985 
*0501 6 (3.0) 1 (0.8) 0.263 0.272 0.032-2.285 
*0602 40 (20.0) 26 (21.7) 0.776 1.106 0.635-1.928 
*0701 59 (29.5) 49 (40.8) 0.050 1.649 1.027-2.650 
*0702 14 (7.0) 5 (4.2) 0.340 0.578 0.203-1.646 
*0704 6 (3.0) 3 (2.5) 1.000 0.829 0.203-3.378 
*0705 0 5 (4.2) 0.007 0 0 
*0715 0 1 (0.8) 0.375 0 0 
*0802 10 (5.0) 10 (8.3) 0.242 1.727 0.697-4.280 
*0804 0 1 (0.8) 0.375 1.008 0.992-1.025 
 
 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
OD, odds ratio ; 95% CI , 95% confidence interval 
 
 
 
 
 
 
 
 
Table 3.12. HLA-DRB1 Allele frequencies in HIV-1 patients compared to controls 
 
 
 
 
DRB1 Controls 
N=200 (%) 
Patients 
N=120 (%) 
 
P OR  95% I C 
*0101 0 2(1.7) 0.140 0 0 
*0102 10 (5.0) 3 (2.5) 0.384 0.487 0.131-1.807 
*0301 48 (24.0) 15 (12.5) 0.013 0.452 0.241-0.850 
*0302 2 (1.0) 2(1.7) 0.632 1.678 0.233-12.070 
*0401 2 (1.0) 1 (0.8) 1.000 0.832 0.075-9.274 
*0402 4 (2.0) 1 (0.8) 0.654 0.412 0.045-3.728 
*0403 3 (1.5) 1 (0.8) 1.000 0.552 0.057-5.366 
*0405 10 (5.0) 6 (5.0) 1.000 1.000 0.354-2.825 
*0406 0 2(1.7) 0.140 0 0 
*0701 30 (15.0) 16 (13.3) 0.744 0.872 453-1.677 
*0804 43 (21.5) 27 (22.5) 0.889 1.060 0.614-1.829 
*0901 0 1 (0.8) 0.375 0 0 
*1001 23 (11.5) 16 (13.3) 0.724 1.184 0.598-2.343 
*1101 32 (16.0) 29 (24.2) 0.079 1.673 0.952-2.939 
*1102 14 (7.0) 16 (13.3) 0.074 2.044 0.959-4.355 
*1103 2 (1.0) 0 0.530 0 0 
*1104 7 (3.5) 3 (2.5) 0.749 0.707 0.179-2.787 
*1114 0 1 (0.8) 0.375 0 0 
*1202 11 (5.5) 3 (2.5) 0.265 0.441 0.120-1.612 
*1203 42 (21.0) 24 (20.0) 0.887 0.940 0.536-1.650 
*1402 4 (2.0) 1 (0.8) 0.654 0.412 0.045-3.728 
*1403 2 (1.0) 1 (0.8) 1.000 0.832 0.075-9.274 
*1502 11 (5.5) 5 (4.2) 0.792 0.747 0.253-2.205 
*1505 11 (5.5) 5 (4.2) 0.792 0.747 0.253-2.205 
*1601 20 (10.0) 18 (15.0) 0.212 1.588 0.803-3.140 
*1602 10 (5.0) 2 (1.7) 0.222 0.322 0.069-1.495 
*1604 5 (2.5) 0 0.161 0 0 
*1701 18 (9.0) 11 (9.2) 1.000 1.020 0.465-2.241 
*1801 5 (2.5) 7 (5.8) 0.140 2.416 0.749-7.790 
*1116 1 (0.5) 0 1.000 0 0 
*1201 4 (2.0) 1 (0.8) 0.654 0.412 0.045-3.728 
*1301 20 (10.0) 12 (10.0) 1.000 1.000 0.470-2.126 
*1302 47 (23.5) 21 (17.5) 0.259 0.691 0.389-1.225 
*1303 16 (8.0) 11 (9.2) 0.836 1.161 0.520-2.592 
*1316 1 (0.5) 0 1.000 0 0 
*1401 5 (2.5) 1 (0.8) 0.416 0.328 0.038-2.839 
*1404 0 1 (0.8) 0.375 0 0 
*1406 0 2(1.7) 0.140 0 0 
*1501 13 (6.5) 3 (2.5) 0.183 0.369 0.103-1.322 
*1502 12 (6.0) 10 (8.3) 0.495 1.424 0.596-3.405 
*1503 21 (11.5) 21 (17.5) 0.087 1.808 0.941-3.473 
*1601 1 (0.5) 0 1.000 0 0 
*1602 3 (1.5) 3 (2.5) 0 0 0 
 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
OD, odds ratio ; 95% CI , 95% confidence interval 
 
 
 
 
 
 
 
 
Table 3.13. HLA-DQB1 Allele frequencies in HIV-1 patients compared to controls 
 
 
 
 
DQB1 Controls 
N=200 (%) 
Patients 
N=120 (%) 
 
 P OR  (95% I C) 
*0201 72 (36.0) 39 (32.5) 0.546 0.856 0.530-1.382 
*0301 80 (40.0) 51 (42.5) 0.725 1.109 0.700-1.755 
*0302 14 (7.0) 7 (5.8) 0.817 0.823 0.322-2.100 
*0303 7 (3.5) 1 (0.8) 0.266 0.232 0.028-1.907 
*0402 7 (3.5) 8 (6.7) 0.274 1.696 0.696-5.576 
*0501 50 (25.0) 39 (32.5) 0.158 1.444 0.878-2.378 
*0502 4 (2.0) 4 (3.3) 0.479 1.690 0.415-6.885 
*0503 5 (2.5) 2(1.7) 0.715 0.661 0.126-3.462 
*0601 0 10 (8.3) 0.666 1.208 0.519-2.812 
*0602 27 (13.5) 24 (20.0) 0.155 1.602 0.876-2.930 
*0603 26 (13.0) 9 (7.5) 0.142 0.543 0.245-1.201 
*0604 34 (17.0) 10 (8.3) 0.030 0.444 0.211-0.935 
*0608 5 (2.5) 5 (4.2) 0.510 1.696 0.481-5.983 
*0609 15 (7.5) 11 (9.2) 0.674 1.245 0.552-2.807 
 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
OD, odds ratio ; 95% CI , 95% confidence interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.14. HLA-DPB1 Allele frequencies in HIV-1 patients compared to controls 
 
 
 
 
DPB1 Controls 
N=200 (%) 
Patients 
N=120 (%) 
 
P OR 95% C I 
*0101  29 (24.2)    
*0201 102 (51.0) 50 (41.7) 0.133 0.686 0.435-1.084 
*0301 40 (20.0) 20 (16.7) 0.554 0.800 0.443-1.446 
*0401 70 (35.0) 36 (30.0) 0.392 0.796 0.489-1.295 
*0402 44 (22.0) 35 (29.2) 0.180 1.460 0.871-2.447 
*0801 1 (0.5) 0 1.000 0 0 
*0901 2 (1.0) 1 (0.8) 1.000 0.832 0.075-9.274 
*0902 15 (7.5) 10 (8.3) 0.831 1.121 0.487-2.582 
*1101 10 (5.0) 4 (3.3) 0.581 0.655 0.201-2.137 
*1401 4 (2.0) 0 0.301 0 0 
*1501 5 (2.5) 0 0.161 0 0 
*1701 37 (18.5) 19 (15.8) 0.649 0.829 0.452-1.520 
*1801 1 (0.5) 0 1.000 0 0 
*3001 12 (6.0) 4 (3.3) 0.428 0.540 0.170-1.715 
*3301 1 (0.5) 0 1.000 0 0 
*3401 1 (0.5) 3 (2.5) 0.150 5.103 0.525-49.620 
*3901 0 3 (2.5) 0.052 1.026 0.997-1.055 
*4001 1 (0.5) 0 1.000 0 0 
*4701 0 1 (0.8) 0.375 0 0 
*5001 1 (0.5) 0 1.000 0 0 
*5501 0 2(1.7) 0.140 0 0 
*7201 0 1 (0.8) 0.375 0 0 
*9101 1 (0.5) 0 1.000 0 0 
*9201 0 1 (0.8) 0.375 
 
0 0 
 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
OD, odds ratio; 95% CI, 95% confidence interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.15. HLA-A Allele frequencies defined by disease progression among HIV-1 Sudanese 
patients. 
 
 
    A Slow Progression 
     N=77 (%) 
Rapid Progression 
     N= 43 (%) 
 
p OR 95% C I 
*0101 14 (18.2) 3 (7.0) 0.108 0.338 0.091-1.249 
*0103 0 1 (2.3) 0.358 1.024 0.978-1.072 
*0201 22 (28.6) 11 (25.6) 0.832 0.859 0.369-2.000 
*0202 5 (6.5) 4 (9.3) 0.720 1.477 0.375-5.820 
*0205 5 (6.5) 4 (9.3) 0.720 1.477 0.375-5.820 
*0214 1 (1.3) 0 1.000 0 0 
*0301 6 (7.8) 3 (7.0) 1.000 0.888 0.210-3.742 
*0302 4 (5.2) 0 0.295 0 0 
*0304 0 1 (2.3) 0.358 0 0 
*0305 0 1 (2.3) 0.358 0 0 
*1101 2 (2.6) 0 0.536 0 0 
*2301 9 (11.7) 6 (14.0) 0.777 1.225 0.405-3.710 
*2402 5 (6.5) 4 (9.3) 0.720 1.477 0.375-5.820 
*2403 2 (2.6) 1 (2.3) 1.000 0.893 0.079-10.142 
*2601 0 3 (7.0) 0.044 0 0 
*2612 4 (5.2) 5 (6.5) 0.653 0.435 0.047-4.017 
*2901 2 (2.6) 0 0.536 0 0 
*2902 6 (7.8) 9 (20.9) 0.047 3.132 1.031-9.514 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
OD, odds ratio ; 95% CI , 95% confidence interval 
 
 
 
Table 3.16. HLA-B Allele frequencies defined by disease progression among HIV-1 Sudanese 
patients. 
 
 
   B Slow Progression 
     N=77 (%) 
Rapid Progression 
     N= 43 (%) 
 
p OR 95% C I 
*0702 4 (5.2) 2 (4.7) 1.000 0.890 0.156-5.072 
*0705 0 0 0 0 0 
*0801 2 (2.6) 3 (7.0) 0.348 2.813 0.451-17.531 
*1301 1 (1.3) 0 1.000 0 0 
*1302 7 (9.1) 6 (14.0) 0.541 1.622 0.508-5.178 
*1401 0 1 (2.3) 0.358 0 0 
*1402 4 (5.2) 3 (7.0) 0.700 1.369 0.292-6.422 
*1403 0 1 (2.3) 0.358 0 0 
*1501 0 0 0 0 0 
*1503 7 (9.1) 7 (16.3) 0.251 1.944 0.633-5.972 
*1510 1 (1.3) 0 1.000 0 0 
*1516 0 0 0 0 0 
*1517 3 (3.9) 0 0.552 0 0 
*1518 1 (1.3) 0 1.000 0 0 
*1531 0 1 (2.3) 0.358 0 0 
*1537 0 1 (2.3) 0.358 0 0 
*1555 1 (1.3) 0 1.000 0 0 
*1567 1 (1.3) 0 1.000 0 0 
*3001 9 (11.7) 6 (14.0) 0.777 1.225 0.405-3.710 
*3002 6 (7.8) 4 (9.3) 0.744 1.214 0.323-4.562 
*3004 10 (13.0) 7 (16.3) 0.599 1.303 0.457-3.713 
*3101 0 1 (2.3) 0.358 0 0 
*3104 3 (3.9) 2 (4.7) 1.000 1.203 0.193-7.497 
*3201 6 (7.8) 1 (2.3) 0.419 0.282 0.033-2.421 
*3301 2 (2.6) 3 (7.0) 0.348 2.813 0.451-17.531 
*3303 10 (13.0) 3 (7.0) 0.374 0.503 0.130-1.935 
*3402 2 (2.6) 2 (4.7) 0.617 1.829 0.248-13.471 
*3601 0 0 0 0 0 
*6601 1 (1.3) 0 0.358 0 0 
*6602 0 1 (2.3) 1.000 0.893 0.079-10.142 
*6801 2 (2.6) 1 (2.3) 0.328 0.421 0.085-2.078 
*6802 8 (10.4) 2 (4.7) 0 0 0 
*6901 0 0 0 0 0 
*7401 0 1 (2.3) 0.358 0 0 
*7403 1 (1.3) 0 1.000 0 0 
*8001 1 (1.3) 0 0 0 0 
      
*1801 5 (6.5) 1 (2.3) 0.418 0.343 0.039-3.035 
*1807 0 0 0 0 0 
*2702 0 0 0 0 0 
*2703 0 1 (2.3) 0.358 0 0 
*2705 0 0 0 0 0 
*2707 1 (1.3) 0 1.000 0 0 
*3501 6 (7.8) 8 (18.6) 0.135 2.705 0.871-8.400 
*3502 3 (3.9) 2 (4.7) 1.000 1.203 0.193-7.497 
*3503 1 (1.3) 0 1.000 0 0 
*3508 2 (2.6) 0 0.536 0 0 
*3701 2 (2.6) 0 0.536 0 0 
*3801 3 (3.9) 2 (4.7) 1.000 1.203 0.193-7.497 
*3809 1 (1.3) 0 1.000 0 0 
*3910 11 (14.3) 2 (4.7) 0.132 0.293 0.062-1.388 
*3924 0 0 0 0 0 
*4001 0 0 0 0 0 
*4002 2 (2.6) 0 0.536 0 0 
*4012 1 (1.3) 1 (2.3) 1.000 1.810 0.110-29.677 
*4016 0 0 0 0 0 
*4101 10 (13.0) 3 (7.0) 0.374 0.503 0.130-1.935 
*4201 2 (2.6) 2 (4.7) 0.617 1.829 0.248-13.471 
*4202 0 0 0 0 0 
*4402 0 0 0 0 0 
*4403 0 2 (4.7) 0.126 0 0 
*4407 1 (1.3) 0 1.000 0 0 
*4418 0 1 (2.3) 0.358 0 0 
*4501 4 (5.2) 1 (2.3) 0.653 0.435 0.047-4.017 
*4701 1 (1.3) 0 1.000 0 0 
*4703 6 (7.8) 3 (7.0) 1.000 0.888 0.210-3.742 
*4901 6 (7.8) 2 (4.7) 0.710 0.577 0.111-2.993 
*5001 4 (5.2) 4 (9.3) 0.455 1.872 0.444-7.895 
*5002 1 (1.3) 0 1.000 0 0 
*5101 5 (6.5) 7 (16.3) 0.114 2.800 0.830-9.440 
*5108 0 0 0 0 0 
*5133 1 (1.3) 0 1.000 0 0 
*5201 4 (5.2) 1 (2.3) 0.653 0.435 0.047-4.017 
*5301 11 (14.3) 5 (11.6) 0.785 0.789 0.255-2.444 
*5501 0 0 0 0 0 
*5601 0 0 0 0 0 
*5701 1 (1.3) 3 (7.0) 0.131 5.700 0.574-56.588 
*5702 4 (5.2) 0 0.295 0 0 
*5703 1 (1.3) 0 1.000 0 0 
*5801 12 (15.6) 4 (9.3) 0.410 0.556 0.167-1.843 
*5802 0 1 (2.3) 0.358 0 0 
*5808 1 (1.3) 0 1.000 0 0 
*7301 1 (1.3) 1 (2.3) 1.000 1.810 0.110-29.677 
*7801 2 (2.6) 0 0.536 0 0 
*8101 1 (1.3) 0 1.000 0 0 
*8202 0 1 (2.3) 0.358 0 0 
 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
OD, odds ratio; 95% CI , 95% confidence interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.17. HLA-Cw Allele frequencies defined by disease progression among HIV-1 
Sudanese patients. 
 
        
Cw Slow Progression 
     N=77 (%) 
Rapid Progression 
     N= 43 (%) 
 
p OR 95% C I 
*0102 0 0 0 0 0 
*0202 2 (2.6) 2 (4.7) 0.617 1.829 0.248-13.471 
*0214 0 0 0 0 0 
*0302 5 (6.5) 2 (4.7) 1.000 0.702 0.130-3.784 
*0303 1 (1.3) 0 1.000 0 0 
*0304 0 0 0 0 0 
*0401 16 (20.8) 13 (30.2) 0.272 1.652 0.704-3.875 
*0404 1 (1.3) 0 1.000 0 0 
*0407 1 (1.3) 0 1.000 0 0 
*0418 1 (1.3) 0 1.000 0 0 
*0501 1 (1.3) 0 1.000 0 0 
*0602 16 (20.8) 10 (23.3) 0.819 1.155 0.471-2.832 
*0701 30 (39.0) 19 (44.2) 0.699 1.240 0.582-2.642 
*0702 2 (2.6) 3 (7.0) 0.348 2.813 0.451-17.531 
*0704 3 (3.9) 0 0.552 0 0 
*0705 4 (5.2) 1 (2.3) 0.653 0.435 0.047-4.017 
*0715 0 1 (2.3) 0.358 0 0 
*0802 5 (6.5) 5 (11.6) 0.492 1.895 0.516-6.955 
*0804 0 1 (2.3) 0.358 0 0 
*1202 3 (3.9) 0 0.552 0 0 
*1203 20 (26.0) 4 (9.3) 0.033 0.292 0.093-0.921 
*1402 1 (1.3) 0 1.000 0 0 
*1403 0 1 (2.3) 0.358 0 0 
*1502 4 (5.2) 1 (2.3) 0.653 0.435 0.047-4.017 
*1505 2 (2.6) 3 (7.0) 0.348 2.813 0.451-17.531 
*1601 10 (13.0) 8 (18.6) 0.433 1.531 0.555-4.228 
*1602 1 (1.3) 1 (2.3) 1.000 1.810 0.110-29.677 
*1604 0 0 0 0 0 
*1701 8 (10.4) 3 (7.0) 0.744 0.647 0.162-2.579 
*1801 6 (7.8) 1 (2.3) 0.419 0.282 0.033-2.421 
 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
OD, odds ratio ; 95% CI , 95% confidence interval 
 
 
 
 
 
 
 
 
Table 3.18. HLA-DRB1 Allele frequencies defined by disease progression among HIV-1 
Sudanese patients. 
 
 
 
DRB1 Slow Progression 
     N=77 (%) 
Rapid Progression 
     N= 43 (%) 
 
p OR 95% CI 
*0101 0 2 (4.7) 0.126 0 0 
*0102 2 (2.6) 1 (2.3) 1.000 0.893 0.079-10.142 
*0301 10 (13.0) 5 (11.6) 1.000 0.882 0.281-2.770 
*0302 1 (1.3) 1 (2.3) 1.000 1.810 0.110-29.677 
*0401 1 (1.3) 0 1.000 0 0 
*0402 1 (1.3) 0 1.000 0 0 
*0403 0 1 (2.3) 0.358 0 0 
*0405 4 (5.2) 2 (4.7) 1.000 0.890 0.156-5.072 
*0406 2 (2.6) 0 0.536 0 0 
*0701 10 (13.0) 6 (14.0) 1.000 1.086 0.366-3.228 
*0804 15 (19.5) 12 (27.9) 0.363 1.600 0.668-3.830 
*0901 0 1 (2.3) 0.358 0 0 
*1001 11 (14.3) 5 (11.6) 0.785 0.789 0.255-2.444 
*1101 17 (22.1) 12 (27.9) 0.510 1.366 0.580-3.218 
*1102 6 (7.8) 10 (23.3) 0.024 3.586 1.202-10.699 
*1103 0 0 0 0 0 
*1104 1 (1.3) 2 (4.7) 0.292 3.707 0.326-42.124 
*1114 0 1 (2.3) 0.358 0 0 
*1116 0 0 0 0 0 
*1201 0 1 (2.3) 0.358 0 0 
*1301 10 (13.0) 2 (4.7) 0.208 0.327 0.068-1.566 
*1302 15 (19.5) 6 (14.0) 0.617 0.670 0.239-1.879 
*1303 9 (11.7) 2 (4.7) 0.324 0.369 0.076-1.790 
*1316 0 0 0 0 0 
*1401 1 (1.3) 0 1.000 0.987 0.962-1.013 
*1404 0 1 (2.3) 0.358 1.024 0.978-1.027 
*1406 1 (1.3) 1 (2.3) 1.000 1.810 0.110-29.677 
*1501 1 (1.3) 2 (4.7) 0.292 3.707 0.326-42.124 
*1502 9 (11.7) 1 (2.3) 0.094 0.180 0.022-1.471 
*1503 18 (23.4) 3 (7.0) 0.025 0.246 0.068-0.890 
*1601 0 0 0 0 0 
*1602 1 (1.3) 2 (4.7) 0.292 3.707 0.326-42.124 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
OD, odds ratio ; 95% CI , 95% confidence interval 
 
 
 
 
 
 
 
Table 3.19. HLA-DQB1 Allele frequencies defined by disease progression among HIV-1 
Sudanese patients. 
 
 
 
 
DQB1 Slow Progression 
     N=77 (%) 
Rapid Progression 
     N= 43 (%) 
 
p OR (95% I C) 
*0201 22 (28.6) 17 (39.5) 0.230 1.635 0.745-3.588 
*0301 28 (36.4) 23 (53.5) 0.084 2.013 0.943-4.295 
*0302 6 (7.8) 1 (2.3) 0.419 0.282 0.033-2.421 
*0303 1 (1.3) 0 1.000 0 0 
*0402 5 (6.5) 3 (7.0) 1.000 1.080 0.245-4.757 
*0501 22 (28.6) 17 (39.5) 0.230 1.635 0.745-3.588 
*0502 2 (2.6) 2 (4.7) 0.617 1.829 0.248-13.471 
*0503 1 (1.3) 1 (2.3) 1.000 1.810 0.110-29.677 
*0601 9 (11.7) 1 (2.3) 0.094 0.180 0.022-1.471 
*0602 20 (26.0) 4 (9.3) 0.033 0.292 0.093-0.921 
*0603 8 (10.4) 1 (2.3) 0.155 0.205 0.025-1.701 
*0604 9 (11.7) 1 (2.3) 0.094 0.180 0.022-1.471 
*0608 4 (5.2) 1 (2.3) 0.653 0.435 0.047-4.017 
*0609 6 (7.8) 5 (11.6) 0.521 1.557 0.446-5.437 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
OD, odds ratio; 95% CI , 95% confidence interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.20. HLA- DPB1 Allele frequencies defined by disease progression among HIV-1 
Sudanese patients. 
 
 
 
DPB1 Slow Progression 
     N=77 (%) 
Rapid Progression 
     N= 43 (%) 
 
P OR 95% C I 
*0101 13 (16.9) 16 (37.2)    
*0201 32 (41.6) 18 (41.9) 1.000 1.013 0.475-2.158 
*0301 14 (18.2) 6 (14.0%) 0.618 0.730 0.258-2.062 
*0401 25 (32.5%) 11(25.6%) 0.534 0.715 0.310-1.648 
*0402 23 (29.9%) 12 (27.9%) 1.000 0.909 0.598-2.076 
*0801 0 0 0 0 0 
*0901 1 (1.3%) 0 1.000 0 0 
*0902 8 (10.4%) 2 (4.7%) 0.328 0.421 0.085-2.078 
*1101 4 (5.2) 0 0.295 0 0 
*1401 0 0 0 0 0 
*1501 0 0 0 0 0 
*1701 11 (14.3%) 8 (18.6%) 0.605 1.371 0.505-3.723 
*1801 0 0 0 0 0 
*3001 4 (5.2%) 0 0.295 0 0 
*3301 0 0 0 0 0 
*3401 2 (2.6%) 1 (2.3%) 1.000 0.983 0.079-10.142 
*3901 1 (1.3%) 2 (4.7%) 0.292 3.707 0.326-42.124 
*4001 0 0 0 0 0 
*4701 1 (1.3%) 0 1.000 0 0 
*5001 0 0 0 0 0 
*5501 1 (1.3%) 1 (2.3%) 1.000 1.810 0.110-29.677 
*7201 1 (1.3%) 0 1.000 0 0 
*9101 0 0 0 0 0 
*9201 0 1 (2.3%) 0.358 0 0 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
OD, odds ratio; 95% CI , 95% confidence interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.21. Distribution of HLA-A alleles among HIV-1 Sudanese patients, stratified by the 
stage of the  disease 
 
 
 
 
    A Stage I 
N=58 
Stage II 
N=19 
Stage III 
N=43 
P 
*0101 12 (20.7) 2 (10.5) 3 (7.0) 0.091 
*0103 0 0 1 (2.3) 0.253 
*0201 17 (29.3) 5 (26.3) 11 (25.6) 0.852 
*0202 4 (6.9) 1 (5.3) 4 (9.3) 0.507 
*0205 4 (6.9) 1 (5.3) 4 (9.3) 0.708 
*0214 1 (1.7) 0 0 0.597 
*0301 4 (6.9) 2 (10.5) 3 (7.0) 0.931 
*0302 3 (5.2) 1 (5.3) 0 0.284 
*0304 0 0 1 (2.3) 0.253 
*0305 0 0 1 (2.3) 0.253 
*1101 1 (1.7) 1 (5.3) 0 0.452 
*2301 7 (12.1) 2 (10.5) 6 (14.0) 0.730 
*2402 4 (6.9) 1 (5.3) 4 (9.3) 0.708 
*2403 1(1.7) 1 (5.3) 1 (2.3) 0.961 
*2601 0 0 3 (7.0) 0.046 
*2612 2 (3.4) 2 (10.5) 1 (2.3) 0.949 
*2901 1(1.7) 1 (5.3) 0 0.874 
*2902 6 (10.3) 0 9 (20.9) 0.301 
*3001 8 (13.8) 1 (5.3) 6 (14.0) 0.566 
*3002 4 (6.9) 2 (10.5) 4 (9.3) 0.314 
*3004 6 (10.3) 4 (21.1) 7 (16.3) 0.254 
*3101 0 0 1 (2.3) 0.253 
*3104 3 (5.2) 0 2 (4.7) 0.751 
*3201 4 (6.9) 2 (10.5) 1 (2.3) 0.266 
*3301 1(1.7) 1 (5.3) 3 (7.0) 0.281 
*3303 7 (12.1) 3 (15.8) 3 (7.0) 0.301 
*3402 2 (3.4) 0 2 (4.7) 0.843 
*3601 0 0 0 0 
*6601 1 (1.7) 0 0 0.597 
*6602 0 0 1 (2.3) 0.253 
*6801 2 (3.4) 0 1 (2.3) 0.355 
*6802 5 (8.6) 3 (15.8) 2 (4.7) 0.234 
*6901 0 0 0 0 
*7401 0 0 1 (2.3) 0.253 
*7403 1 (1.7) 0 0 0.172 
*8001 1(1.7) 0 0 0.172 
 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
 
               
Table 3.22. Distribution of HLA-B alleles among HIV-1 Sudanese patients, stratified by the 
stage of the disease 
 
 
 
    B Stage I Stage II Stage III P 
*0702 3 (5.2) 1 (5.3) 2 (4.7) 0.994 
*0705 0 0 0 0 
*0801 2 (3.4) 0 3 (7.0) 0.281 
*1301 1 (1.7) 0 0 0.172 
*1302 6 (10.3) 1 (5.3) 6 (14.0) 0.666 
*1401 0 0 1 (2.3) 0.253 
*1402 4 (6.9) 0 3 (7.0) 0.888 
*1403 0 0 1 (2.3) 0.253 
*1501 0 0 0 0 
*1503 6 (10.3) 1 (5.3) 7 (16.3) 0.458 
*1510 0 1 (5.3) 0 0.759 
*1516 0 0 0 0 
*1517 1 (1.7) 2 (10.5) 0 0.661 
*1518 1 (1.7) 0 0 0.597 
*1531 0 0 1 (2.3) 0.253 
*1537 0 0 1 (2.3) 0.253 
*1555 1 (1.7) 0 0 0.759 
*1567 1 (1.7) 0 0 0.597 
*1801 4 (6.9) 1 (5.3) 1 (2.3) 0.185 
*1807 0 0 0 0 
*2702 0 0 0 0 
*2703 0 0 1 (2.3) 0.253 
*2705 0 0 0 0 
*2707 1 (1.7) 0 0 0.172 
*3501 4 (6.9) 2 (10.5) 8 (18.6) 0.091 
*3502 2 (3.4) 1 (5.3) 2 (4.7) 0.949 
*3503 1 (1.7) 0 0 0.172 
*3508 2 (3.4) 0 0 0.053 
*3701 1 (1.7) 1 (5.3) 0 0.452 
*3801 2 (3.4) 1 (5.3) 2 (4.7) 0.949 
*3809 1 (1.7) 0 0 0.597 
*3910 8 (13.8) 3 (15.8) 2 (4.7) 0.429 
*3924 0 0 0 0 
*4001 0 0 0 0 
*4002 2 (3.4) 0 0 0.452 
*4012 1 (1.7) 0 1 (2.3) 0.663 
*4016 0 0 0 0 
*4101 9 (15.5) 1 (5.3) 3 (7.0) 0.201 
*4201 1 (1.7) 1 (5.3) 2 (4.7) 0.297 
*4202 0 0 0 0 
*4402 0 0 0 0 
*4403 0 0 2 (4.7) 0.105 
*4407 1 (1.7) 0 0 0.597 
*4418 0 0 1 (2.3) 0.253 
*4501 4 (6.9) 0 1 (2.3) 0.113 
*4701 0 1 (5.3) 0 0.759 
*4703 4 (6.9) 2 (10.5) 3 (7.0) 0.931 
*4901 3 (5.2) 3 (15.8) 2 (4.7) 0.776 
*5001 2 (3.4) 2 (10.5) 4 (9.3) 0.231 
*5002 0 1 (5.3) 0 0.759 
*5101 5 (8.6) 0 7 (16.3) 0.265 
*5108 0 0 0 0 
*5133 1 (1.7) 0 0 0.172 
*5201 3 (5.2) 1 (5.3) 1 (2.3) 0.657 
*5301 8 (13.8) 3 (15.8) 5 (11.6) 0.356 
*5501 0 0 0 0 
*5601 0 0 0 0 
*5701 1 (1.7) 0 3 (7.0) 0.142 
*5702 1 (1.7) 3 (15.8) 0 0.843 
*5703 1 (1.7) 0 0 0.597 
*5801 10 (17.2) 2 (10.5) 4 (9.3) 0.251 
*5802 0 0 1 (2.3) 0.253 
*5808 1 (1.7) 0 0 0.172 
*7301 1 (1.7) 0 1 (2.3) 0.663 
*7801 1 (1.7) 1 (5.3) 0 0.874 
*8101 1 (1.7) 0 0 0.172 
*8202 0 0 1 (2.3) 0.253 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.23. Distribution of HLA-Cw alleles among HIV-1 Sudanese patients, stratified by the 
stage of the  disease 
 
 
Cw Stage I Stage II Stage III P 
 
*0102 0 0 0 0 
*0202 2 (3.4) 0 2 (4.7) 0.843 
*0214 0 0 0 0 
*0302 4 (6.9) 1 (5.3) 2 (4.7) 0.430 
*0303 1 (1.7) 0 0 0.172 
*0304 0 0 0 0 
*0401 12 (20.7) 4 (21.1) 13 (30.2) 0.772 
*0404 1 (1.7) 0 0 0.597 
*0407 0 1 (5.3) 0 0.759 
*0418 1 (1.7) 0 0 0.172 
*0501 0 1 (5.3) 0 0.759 
*0602 11 (19.0) 5 (26.3) 10 (23.3) 0.922 
*0701 22 (37.9) 8 (42.1) 19 (44.2) 0.282 
*0702 2 (3.4) 0 3 (7.0) 0.486 
*0704 3 (5.2) 0 0 0.058 
*0705 3 (5.2) 1 (5.3) 1 (2.3) 0.410 
*0715 0 0 1 (2.3) 0.253 
*0802 5 (8.6) 0 5 (11.6) 0.647 
*0804 0 0 1 (2.3) 0.253 
*1202 3 (5.2) 0 0 0.158 
*1203 15 (25.9) 5 (26.3) 4 (9.3) 0.172 
*1402 0 0 0 0.597 
*1403 0 0 1 (2.3) 0.253 
*1502 4 (6.9) 0 1 (2.3) 0.410 
*1505 0 0 3 (7.0) 0.281 
*1601 8 (13.8) 2 (10.5) 8 (18.6) 0.580 
*1602 1 (1.7) 0 1 (2.3) 0.874 
*1604 0 0 0 0 
*1701 6 (10.3) 2 (10.5) 3 (7.0) 0.605 
*1801 4 (6.9) 2 (10.5) 1 (2.3) 0.642 
 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.24. Distribution of HLA-DRB1 alleles among HIV-1 Sudanese patients, stratified by 
the stage of the disease 
 
 
 
DRB1 Stage I  Stage II Stage III P 
*0101 0 0 2 (4.7) 0.105 
*0102 2 (3.4) 0 1 (2.3) 0.355 
*0301 6 (10.3) 4 (21.4) 5 (11.6) 0.566 
*0302 0 1 (5.3) 1 (2.3) 0.304 
*0401 1 (1.7) 0 0 0.597 
*0402 1 (1.7) 0 0 0.172 
*0403 0 0 1 (2.3) 0.253 
*0405 3 (5.2) 1 (5.3) 2 (4.7) 0.944 
*0406 1 (1.7) 1 (5.3) 0 0.874 
*0701 8 (13.8) 2 (10.5) 6 (14.0) 0.677 
*0804 14 (24.1) 1 (5.3) 12 (27.9) 0.841 
*0901 0 0 1 (2.3) 0.253 
*1001 6 (10.3) 5 (26.3) 5 (11.6) 0.677 
*1101 14 (24.1) 3 (15.8) 12 (27.9) 0.948 
*1102 4 (6.9) 2 (10.5) 10 (23.3) 0.048 
*1103 0 0 0 0 
*1104 1 (1.7) 0 2 (4.7) 0.593 
*1114 0 0 1 (2.3) 0.253 
*1116 0 0 0 0 
*1201 0 0 1 (2.3) 0.253 
*1301 5 (8.6) 5 (26.3) 2 (4.7) 0.685 
*1302 12 (20.7) 3 (15.8) 6 (14.0) 0.509 
*1303 5 (8.6) 4 (21.1) 2 (4.7) 0.993 
*1316 0 0 0 0 
*1401 1 (1.7) 0 0 0.172 
*1404 0 0 1 (2.3) 0.253 
*1406 1 (1.7) 0 1 (2.3) 0.663 
*1501 1 (1.7) 0 2 (4.7) 0.593 
*1502 7 (12.1) 2 (10.5) 1 (2.3) 0.082 
*1503 15 (25.9) 3 (15.8) 3 (7.0) 0.063 
*1601 0 0 0 0 
*1602 1 (1.7) 0 2 (4.7) 0.593 
 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
 
 
 
 
 
 
 
 
Table 3.25. Distribution of HLA-DQB1 alleles among HIV-1 Sudanese patients, stratified by 
the stage of the disease 
 
 
 
 
 
DQB1 Stage I Stage II Stage III P 
*0201 15 (25.9) 7 (36.8) 17 (39.5) 0.031 
*0301 24 (41.4) 4 (21.1) 23 (53.5) 0.678 
*0302 5 (8.6) 1 (5.3) 1 (2.3) 0.266 
*0303 1 (1.7) 0 0 0.597 
*0402 3 (5.2) 2 (10.5) 3 (7.0) 0.556 
*0501 16 (27.6) 6 (31.6) 17 (39.5) 0.307 
*0502 1 (1.7) 1 (5.3) 2 (4.7) 0.535 
*0503 1 (1.7) 0 1 (2.3) 0.874 
*0601 7 (12.1) 2 (10.5) 1 (2.3) 0.082 
*0602 16 (27.6) 4 (21.1) 4 (9.3) 0.081 
*0603 5 (8.6) 3 (15.8) 1 (2.3) 0.175 
*0604 7 (12.1) 2 (10.5) 1 (2.3) 0.143 
*0608 3 (5.2) 1 (5.3) 1 (2.3) 0.657 
*0609 4 (6.9) 2 (10.5) 5 (11.6) 0.592 
 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.26. Distribution of HLA-DPB1 alleles among HIV-1 Sudanese patients, stratified by 
the stage of the disease 
 
 
DPB1 Stage I Stage II Stage III p 
*0101 8 (13.8) 4 (21.1) 17 (39.5)  
*0201 25 (43.1) 7 (36.8) 18 (41.9) 0.959 
*0301 10 (17.2) 4 (21.1) 6 (14.0) 0.786 
*0401 20 (34.5) 5 (26.3) 11 (25.6) 0.196 
*0402 18 (31.0) 5 (26.3) 12 (27.9) 0.717 
*0801 0 0 0 0 
*0901 0 1 (5.3) 0 0.759 
*0902 8 (13.8) 0 2 (4.7) 0.082 
*1101 3 (5.2) 1 (5.3) 0 0.284 
*1401 0 0 0 0 
*1501 0 0 0 0 
*1701 7 (12.1) 4 (21.1) 8 (18.6) 0.214 
*1801 0 0 0 0 
*3001 4 (6.9) 0 0 0.019 
*3301 0 0 0 0 
*3401 2 (3.4) 0 1 (2.3) 0.355 
*3901 1 (1.7) 0 2 (4.7) 0.593 
*4001 0 0 0 0 
*4701 0 1 (5.3) 0 0.759 
*5001 0 0 0 0 
*5501 1 (1.7) 0 1 (2.3) 0.874 
*7201 0 1 (5.3) 0 0.759 
*9101 0 0 0 0 
*9201 0 0 1 (2.3) 0.253 
 
P values were computed by Fisher’s exact test. The boldfaced is significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.27. HLA-A Allele frequencies in HIV-1 asymptomatic patients compared to 
symptomatic patients  
 
 
 
    A Asymptomatic 
N=29 
Symptomatic
N=91 
 
p OR 95% CI 
*0101 5 (17.2) 12 (13.2) 0.555 1.372 0.439-4,284 
*0103 0 1 (1.1) 1.000 0 0 
*0201 5 (17.2) 28 (30.8) 0.232 0.469 0.162-1.355 
*0202 1 (3.4) 8 (8.8) 0.686 0.371 0.044-3.095 
*0205 2 (6.9) 7 (7.7) 1.000 0.889 0.174-4.538 
*0214 0 1 (1.1) 1.000 0 0 
*0301 2 (6.9) 7 (7.7) 1.000 0.889 0.174-4.538 
*0302 1 (3.4) 3 (3.3) 1.000 1.048 0.105-10.478 
*0304 0 1 (1.1) 1.000 0 0 
*0305 0 1 (1.1) 1.000 0 0 
*1101 1 (3.4) 1 (1.1) 0.426 3.214 0.195-53.073 
*2301 3 (10.3) 12 (13.2) 1.000 0.760 0.199-2.903 
*2402 2 (6.9) 7 (7.7) 1.000 0.889 0.174-4.538 
*2403 1 (3.4) 2 (2.2) 0.567 1.589 0.139-18.193 
*2601 0 3 (3.3) 1.000 0 0 
*2612 1 (3.4) 4 (4.4) 1.000 0.777 0.083-7.241 
*2901 0 2 (2.2) 1.000 0 0 
*2902 4 (13.8) 11 (12.1) 0.756 1.164 0.340-3.978 
*3001 6 (20.7) 9 (9.9) 0.193 2.377 0.766-7.871 
*3002 0 10 (11.0) 0.116 0 0 
*3004 2 (6.9) 15 (16.5) 0.239 0.375 0.081-1.750 
*3101 0 1 (1.1) 1.000 0 0 
*3104 0 5 (5.5) 0.334 0 0 
*3201 3 (10.3) 4 (4.4) 0.358 2.510 0.528-11.940 
*3301 1 (3.4) 4 (4.4) 1.000 0.777 0.083-7.241 
*3303 5 (17.2) 8 (8.8) 0.300 2.161 0.647-7.221 
*3402 1 (3.4) 3 (3.3) 1.000 1.048 0.105-10.478 
*3601 0 0 0 0 0 
*6601 0 1 (1.1) 1.000 0 0 
*6602 0 1 (1.1)  1.000 0 0 
*6801 2 (6.9) 2 (2.2) 0.145 6.667 0.528-11.940 
*6802 5 (17.2) 5 (5.5) 0.060 3.583 0.958-13.408 
*6901 0 0 0 0 0 
*7401 0 1 (1.1) 1.000 0 0 
*7403 1 (3.4) 0 0.242 0 0 
*8001 1 (3.4) 0 0.242 0 0 
 
 
 
 
 
 
 
Table 3.28. HLA-B Allele frequencies in HIV-1 asymptomatic patients compared to 
symptomatic patients  
 
 
 
    B Asymptomatic 
N=29 
Symptomatic
N=91 
 
P OR  95% I C 
*0702 1 (3.4) 5 (5.5) 1.000 0.614 0.069-5.483 
*0705 0 0 0 0 0 
*0801 0 5 (5.5) 0.334 0 0 
*1301 1 (3.4) 0 0.242 0 0 
*1302 3 (10.3) 10 (11.0) 1.000 0.935 0.239-3.655 
*1401 0 1 (1.1) 1.000 0 0 
*1402 2 (6.9) 5 (5.5) 0.675 1.274 0.234-6.945 
*1403 0 1 (1.1) 1.000 0 0 
*1501 0 0 1.000 0 0 
*1503 3 (10.3) 11 (12.1) 1.000 0.839 0.217-3.241 
*1510 0 1 (1.1) 1.000 0 0 
*1516 0 0 0 0 0 
*1517 1 (3.4) 2 (2.2) 0.567 1.589 0.139-18.193 
*1518 0 1 (1.1) 1.000 0 0 
*1531 0 1 (1.1) 1.000 0 0 
*1537 0 1 (1.1) 1.000 0 0 
*1555 0 1 (1.1) 1.000 0 0 
*1567 0 1 (1.1) 1.000 0 0 
*1801 3 (10.3) 3 (3.3) 0.151 3.385 0.644-17.783 
*1807 0 0 0 0 0 
*2702 0 0 0 0 0 
*2703 0 1 (1.1) 1.000 0 0 
*2705 0 0 1.000 0 0 
*2707 1 (3.4) 0 0.242 0 0 
*3501 2 (6.9) 12 (13.2) 0.514 0.488 0.103-2.319 
*3502 2 (6.9) 3 (3.3) 0.593 2.173 0.345-13.687 
*3503 1 (3.4) 0 0.242 0 0 
*3508 2 (6.9) 0 0.057 0 0 
*3701 1 (3.4) 1 (1.1) 0.426 3.214 0.195-53.073 
*3801 2 (6.9) 3 (3.3) 0.593 2.173 0.345-13.687 
*3809 0 1 (1.1) 1.000 0 0 
*3910 2 (6.9) 11 (12.1) 0.732 0.539 0.112-2.586 
*3924 0 0 0 0 0 
*4001 0 0 0 0 0 
*4002 0 2 (2.2) 1.000 0 0 
*4012 0 2 (2.2) 1.000 0 0 
*4016 0 0 0 0 0 
*4101 4 (13.8) 9 (9.9) 0.513 1.458 0.413-5.139 
*4201 0 4 (4.4) 0.571 0 0 
*4202 0 0 0 0 0 
*4402 0 0 0 0 0 
*4403 0 2 (2.2) 1.000 0 0 
*4407 0 1 (1.1) 1.000 0 0 
*4418 0 1 (1.1) 1.000 0 0 
*4501 3 (10.3) 2 (2.2) 0.090 5.135 0.814-32.388 
*4701 0 1 (1.1) 1.000 0 0 
*4703 2 (6.9) 7 (7.7) 1.000 0.889 0.174-4.538 
*4901 1 (3.4) 7 (7.7) 0.678 0.429 0.050-3.637 
*5001 1 (3.4) 7 (7.7) 0.678 2.173 0.345-13.687 
*5002 0 1 (1.1) 1.000 0 0 
*5101 2 (6.9) 10 (11.0) 0.728 0.600 0.124-2.911 
*5108 0 0 0 0 0 
*5133 1 (3.4) 0 0.242 0 0 
*5201 1 (3.4) 4 (4.4) 1.000 0.777 0.083-7.241 
*5301 7 (24.1) 9 (9.9) 0.063 2.899 0.971-8.658 
*5501 0 0 0 0 0 
*5601 0 0 0 0 0 
*5701 0 4 (4.4) 0.571 0 0 
*5702 0 4 (4.4) 0 0 0 
*5703 0 1 (1.1) 1.000 0 0 
*5801 5 (17.2) 11 (12.1) 0.533 1.515 0.479-4.792 
*5802 0 1 (1.1) 1.000 0 0 
*5808 1 (3.4) 0 0.242 0 0 
*7301 0 2 (2.2) 1.000 0 0 
*7801 0 2 (2.2) 1.000 0 0 
*8101 1 (3.4) 0 0.242 0 0 
*8202 0 1 (1.1) 1.000 0 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.29. HLA-Cw Allele frequencies in HIV-1 asymptomatic patients compared to 
symptomatic patients  
 
  
Cw Asymptomatic 
N=29 
Symptomatic
N=91 
 
P OR  95% I C 
*0102 0 0 0 0 0 
*0202 1 (3.4) 3 (3.3) 1.000 1.048 0.105-10.478 
*0214 0 0 0 0 0 
*0302 3 (10.3) 4 (4.4) 0.358 2.510 0.528-11.940 
*0303 1 (3.4) 0 0.242 0 0 
*0304 0 0 0 0 0 
*0401 10 (34.5) 19 (20.9) 0.144 1.994 0.797-4.992 
*0404 0 1 (1.1) 1.000 0 0 
*0407 0 1 (1.1) 1.000 0 0 
*0418 1 (3.4) 0 0.242 0 0 
*0501 0 1 (1.1) 1.000 0 0 
*0602 8 (27.6) 18 (19.8) 0.439 1.545 0.589-4.051 
*0701 8 (27.6) 41 (45.1) 0.129 0.465 0.186-1.158 
*0702 1 (3.4) 4 (4.4) 1.000 0.777 0.083-7.241 
*0704 2 (6.9) 1 (1.1) 0.145 6.667 0.582-76.386 
*0705 2 (6.9) 3 (3.3) 0.593 2.173 0.345-13.687 
*0715 0 1 (1.1) 1.000 0 0 
*0802 2 (6.9) 8 (8.8) 1.000 0.769 0.154-3.842 
  
 
 
 
 
 
 
 
 
 
Table 3.30. HLA-DRB1 Allele frequencies in HIV-1 asymptomatic patients compared to 
symptomatic patients  
*0804 0 1 (1.1) 1.000 0.989 0.968-1.011 
*1202 1 (3.4) 2 (2.2) 0.567 1.589 0.139-18.193 
*1203 5 (17.2) 19 (20.9) 0.794 0.789 0.266-2.344 
*1402 0 1 (1.1) 1.000 0 0 
*1403 0 1 (1.1) 1.000 0 0 
*1502 1 (3.4) 4 (4.4) 1.000 0.777 0.083-7.241 
*1505 0 5 (5.5) 0.334 0 0 
*1601 4 (13.8) 14 (15.4) 1.000 0.880 0.265-2.920 
*1602 1 (3.4) 1 (1.1) 0.726 3.214 0.195-53.075 
*1604 0 0 0 0 0 
*1701 3 (10.3) 8 (8.8) 0.726 1.197 0.296-4.845 
*1801 1 (3.4) 6 (6.6) 1.000 0.506 0.058-4.386 
DRB1 Asymptomatic 
N=29 (%) 
Symptomatic
N=91 (%) 
 
  P OR  95% I C 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.31. HLA-DQB1 Allele frequencies in HIV-1 asymptomatic patients compared to 
symptomatic patients  
 
 
 
*0101 0 2 (2.2) 1.000 0 0 
*0102 2 (6.9) 1 (1.1) 0.145 6.667 0.582-76.386 
*0301 2 (6.9) 13 (14.3) 0.519 0.444 0.094-2.098 
*0302 0 2 (2.2) 1.000 0 0 
*0401 0 1 (1.1) 1.000 0 0 
*0402 1 (3.4) 0 0.242 0 0 
*0403 0 1 (1.1) 1.000 0 0 
*0405 1 (3.4) 5 (5.5) 1.000 0.614 0.069-5.483 
*0406 0 2 (2.2) 1.000 0 0 
*0701 2 (6.9) 14 (15.4) 0.352 0.407 0.087-1.910 
*0804 9 (31.0) 18 (19.8) 0.212 1.825 0.712-4.675 
*0901 0 1 (1.1) 1.000 0 0 
*1001 3 (10.3) 13 (14.3) 0.759 0.692 0.183-2.622 
*1101 9 (31.0) 20 (22.0) 0.329 1.598 0.630-4.049 
*1102 3 (10.3) 13 (14.3) 0.759 0.692 0.183-2.622 
*1103 0  0 0 0 0 
*1104 1 (3.4) 2 (2.2) 0.567 1.589 0.139-18.193 
*1114 0 1 (1.1) 1.000 0 0 
*1116 0 0 0 0 0 
*1201 0 1 (1.1) 1.000 0 0 
*1301 3 (10.3) 9 (9.9) 1.000 1.051 0.265-4.175 
*1302 5 (17.2) 16 (17.6) 1.000 0.977 0.324-2.947 
*1303 1 (3.4) 10 (11.0) 0.293 0.289 0.035-2.362 
*1316 0 0 0 0 0 
*1401 1 (3.4)  0 0.242 0 0 
*1404 0 1 (1.1) 1.000 0 0 
*1406 0 2 (2.2) 1.000 0 0 
*1501 1 (3.4) 2 (2.2) 0.567 1.589 0.139-18.193 
*1502 4 (13.8) 6 (6.6) 0.252 2.267 0.593-8.669 
*1503 5 (17.2) 5 (17.6) 1.000 0.977 0.324-2.947 
*1601 0 0 0 0 0 
*1602 1 (3.4) 2 (2.2) 0.567 1.589 0.139-18.193 
DQB1 Asymptomatic 
    N=29 (%) 
Symptomatic 
N=91 (%) 
 
  P OR  95% I C 
*0201 3 (10.3) 36 (39.6) 0.003 0.176 0.050-0.626 
*0301 15 (51.7) 36 (39.6) 0.285 1.637 0.706-3.795 
*0302 2 (6.9) 5 (5.5) 0.675 1.274 0.234-6.945 
*0303 0 1 (1.1) 1.000 0 0 
*0402 1 (3.4) 7 (7.7) 0.678 0.429 0.050-3.637 
*0501 9 (31.0) 30 (33.0) 1.000 0.915 0.372-2.250 
*0502 1 (3.4) 3 (3.3) 1.000 1.048 0.105-10.478 
*0503 1 (3.4) 1 (1.1) 0.426 3.214 0.195-53.073 
*0601 4 (13.8) 6 (6.6) 0.252 2.267 0.593-8.669 
*0602 6 (20.7) 18 (19.8) 1.000 1.058 0.375-2.981 
*0603 4 (13.8) 5 (5.5) 0.217 2.752 0.687-11.029 
*0604 3 (10.3) 7 (7.7) 0.703 1.385 0.334-5.741 
*0608 1 (3.4) 4 (4.4) 1.000 0.777 0.083-7.241 
*0609 3 (10.3) 8 (8.8) 0.726 1.197 0.296-4.845 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.32. HLA-DPB1 Allele frequencies in HIV-1 asymptomatic patients compared to 
symptomatic patients  
 
 
 
 
PB1 Asymptomatic 
    N=29 (%) 
Symptomatic
N=91 (%) 
 
 P OR  95% I C 
*0101 5 (17.2) 24 (26.4) 0.456 0.582 0.199-1.696 
*0201 11 (37.9) 39 (42.9) 0.672 0.815 0.346-1.920 
*0301 2 (6.9) 18 (19.8) 0.153 0.300 0.065-1.382 
*0401 12 (41.4) 24 (26.4) 0.163 1.971 0.822-4.721 
*0402 9 (31.0) 26 (28.6) 0.817 1.125 0.453-2.791 
*0801 0 0 0 0 0 
*0901 0 1 (1.1) 1.000 0 0 
*0902 4 (13.8) 6 (6.6) 0.252 2.267 0.593-8.669 
*1101 1 (3.4) 3 (3.3) 1.000 1.048 0.105-10.478 
*1401 0 0 0 0 0 
*1501 0 0 0 0 0 
*1701 2 (6.9) 17 (18.7) 0.156 0.322 0.070-1.489 
*1801 0 0 0 0 0 
*3001 3 (10.3) 1 (1.1) 0.043 10.385 1.036-104.083 
*3301 0 0 0 0 0 
*3401 2 (6.9) 1 (1.1) 0.145 6.667 0.582-76.386 
*3901 1 (3.4) 2 (2.2) 0.567 1.589 0.139-18.193 
*4001 0 0 0 0 0 
*4701 0 1 (1.1) 1.000 0 0 
*5001 0 0 0 0 0 
*5501 1 (3.4) 1 (1.1) 0.426 3.214 0.195-53.073 
*7201 0 1 (1.1) 1.000 0 0 
*9101 0 0 0 0 0 
*9201 0 1 (1.1) 1.000 0 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.33. HLA-A-B two-locus haplotypes frequencies in Sudanese population, and 
comparison between patients and control groups. 
 
 
 
Haplotype 
HLA-A-B 
 
Population 
N=320 (%) 
r Control 
N=200 (%)
Patients  
N=120 (%) 
P 
3402-1302 4 (1.3) 0.234** 1 (0.5) 3 (2.5) n.s. 
3301-1402 5 (1.6) 0.360** 4 (2.0) 1 (0.8) n.s. 
3004-1503 13 (4.1) 0.199** 7 (3.5) 6 (5.0) n.s. 
0205-2703 4 (1.3) 0.200** 3 (1.5) 1 (0.8) n.s. 
2402-3801 6 (1.9) 0.164** 4 (2.0) 2 (1.7) n.s. 
2403-3801 4(1.3) 0.347** 1 (0.5) 3 (2.5) n.s. 
3101-3801 5 (1.6) 0.242** 5 (2.5) 0 n.s. 
0201-3910 18 (5.6) 0.173** 11 (5.5) 7 (5.8) n.s. 
0201-4012 4 (1.3) 0.134* 3 (1.5)) 1 (0.8) n.s. 
3001-4201 6 (1.9) 0.307** 3 (1.5) 3 (2.5) n.s. 
3004-4101 12 (3.8) 0.172** 7 (3.5) 5 (4.2) n.s. 
3201-4101 10 (3.1) 0.226** 8 (4.0) 2 (1.7) n.s. 
3001-4202 4 (1.3) 0.230** 4 (2.0) 0 n.s. 
3001-4501 5 (1.6)  0.125* 1 (0.5) 4 (3.3) 0.048 
0201-4901 14 (4.4) 0.158** 11 (5.0) 3 (2.5) n.s. 
3001-4703 7 (2.2) 0.189** 4 (2.0) 3 (2.5) n.s. 
3004-4703 6 (1.9) 0.113* 3 (1.5) 3 (2.5) n.s. 
3303-4901 5 (1.6) 0.144* 1 (0.5) 4 (3.3) 0.048 
3101-5101 5 (1.6) 0.181** 4 (2.0) 1 (0.8) n.s. 
3201-5101 7 (2.2)  0.134* 5 (2.5) 2 (1.7) n.s. 
6802-5301 10 (3.1) 0.224** 6 (3.0) 4 (3.3) n.s. 
0101-5701 5 (1.6) 0.216** 3 (1.5) 2 (1.7) n.s. 
0205-5801 10 (3.1) 0.204** 6(3.0) 4 (3.3) n.s. 
3104-5801 5 (1.6) 0.248** 2 (1.0) 3 (2.5) n.s. 
 
R, correlation coefficient 
* indicates significant correlation coefficient <0.05 
** indicates significant correlation coefficient <0.01 
P value was calculated to test the significance between patients and control groups. 
n.s. not significant  
 
 
 
 
 
 
 
 
 
 
Table 3.34. HLA-B-Cw two-locus haplotypes frequencies in Sudanese population, and 
comparison between patients and control groups. 
 
 
Haplotype 
B-Cw 
 Population 
N=320 (%) 
R Control 
N=200 (%) 
Patients  
N=120 (%) 
P 
 
3508-0401 5 (1.6) 0.224** 3 (1.5) 2 (1.7) n.s. 
4012-0404 4 (1.3) 0.726** 3 (1.5) 1 (0.8) n.s. 
4403-0401 6 (1.9) 0.191** 4 (2.0) 2 (1.7) n.s. 
5301-0401 23 (7.2) 0.341** 14 (7.0) 9 (7.5) n.s. 
1801-0501 6 (1.9) 0.573** 5 (2.5) 1 (0.8) n.s. 
0702-0702 10 (3.1) 0.570** 7 (3.5) 3 (2.5) n.s. 
0801-0702 9 (2.8) 0.427** 7 (3.5) 2 (1.7) n.s. 
1302-0602 16 (5.0) 0.279** 9 (4.5) 7 (5.8) n.s. 
1517-0701 5 (1.6) 0.145* 2 (1.0) 3 (2.5) n.s. 
3701-0602 6 (1.9) 0.271** 4 (2.0) 2 (1.7) n.s. 
3910-0701 5 (1.6) -0.133* 2 (1.0) 3 (2.5) n.s. 
4501-0602 10 (3.1) 0.229** 8 (4.0) 2 (1.7) n.s. 
4701-0602 5 (1.6) 0.214** 4 (2.0) 1 (0.8) n.s. 
4703-0701 18 (5.6) 0.324** 9 (4.5) 9 (7.5) n.s. 
4901-0701 20 (6.3) 0.285** 13 (6.5) 7 (5.8) n.s. 
5001-0602 14 (4.4) 0.345** 6 (3.0) 8 (6.7) n.s. 
5101-0701 4 (1.3) -0.165** 2 (1.0) 2 (1.7) n.s. 
5301-0701 6 (1.9) -0.123* 4 (2.0) 2 (1.7) n.s. 
5701-0602 5 (1.6) 0.130* 5 (2.5) 0 n.s. 
5703-0701 5 (1.6) 0.145* 4 (2.0) 1 (0.8) n.s. 
5801-0701 27 (8.4) 0.333** 14 (7.0) 13(10.8) n.s. 
0801-0704 7 (2.2) 0.503** 6 (3.0) 1 (0.8) n.s. 
3501-0705 5 (1.6) 0.392** 0 5 (4.2) 0.007 
1402-0802 14 (4.4) 0.828** 7 (3.5) 7 (5.8) n.s. 
5201-1202 14 (4.4) 0.876** 11 (5.5) 3 (2.5) n.s. 
5801-0802 5 (1.6) 0.120* 2 (1.0) 3 (2.5) n.s. 
3801-1203 21 (6.6) 0.471* 16 (8.0) 5 (4.2) n.s. 
3910-1203 27 (8.4) 0.513** 14 (7.0) 13 (10.8) n.s. 
4101-1203 13 (4.1) 0.130* 11 (5.5) 2 (1.7) n.s. 
3501-1505 4 (1.3) 0.123* 2 (1.0) 2 (1.7) n.s. 
4501-1601 9 (2.8) 0.301** 5 (2.5) 4 (3.3) n.s. 
5101-1601 20 (6.3) 0.490** 10 (5.0) 10 (8.3) n.s. 
7301-1505 5 (1.6) 0.549** 3 (1.5) 2 (1.7) n.s. 
5101-1602 4 (1.3) 0.142* 3 (1.5) 1 (0.8) n.s. 
1302-1801 4 (1.3) 0.172** 2 (1.0) 2 (1.7) n.s. 
4101-1701 15 (4.7) 0.396** 9 (4.5) 6 (5.0) n.s. 
4201-1701 8 (2.5) 0.567** 4 (2.0) 4 (3.3) n.s. 
 
R, correlation coefficient 
* indicates significant correlation coefficient <0.05, ** indicates significant correlation 
coefficient <0.01 
P value was calculated to test the significance between patients and control groups. 
n.s. not significant  
 
 
Table 3.35. HLA-A-Cw two-locus haplotypes frequencies in Sudanese population, and 
comparison between patients and control groups. 
 
 
 
Haplotype 
HLA-A-Cw 
 
Population 
N=320 (%) 
r Control 
N=200 (%) 
Patients  
N=120 (%) 
P 
6801-0202 4 (1.3) 0.141* 4 (2.0) 0 n.s. 
0201-0404 5 (1.6) 0.157** 4 (2.0) 1 (0.8) n.s. 
2402-0401 11 (3.4) 0.110* 7 (3.5) 4 (3.3) n.s. 
3004-0401 19 (5.9) 0.146** 11 (5.5) 8 (6.7) n.s. 
0205-0701 17 (5.3) 0.110* 11 (5.5) 6 (5.0) n.s. 
2612-0602 5 (1.6) 0.130* 4 (2.0) 1 (0.8) n.s. 
3002-0701 12 (3.8) 0.131* 7 (3.5) 5 (4.2) n.s. 
3104-0701 7 (2.2) 0.158** 2 (1.0) 5 (4.2) 0.06 
6801-0702 4 (1.3) 0.195** 3 (1.5) 1 (0.8) n.s. 
0302-1202 9 (2.8) 0.652** 6 (3.0) 3 (2.5) n.s. 
3301-0802 6 (1.9) 0.357** 5 (2.5) 1 (0.8) n.s. 
2402-1203 10 (3.1) 0.115* 6 (3.0) 4 (3.3) n.s. 
2403-1203 4 (1.3) 0.185** 1 (0.5) 3 (2.5) n.s. 
0201-1505 9 (2.8) 0.126* 6 (3.0) 3 (2.5) n.s. 
0301-1502 4 (1.3) 0.132* 3 (1.5) 1 (0.8) n.s. 
2402-1502 4 (1.3) 0.132* 3 (1.5) 1 (0.8) n.s. 
3002-1601 8 (2.5) 0.215** 3 (1.5) 5 (4.2) n.s. 
3101-1502 5 (1.6) 0.316** 4 (2.0) 1 (0.8) n.s. 
3004-1602 7 (2.2) 0.236** 6 (3.0) 1 (0.8) n.s. 
3001-1701 9 (2.8) 0.182** 7 (3.5) 2 (1.7) n.s. 
3201-1701 6 (1.9) 0.128* 6 (3.0) 0 n.s. 
 
 
 
R, correlation coefficient 
* indicates significant correlation coefficient <0.05 
** indicates significant correlation coefficient <0.01 
P value was calculated to test the significance between patients and control groups. 
n.s. not significant  
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.36. HLA-DRB1-DQB1 two-locus haplotypes frequencies in Sudanese population, and 
comparison between patients and control groups. 
 
 
 
Haplotype 
HLA-DR-DQ 
Population 
N=320 (%) 
 
R Control 
N=200 (%) 
Patients  
N=120 (%) 
P 
0301-0201 60 (18.8) 0.630** 46 (23.0) 14 (11.7) 0.012 
0301-0301 11 (3.4) -0.236** 7 (3.5) 4 (3.3) n.s. 
0402-0302 5 (1.6) 0.475** 4 (2.0) 1 (0.8) n.s. 
0403-0302 4 (1.3) 0.425** 3 (1.5) 1 (0.8) n.s. 
0405-0201 10 (3.1) 0.134* 7 (3.5) 3 (2.5) n.s. 
0405-0302 7 (2.2) 0.345** 3 (1.5) 4 (3.3) n.s. 
0701-0201 37 (11.6) 0.394** 23 (11.5) 14 (11.7) n.s. 
0804-0201 14 (4.4) -0.163** 9 (4.5) 5 (4.2) n.s. 
0804-0301 59 (18.4) 0.466** 36 (18.0) 23 (19.2) n.s. 
1101-0201 12 (3.8) 0.153** 6 (3.0) 6 (5.0) n.s. 
0302-0402 4 (1.3) 0.507** 2 (1.0) 2 (1.7) n.s. 
1102-0301 29 (9.1) 0.365** 13 (6.5) 16 (13.3) 0.045 
0701-0501 4 (1.3) 0.175** 3 (1.5) 1 (0.8) n.s. 
1302-0301 14 (4.4) -0.215** 11 (5.5) 3 (2.5) n.s. 
1303-0301 24 (7.5) 0.269** 16 (8.0) 8 (6.7) n.s. 
1503-0201 7 (2.2) -0.147** 3 (1.5) 4 (3.3) n.s. 
0102-0501 13 (4.1) 0.332** 10 (5.0) 3 (2.5) n.s. 
0301-0501 10 (3.1) -0.132* 5 (2.5) 5 (4.2) n.s. 
0804-0402 10 (3.1) 0.240** 5 (2.5) 5 (4.2) n.s. 
0804-0501 12 (3.8) -0.126* 6 (3.0) 6 (5.0) n.s. 
1001-0501 39 (12.2) 0.600** 23 (11.5) 16 (13.3) n.s. 
1101-0501 35 (10.9) 0.320** 19 (9.5) 16 (13.3) n.s. 
1302-0501 12 (3.8) -0.118* 8 (4.0) 4 (3.3) n.s. 
1401-0503 6 (1.9) 0.924** 5 (2.5) 1 (0.8) n.s. 
1301-0603 21 (6.6) 0.584** 17 (8.5) 4 (3.3) n.s. 
1302-0604 41 (12.8) 0.702** 32 (16.0) 9 (7.5) 0.037 
1501-0602 13 (4.1) 0.409** 11 (5.5) 2 (1.7) n.s. 
1602-0502 3 (0.9) 0.421** 1 (0.5) 2 (1.7) n.s. 
1503-0602 35 (10.9) 0.716** 16 (8.0) 19 (15.8) 0.041 
1503-0603 10 (3.1) 0.160** 8 (4.0) 2 (1.7) n.s. 
1301-0608 8 (2.5) 0.419** 3 (1.5) 5 (4.2) n.s. 
1302-0609 24 (7.5) 0.517** 14 (7.0) 10 (8.3) n.s. 
0701-0303 8 (2.5) 0.391** 7 (3.5) 1 (0.8) n.s. 
1502-0601 22 (6.9) 0.954** 12 (6.0) 10 (8.3) n.s. 
 
 
R, correlation coefficient 
* indicates significant correlation coefficient <0.05 
** indicates significant correlation coefficient <0.01 
P value was calculated to test the significance between patients and control groups. 
n.s. not significant  
 
Table 3.37. HLA-DRB1-DPB1 two-locus haplotypes frequencies in Sudanese population, and 
comparison between patients and control groups. 
 
 
 
 
Haplotype 
HLA-DR- DP    
 
Population 
N=320 (%) 
R Control 
N=200 (%) 
Patients  
N=120 (%) 
P 
0405-0301 6 (1.9) 0.110* 3 (1.5) 3 (2.5) n.s. 
0804-0201 41 (12.8) 0.117* 29 (14.5) 12 (10.0) n.s. 
1301-0201 23 (7.2) 0.163** 16 (8.0) 7 (5.8) n.s. 
1406-0401 2 (0.6) 0.113* 0 2 (1.7) n.s. 
1502-0401 18 (5.6) 0.281** 9 (4.5) 9 (7.5) n.s. 
1503-0401 5 (1.6) -0.175** 3 (1.5) 2 (1.7) n.s. 
1102-0402 12 (3.6) 0.114* 4 (2.0) 8 (6.7) 0.034 
1503-0402 21 (6.6) 0.228** 8 (4.0) 13 (10.8) 0.017 
1001-1701 13 (4.1) 0.155** 7 (3.5) 6 (5.0) n.s. 
1503-3001 8 (2.5) 0.251** 6 (3.0) 2 (1.7) n.s. 
 
 
R, correlation coefficient 
* indicates significant correlation coefficient <0.05 
** indicates significant correlation coefficient <0.01 
P value was calculated to test the significance between patients and control groups. 
n.s. not significant  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.38. HLA-DQB1-DPB1 two-locus haplotypes frequencies in Sudanese population, and 
comparison between patients and control groups. 
 
 
 
Haplotype 
HLA_DQ-DP 
Population 
N=320 (%) 
 
r Control 
N=200 (%) 
Patients  
N=120 (%) 
P 
0302-0301 8 (2.5) 0.131* 5 (2.5) 3 (2.5) n.s. 
0601-0401 18 (5.6) 0.253** 9 (4.5) 9 (7.5) n.s. 
0602-0401 8 (2.5) -0.161** 6 (3.0) 2 (1.7) n.s. 
0603-0201 23 (7.2) 0.128* 20 (10.0) 3 (2.5) 0.013 
0604-0401 22 (6.9) 0.143* 16 (8.0) 6 (5.0) n.s. 
0608-0201 8 (2.5) 0.117* 4 (2.0) 4 (3.3) n.s. 
0303-0402 5 (1.6) 0.140* 4 (2.0) 1 (0.8) n.s. 
0602-0402 26 (8.1) 0.266** 12 (6.0) 14 (11.7) n.s. 
0604-0402 5 (1.6) -0.123* 4 (2.0) 1 (0.8) n.s. 
0501-1101 9 (2.8) 0.174** 6 (3.0) 3 (2.5) n.s. 
0501-1701 24 (7.5) 0.155** 15 (7.5) 9 (7.5) n.s. 
0603-3001 7 (2.2) 0.241** 5 (2.5) 2 (1.7) n.s. 
 
 
 
R, correlation coefficient 
* indicates significant correlation coefficient <0.05 
** indicates significant correlation coefficient <0.01 
P value was calculated to test the significance between patients and control groups. 
n.s. not significant  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3.39. The distribution of CCR5 and CCR5-∆32 alleles among HIV-1 patients compared 
to Controls 
 
 
            
Allele Controls Patients Total 
CCR5/CCR5 199 119 318 
CCR5/ CCR5-∆32 0 0 0 
CCR5-∆32/ CCR5-∆32 1 1 2 
Total 200 120 320 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1A. Sequence chromatogram showing the nucleotide variation of the new allele 
Cw*0418 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                             95                 100                 105 
Cw*040101   *GG TCT CAC ACC CTC CAG AGG ATG TTT GGC TGC GAC CTG GGG CCG  
Cw*0418     --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---   
                            110                 115                 120 
Cw*040101   GAC GGG CGC CTC CTC CGC GGG TAT AAC CAG TTC GCC TAC GAC GGC 
Cw*0418     --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---    
                            125                 130                 135               
Cw*040101   AAG GAT TAC ATC GCC CTG AAC GAG GAT CTG CGC TCC TGG ACC GCC   
Cw*0418     --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
                            140                 145                 150 
Cw*040101   GCG GAC ACG GCG GCT CAG ATC ACC CAG CGC AAG TGG GAG GCG GCC 
Cw*0418     --- --- --- --- --- --- --- --- --- --- --- --- A-- --- --- 
                            155                 160                 165 
Cw*040101   CGT GAG GCG GAG CAG CGG AGA GCC TAC CTG GAG GGC ACG TGC GTG  
Cw*0418     --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
                            170                 175                 180                 
Cw*040101   GAG TGG CTC CGC AGA TAC CTG GAG AAC GGG AAG GAG ACG CTG CAG  
Cw*0418     --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
 
Cw*040101   CGC GCG G** 
Cw*0418     --- --- --- 
 
 
 
 
 
                             95                 100                 105 
Cw*040101   *** Ser His Thr Leu Gln Arg Met Phe Gly Cys Asp Leu Gly Pro  
Cw*0418     --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---   
                            110                 115                 120 
Cw*040101   Asp Gly Arg Leu Leu Arg Gly Tyr Asn Gln Phe Ala Tyr Asp Gly 
Cw*0418     --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---    
                            125                 130                 135               
Cw*040101   Lys Asp Tyr Ile Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala   
Cw*0418     --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
                            140                 145                 150 
Cw*040101   Ala Asp Thr Ala Ala Gln Ile Thr Gln Arg Lys Trp Glu Ala Ala 
Cw*0418     --- --- --- --- --- --- --- --- --- --- --- --- Lys --- --- 
                            155                 160                 165 
Cw*040101   Arg Glu Ala Glu Gln Arg Arg Ala Tyr Leu Glu Gly Thr Cys Val  
Cw*0418     --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
                            170                 175                 180                 
Cw*040101   Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys Glu Thr Leu Gln  
Cw*0418     --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
 
Cw*040101   Arg Ala *** 
Cw*0418     --- --- --- 
 
 
 
Figure 3.1B. Alignment of the nucleotide and amino acid sequences of exon 3 of 
Cw*0418 compared with Cw*040101 allele. A dash indicates identity with Cw*040101 
sequence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2A Sequence chromatogram showing the nucleotide variation of the new allele 
Cw*0214 
 
 
 
 
 
 
 
 
 
 
 
 
                              5                  10                  15 
Cw*020204  *GC TCC CAC TCC ATG AGG TAT TTC TAC ACC GCT GTG TCC CGG CCC   
Cw*0214    --- --- --- --- --- --- --- --- G-- --- --- --- --- --- --- 
                             20                  25                  30 
Cw*020204  AGC CGC GGA GAG CCC CAC TTC ATC GCA GTG GGC TAC GTG GAC GAC  
Cw*0214    --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
                             35                  40                  45 
Cw*020204  ACG CAG TTC GTG CGG TTC GAC AGC GAC GCC GCG AGT CCA AGA GGG 
Cw*0214    --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
                             50                  55                  60 
Cw*020204  GAG CCG CGG GCG CCG TGG GTG GAG CAG GAG GGG CCG GAG TAT TGG  
Cw*0214    --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
                             65                  70                  75 
Cw*020204  GAC CGG GAG ACA CAG AAG TAC AAG CGC CAG GCA CAG ACT GAC CGA  
Cw*0214    --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
                             80                  85                  90 
Cw*020204  GTG AAC CTG CGG AAA CTG CGC GGC TAC TAC AAC CAG AGC GAG GCC 
Cw*0214    --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
 
  
 
 
 
 
 
 
                              5                  10                  15 
Cw*020104   *** Ser His Ser Met Arg Tyr Phe Tyr Thr Ala Val Ser Arg Pro  
Cw*0214     --- --- --- --- --- --- --- --- Asp --- --- --- --- --- ---   
                             20                  25                  30 
Cw*020104   Ser Arg Gly Glu Pro His Phe Ile Ala Val Gly Tyr Val Asp Asp  
Cw*0214     --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---    
                             35                  40                  45               
Cw*020104   Thr gln Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Gly   
Cw*0214     --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
                             50                  55                  60 
Cw*020104   Glu pro Arg Ala Pro Trp Val Glu Gln Glu Gly Pro Glu Tyr Trp 
Cw*0214     --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
                             65                  70                  75 
Cw*020104   Asp Arg Glu Thr Gln Lys Tyr Lys Arg Gln Ala Gln Thr Asp Arg  
Cw*0214     --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
                             80                  85                  90                 
Cw*020104   Val Asn Leu Arg Lys Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala  
Cw*0214     --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
 
 
Figure 3.2B Alignment of the nucleotide and amino acid sequences of exon 2 of Cw*0214 
compared with Cw*020104 allele. A dash indicates identity with Cw*020104 sequence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3A Sequence chromatogram showing the nucleotide variation of the new allele 
Cw*040104 
 
 
 
 
 
 
 
 
 
 
 
 
 
                             95                 100                 105 
Cw*040101 *GG TCT CAC ACC CTC CAG AGG ATG TTT GGC TGC GAC CTG GGG CCG 
Cw*040104  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
                            110                 115                 120 
Cw*040101 GAC GGG CGC CTC CTC CGC GGG TAT AAC CAG TTC GCC TAC GAC GGC  
Cw*040104  --- --- --- --T --- --- --- --- --- --- --- --- --- --- ---                
                       125                 130                 135      
Cw*040101  AAG GAT TAC ATC GCC CTG AAC GAG GAT CTG CGC TCC TGG ACC GCC 
Cw*040104  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
                            140                 145                 150                 
Cw*040101  GCG GAC ACG GCG GCT CAG ATC ACC CAG CGC AAG TGG GAG GCG GCC  
Cw*040104  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
                            155                 160                 165       
Cw*040101  CGT GAG GCG GAG CAG CGG AGA GCC TAC CTG GAG GGC ACG TGC GTG 
Cw*040104  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
                            170                 175                 180 
Cw*040101  GAG TGG CTC CGC AGA TAC CTG GAG AAC GGG AAG GAG ACG CTG CAG 
Cw*040104  --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 
Cw*040101  CGC GCG G** 
Cw*040104  --- --- --- 
 
 
 
                             95                 100                 105 
Cw*040101   *** Ser His Thr Leu Gln Arg Met Phe Gly Cys Asp Leu Gly Pro  
Cw*040104   --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---   
                            110                 115                 120 
Cw*040101   Asp Gly Arg Leu Leu Arg Gly Tyr Asn Gln Phe Ala Tyr Asp Gly 
Cw*040104   --- --- --- Leu --- --- --- --- --- --- --- --- --- --- ---    
                            125                 130                 135               
Cw*040101   Lys Asp Tyr Ile Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala   
Cw*040104   --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
                            140                 145                 150 
Cw*040101   Ala Asp Thr Ala Ala Gln Ile Thr Gln Arg Lys Trp Glu Ala Ala 
Cw*040104   --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
                            155                 160                 165 
Cw*040101   Arg Glu Ala Glu Gln Arg Arg Ala Tyr Leu Glu Gly Thr Cys Val  
Cw*040104   --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
                            170                 175                 180                 
Cw*040101   Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys Glu Thr Leu Gln  
Cw*040104    --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
 
Cw*040101   Arg Ala *** 
Cw*040104   --- --- --- 
 
 
Figure 3.3B Alignment of the nucleotide and amino acid sequences of exon 3 of 
Cw*040404 compared with Cw*040101 allele. A dash indicates identity with Cw*040101 
sequence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4A Sequence chromatogram showing the nucleotide variation of the new allele 
Cw*070105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                            95                 100                 105 
Cw*070101  *GG TCT CAC ACC CTC CAG AGG ATG TAT GGC TGC GAC CTG GGG CCC 
Cw*070105  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
                            110                 115                 120 
Cw*070101  GAC GGG CGC CTC CTC CGC GGG TAT GAC CAG TCC GCC TAC GAC GGC  
Cw*070105  --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---                
                            125                 130                 135      
Cw*070101  AAG GAT TAC ATC GCC CTG AAC GAG GAC CTG CGC TCC TGG ACC GCC 
Cw*070105  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
                            140                 145                 150                 
Cw*070101  GCG GAC ACC GCG GCT CAG ATC ACC CAG CGC AAG TTG GAG GCG GCC  
Cw*070105  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
                            155                 160                 165       
Cw*070101  CGT GCG GCG GAG CAG CTG AGA GCC TAC CTG GAG GGC ACG TGC GTG 
Cw*070105  --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
                            170                 175                 180 
Cw*070101  GAG TGG CTC CGC AGA TAC CTG GAG AAC GGG AAG GAG ACG CTG CAG 
Cw*070105  --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 
Cw*070101  CGC GCA G** 
Cw*070105  --- --G --- 
 
 
                             95                 100                 105 
Cw*070101   *** Ser His Thr Leu Gln Arg Met Tyr Gly Cys Asp Leu Gly Pro  
Cw*070105   --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---   
                            110                 115                 120 
Cw*070101   Asp Gly Arg Leu Leu Arg Gly Tyr Asp Gln Ser Ala Tyr Asp Gly 
Cw*070105   --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---    
                            125                 130                 135               
Cw*070101   Lys Asp Tyr Ile Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala   
Cw*070105   --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
                            140                 145                 150 
Cw*070101   Ala Asp Thr Ala Ala Gln Ile Thr Gln Arg Lys Leu Glu Ala Ala 
Cw*070105   --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
                            155                 160                 165 
Cw*070101   Arg Ala Ala Glu Gln Leu Arg Ala Tyr Leu Glu Gly Thr Cys Val  
Cw*070105   --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
                            170                 175                 180 
Cw*070101   Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys Glu Thr Leu Gln  
Cw*070105   --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
 
Cw*070101   Arg Ala *** 
Cw*070105   --- Ala --- 
 
 
Figure 3.4B Alignment of the nucleotide and amino acid sequences of exon 3 of 
Cw*070105 compared with Cw*070101 allele. A dash indicates identity with Cw*070101 
sequence 
 
 
 
 
 
 
 
4. Discussion. 
 
In the present study, we examined the distribution of alleles of the HLA class I and class II 
loci defined by the application of molecular high-resolution testing methods. The use of these 
procedures allowed us to characterize and make distinctions between alleles having slight but 
highly informative structural and functional variation. These differences might not be 
detected, if either serologic- or intermediate-resolution molecular methods are applied. 
 
We observed many alleles of HLA-A, HLA-B, and HLA-C loci, which are only found in the 
African continent; these alleles, therefore, may have arisen in Africa either after the 
“migrations out of Africa” or were not transmitted to the non-African populations (165).  
 
Among HLA-A locus, A* 0201 was the most frequent allele in our population which was 
shown previously found in African population in relatively lower frequencies compared to our 
population (165); this allele was the most frequent in North African and European population 
(142,143); followed by A* 3004 an African- specific allele found in a frequency higher than 
in Sub-Saharan African (165) and North African populations (166, 167), reflecting the degree 
of admixture of the study population. We also detected other African-specific alleles in this 
locus, such as A* 0202, A* 0214, A* 2612, A* 3104, A* 3402, A* 3601, A* 4301, A* 6602, 
A* 7401, A* 8001, A* 3402, A* 3601, A* 4301, A* 7401, A* 8001 in a frequency similar to 
those observed in other African populations (165). 
 
In this study we revealed significant differences between different ethnic groups & allelic 
distribuation in this locus. A* 0302, A* 1101, A* 2402 and A* 3201 were found to be 
significantly higher in Afro-Asiatic compared to other ethnic groups.  
 
A* 1101 was detected only in Afro-Asiatic and in only one Sub-Saharan population with a 
lower frequency than Afro- Asiatic. A* 0302 was also found in one Sub-Saharan population 
with a frequency lower than that observed in Afro- Asiatic population (162,165); these alleles 
were found in Arabs and Caucasians in frequencies similar to those in the study population. In 
Nilo-Saharan, A*0202, and A*2902 were highly frequent than in other ethnic groups, whereas 
in Niger-Congo, A* 3301 was highly frequent compared to other Sudanese and Sub-Saharan 
populations (165). These ethnic variations probably reflect the historical inter-mixing of 
African populations with Arabs and Caucasians (168).  
The HLA-B locus has the largest number of alleles in our population, and this is the same as 
previously shown in other populations (169-172); however, it shows that the B locus is more 
diverse in Sudanese compared to other African populations. The highly frequent alleles were 
B* 1503 and B*4101, which were higher in North Africans and Caucasians (162), which 
further suggested that the study population is close to these populations.  
 
In this study we identified several alleles that have been confined to African populations, 
these alleles include B*1503, B*4201, B*1403, B*7801, B*1510, B*2703, B*3910, B*4012, 
B*4703, and B*7801. B*1503 was found to be significantly higher in Nilo-Saharan, whereas 
B*4201, B*1403, B*7801 were significantly higher in Niger-Congo,  All these alleles were 
presented in low frequencies in Sudanese and other African populations, except B*3910 
which was presented in Sudanese in a higher frequency compared to all other populations 
(162). Interestingly, unique alleles were found in the population; B*1567 found in the study 
population in a low frequency, but it was not detected in African populations so far, and 
B*5133 which was initially characterized in Kenyan population (173) was found in a low 
frequency in our population. The distribution of B*3924 allele that appears to be restricted to 
Mediterranean and Arabian Caucasians (174) was detected in Afro-Asiatic and Nilo-Saharan; 
this indicates the identity between Sudanese and Arabs. 
 
In the study population, the most frequent alleles in the HLA-C locus were Cw* 0701, Cw* 
0401, Cw* 0602, and Cw* 1203.  Cw* 0701, Cw* 0401 were the most common alleles in our 
population as previously shown in other populations (175). They were all found in Sub-
Saharan populations in similar frequencies; except Cw* 1203 which was lower in Africans 
compared to the Sudanese population (165). Cw* 1202 was highly significant in Afro-Asiatic, 
and was absent in Niger-Congo. It was found in a lower frequency in Sub-Saharan (165), 
North Africans and Caucasians (162), whereas Cw* 0701 was frequently high in Nilo- 
Saharan, reflecting different genetic background between these populations. The only 
African-Specific alleles in this locus, Cw* 0804 and Cw* 1801 were significantly higher in 
Niger-Congo, which further strongly suggested limited admixture of this ethnic group. 
Among the DRBI locus, we noted that DRB1* 1302 had the highest frequency among the 
Sudanese in agreement with previously reported findings in North-Africans and Sub-Saharan 
Africans (12,143). Also DRB1* 1101, a common allele in all populations showed a higher 
frequency in our population (143). Sudanese had unique DRB1 alleles DRB1* 0701 and 
DRB1* 0804 were highly frequent; interestingly, no allelic variation was observed for these 
alleles. DRB1* 0701 was found at relatively high frequencies in North Africans and 
Caucasians (54, 143). The similarity may be explained by the admixture brought about by the 
migration of Arabs to the Sudan.  In addition, DRB1*0301 was highly frequent in Sudanese 
as well as In Saudi (176), Kuwaiti (177) and some other Arabs (178, 179), indicating that 
Sudanese Arabs share some HLA components with some Arab populations, since this allele 
was highly frequent in Afro-Asiatic but the difference was marginally significant. 
 
The Sudanese showed a higher frequency of DQB1* 0301, DQB1* 0201 and DQB1* 0501; 
these alleles were frequent in Europeans (180-182) & North Africans (45) as well as in Sub-
Saharan African populations (162), they probably share a common genetic background with 
these populations. Within the Sudanese populations, DQB1*0601 was higher in Afro-Asiatic 
compared to other groups; it was presented in Arabs in a similar frequency and in one Sub-
Saharan populations with a lower frequency (57, 178). Furthermore, DQB1*0602 was higher 
in Nilo-Saharan group compared to other population and Sub-Saharan populations (4, 143); 
this may reflect the degree of admixture of the study population. 
 
The most frequent HLA-DPB1 Alleles found were DPB1*0201, DPB1*0401 and DPB1*0402 
in agreement with a previous study in Sudanese population (183); these alleles are frequent in 
Caucasians (180,184) and North Africans (143). DPB1*0101 was significantly higher in 
Niger-Congo compared to other ethnic groups, whereas as DPB1*0401 was higher in Afro-
Asiatic and DPB1*0402 was higher in Nilo- Saharan group. These results could be explained 
by the great admixture of the study population. There are no sufficient DPB1 data available 
for African populations at the moment to compare these results (184). 
 
This study confirmed some of the previous findings in the Sudanese population, although 
some were with disease association (183, 185, 186), with slight differences which may be due 
to the small sample size, and the different ethnic classification compared to our study. The 
results obtained for the serological specificities were not far from those estimated by applying 
molecular techniques; the main improvement brought by the molecular techniques is the 
detection of previously undetected alleles, which resolves most of the blank frequency.  
 
In this study we explored the influence of the host genetic make up on HIV disease 
susceptibility and progression in the Sudanese HIV-infected individuals.  
Our data indicated that class I is one of the host factors involved in the retardation of HIV 
disease progression as also reported in the previous studies (25, 187). However, the alleles 
associated with this resistance were not the same because of divergent host genetic 
background (37). 
 The results showed that HLA-A*2902 occurs in patients and the rapid progressors group 
significantly more frequently than in controls and in the slow progressors group, which 
indicates its association with susceptibility to HIV-1 infection. In contrast, A*3101 was highly 
frequent in controls than in patients, suggesting a protective effect from HIV-1 infection. 
A*3101 was previously reported by serology to be associated with HIV-1 infection in African 
Americans (104). It indicates that the molecular typing allow for more precise allele 
identification and wide allelic variation. 
 
In this study, HLA-A*2601 was observed in a higher frequency in the rapid progressors group 
compared to slow progressors group. It was also higher in patients with stage III of the disease 
compared to other stages, supporting the association of this allele with rapid progression of 
the disease as has been previously shown (124). 
  
Elaborate studies have been performed to study the relationship between HIV and particular 
HLA-B alleles, revealing that the protection is strongly associated with particular B alleles. 
HLA-B*27, B*57, B*58 alleles that were reported to be associated with resistance to HIV 
infection in the North American, European and African populations were not found or 
significantly changed in frequency in our cohort (59, 112, 116). Analysis of HLA-B in 
Sudanese population revealed that carriers of these known HIV-resistant alleles   were low in 
frequency. This may contribute to the rapid progression in our population. 
B*3508 was found only in asymptomatic group compared to symptomatic group, but the 
difference was of marginal significance, so it may indicate tendency towards slow progression 
of the disease. In previous studies, B*35 has been consistently associated with faster 
progression of HIV-1 disease. The strong association of B*35 with rapid progression to AIDS 
has been observed in many studies on a wide varieties of risk groups (188, 189), in both 
Caucasians and Africans (190, 191). This could be explained by the high degree of admixture 
of the study population. 
 
HLA-Cw*0705 was found to be much frequent in patients than in controls; thus, this allele is 
associated with disease susceptibility, as has been previously described (111) whereas 
Cw*0202 and Cw*0304 were highly frequent in controls than in patients, suggesting a 
protective effect against HIV-1 infection. Furthermore, the present study confirms the relation 
of Cw*1203 to the disease progression as has been reported in other studies (44). 
 Our study is in agreement with other studies reporting the significant association of HLA class 
II with rapid progression of HIV infection (192-194). Thus, DRB1*1102 was found to be 
associated with rapid progression; it was highly frequent in the rapid progressors compared to 
slow progressors group as well as in stage III patients, which supports the positive effect of 
this allele. This was in contrast with what has been reported in African Americans in whom 
this allele was associated with slow progression, which could be explained by the great degree 
of admixture of the study population. Furthermore, DRB1*1203 was associated with slow 
progression as shown previously (104, 126).  
 
Also DRB1*0301 was found significantly higher in controls compared to patients, which 
supports its association with protection in contrast with what has been previously reported; 
however, it  was associated with rapid progression in Caucasians and Africans (13, 195). 
 
In our cohort, DQB1*0604 was found to be associated with protection from HIV-1 infection, 
whereas DQB1*0602 was associated with slow progression in agreement with previous 
studies in African Americans (57).  
 
DPB1* 3001 was found exclusively in patients with stage I of the disease compared to other 
groups, which support its association with slow progression of the disease.  
Several HLA haplotypes were identified in the study population as well as in other 
populations, though at different frequencies, reflecting different genetic background. 
DRB1*0301-DQB1*0201 and DRB1*0102-DQB1*0501 haplotypes were found in the study 
population in a frequency similar to that observed in North African and Caucasians (167), 
which probably reflects the relationship between the Sudanese and those populations. In 
addition, DRB1*1301-DPB1*0201, and DRB1*1502-DPB1*0401 that were reported in this 
study were only detected in Greeks (143), suggests some additional links with southern 
European populations. Moreover, A*0101-B* 5701, and B*1402-Cw*0802 which have been 
previously reported in North African and Mediterranean populations (142, 143), as well as 
DRB1*0701-DQB1*0201, and DRB1*0701-DQB1*0303 which were common in Arabs and 
Caucasians (45, 196) were detected in the study population with similar frequencies, 
suggesting that Sudanese population is more closely related to those populations than to Sub-
Saharan African populations. 
   
This study has identified several additional haplotypes, not previously reported or tested in 
other populations, so far, namely A*0201-B*3910, A*3004-B*4101, A*3201-B*4101, 
B*4101-Cw*1203, A*3004-Cw*0401, A*3002-Cw*0701, A*2402-Cw*1203, DRB1*0301-
DQB1*0301, DRB1*0804-DQB1*0201, DRB1*1302-DQB1*0301, and DRB1*0804-
DPB1*0201 . They might be considered as markers for this population.  
 
Several haplotypes have been reported to have a profound effect on the susceptibility or 
protection from the disease. DRB1*1502-DQB1*0602 was associated with the susceptibility 
to HIV-1 infection, in agreement with previous studies (4, 197). Furthermore, DRB1*1102-
DQB1*0301, DRB1*1102-DPB1*0402, and DRB1*1503-DPB1*0402 were found to be 
associated with the susceptibility to HIV-1 infection. In regard to the protection from HIV-1 
infection, we observed that DRB1*0301-DQB1*0201 was associated with protection, in 
contrast with previous studies (4, 14) whereas DRB1*1302-DQB1*0604 was associated with 
protection, in agreement with previous studies (115, 198, 199). Some individual alleles, like 
DRB1*1503, DQB1*0602, and DQB1*0201, alone were associated with either susceptibility 
or protection from infection, but in a haplotypic combination they may reverse their effects. 
This suggests that specific haplotypes combination, rather than individual alleles, are 
important in HIV-1 susceptibility or protection. In addition, we also identified for the first 
time 3 haplotypes that significantly associated with the susceptibility of HIV-1 infection; 
A*3001-B*4501, A*3303-B*4901, and DRB1*1102-DPB1*0402. 
 
Regarding CCR5, We found that the CCR5-∆32 allele frequency in Sudanese was similar to 
that reported in African populations; it may contribute to the disease susceptibility and 
progression in the study population. The mutant allele was not detected in Sudanese before 
(73). One of those who carried the mutant allele was HIV-1 positive; this individual was the 
only patient with ∆32 homozygous genotype detected among 120 HIV-infected patients 
indicating that whilst it is a very rare occurrence, individuals with this genotype can be 
infected with HIV.  
This patient was asymptomatic for 3 years. It is possible that this patient was infected by M-
tropic strain via a CCR5 related molecule such as CCR1, CCR 2b or CCR 3, but the ability of 
these receptors to allow viral replication in the absence of CCR 5 appears to be poor. 
Alternatively, this patient may have been infected by a T cell-tropic or dual tropic virus, 
bypassing the requirement for functional ccr5 molecule. It clearly suggests that ccr5 is not 
essential as a coreceptor for all primary HIV-infection (132-134). 
 Our findings confirm previous studies showing that the presence of CCR5-∆32 fails to protect 
against the disease (128, 132-134), and also suggest that the CCR5-∆32 receptor does not play 
an important role in HIV infection in Sudanese population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   4.1. Conclusions. 
 
• This study points the differences in the origins of ethnic groups brought about possibly 
by the admixture of original inhabitants with neighboring and distant populations. 
• The HLA distribution in the study population reflects the unique HLA genes pattern in 
Sudanese, which indicates that the Sudanese are very close to Arab and North African 
than to Sub-Saharan African populations. 
• This result may be a reflection of a higher degree of admixture in the Sudanese 
population, which leads to detection of large number of HLA alleles in the population. 
• Some new alleles were found in the study population; indicate that the population is 
yet insufficiently explored. 
• The association of AIDS outcome with certain HLA alleles supports a genetic 
component in AIDS pathogenesis. This study indicates that certain HLA alleles exhibit 
better control of HIV-1. 
• The present data have given information supporting the role of HLA as genetic 
markers predicting HIV disease progression. 
• Our study has identified several additional HLA haplotypes, not previously reported, 
some of which have a profound effect on the disease progression; they might be 
considered as markers for this population. 
• The study suggests that CCR5-∆32 does not play an important role in HIV infection in 
the Sudanese population. 
• This study provides the data of HLA alleles and haplotypes frequencies in the 
Sudanese population, which would be a useful reference for further anthropological 
studies, transplantation studies, as well as associations between HLA and diseases studies. 
 
 
 
 
 
 
          4.2. Recommendations. 
 
 
• A larger study that addresses the class I and class II genotype distribution among
HIV-1 patients will be needed to fully elucidate the contribution of HLA alleles and
haplotypes to the genetic susceptibility of infection. 
 
•   Rare alleles were detected in the study population, thus further elaborate studies
are necessary to confirm the existence of non-predominant alleles. 
•  Some haplotypes are present in low frequency, so more data are necessary to confirm their
existence at the calculated frequencies. 
•  More population studies of HLA polymorphism should be undertaken to explore the
genetic diversity in the population, and to allow comparison of the patterns of inter-
population diversity among different HLA loci. 
•  It will be important to search for additional polymorphism in CCR5 in our
population, as this may help explain different clinical outcomes, such as exposed-uninfected
and long-term survivors. 
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Appendix I 
 
Clinical questionnaire 
 
 
Date…………………………………………………Sample ID…………………………. 
 
Name………………………………………………..Age…………………………….…… 
 
Sex………… ( ) Male……… ………..( ) Female……………………………………….. 
 
Marital status……………………...................................................................................... 
 
Tribe………………………………………………………………………………………. 
 
Present residence…………………………………………………………………………. 
_______________________________________________________________________ 
 
 
Present Complaints 
 
(  ) No symptoms………………………………………………………...………………… 
(  ) Fever…………………………………………………………………...………………. 
(  ) Loss of weight…………………………………………………………..…………...… 
(  ) Anorexia…………………………………………………………………..………….... 
(  ) Diarrhea……………………………………………………………………..…………. 
(  ) Night sweat…………………………………………………………………………….. 
(  ) Skin rash…………………………………………………………….……….………… 
(  ) Candidasis……………………………………………………………………………... 
(  ) Persistent cough……………………………………………………………………….. 
(  ) Lymphadenopathy…………………………………………………………………….. 
(  ) Kaposi`s sarcoma…………………………………………………………………........ 
(  ) Others (specify)……………………………………………………………………….. 
 
Age at onset of symptoms………………………………………………...…………....... 
 
Duration of symptoms…………………………………………………………………… 
_______________________________________________________________________ 
 
 
Co-infections 
 
(  ) Tuberculosis…………………………………………………………………………... 
(  ) Malaria…………………………………………………………………………………. 
(  ) Hepatitis………………………………………………………………………………... 
(  ) Others (specify)……………………………………………………………………….... 
_______________________________________________________________________ 
 
 
 
 
Mode of transmission 
 
 
(  ) Blood or blood products transfusion…………………………………………………... 
(  ) Sexual contact          (  ) Heterosexual…………    (  ) Homosexual…………………... 
(  ) Injecting drugs abusers………………………………………………………………… 
(  ) Vertical transmission………………………………………………………………… 
(  ) Multiple……………………………………………………………………………... 
(  ) Others (specify)……………………………………………………………………….. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
